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GCN5 IMPACTS FGF SIGNALING AT MULTIPLE LEVELS AND 
ACTIVATES C-MYC TARGET GENES DURING EARLY 
DIFFERENTIATION OF EMBRYOID BODIES 
 
Li Wang, B.Sc. 
Advisory Professor: Sharon Y.R. Dent, Ph.D. 
 
Precise control of gene expression during development is orchestrated by 
transcription factors, signaling pathways and co-regulators, with complex 
cross-regulatory events often occurring. Growing evidence has identified 
chromatin modifiers as important regulators for development as well, yet how 
particular chromatin modifying enzymes affect specific developmental 
processes remains largely unclear. Embryonic stem cells (ESCs) are self-
renewing, pluripotent, and have the abilities to generate almost all cell types 
in adult tissues. The dual capacity of ESCs to self-renew and differentiate 
offers unlimited potential for studying gene regulation events at specific 
developmental stages in vitro that parallel developmental events during 
embryogenesis in vivo.  
 
In this dissertation project, we use a murine ESC aggregation assay 
(embryoid body formation, EB) to model the early development stages that 
proceed gastrulation, and report that GCN5, a histone acetyltransferase 
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(HAT) essential for embryonic development, is required for proper expression 
of multiple genes encoding components of the FGF signaling pathway, and 
for normal activation of ERK and p38 downstream of FGF signaling at early 
stages of EB formation. Loss of Gcn5 is associated with disorganized 
cytoskeletal networks, and compromised capacity of ESCs to differentiate 
toward mesodermal and endodermal lineages. We identified 7 genes as 
putative direct targets of GCN5 during early differentiation by using RNAseq 
and H3K9ac ChIPseq. These genes are reportedly involved in signaling and 
metabolism, and most interestingly, 4 of them are c-MYC targets. These 
findings established a novel link between GCN5 and FGF signaling pathway, 
and highlighted the GCN5-MYC partnership in gene regulation during early 
differentiation.   
 
  
 ix 
TABLE OF CONTENTS 
               PAGE 
APPROVAL PAGE                i 
TITLE PAGE             ii 
ACKNOWLEDGMENTS                                                                                 iii 
ABSTRACT                     vii 
TABLE OF CONTENTS          ix 
LIST OF FIGURES          xii 
LIST OF TABLES           xiv  
LIST OF APPENDIXES           xv  
Chapter 1. Introduction ................................................................................. 1	
1.1 Chromatin and gene transcription: Histone acetylation ............................. 2	
1.2 GCN5 functions: from gene transcription to embryonic development ...... 4	
1.3 Embryonic stem cells: in vitro model system for developmental gene 
expression studies ................................................................................................ 9	
1.4 GCN5 – MYC partnership in the stem cell state ......................................... 13	
1.5 Is GCN5 important in ESC differentiation? ................................................. 17	
1.6 Significance ................................................................................................... 19	
Chapter 2. Materials and Methods ............................................................. 21	
Chapter 3. Gcn5 loss leads to defective morphogenesis of EBs at 
epiblast stage ............................................................................................... 46	
 x 
3.1 Embryoid body (EB) assay models embryogenesis leading to 
gastrulation .......................................................................................................... 47	
3.2 Gcn5-/- EBs do not exhibit defective proliferation or apoptosis at day5 .. 47	
3.3 Gcn5-/- epiblast is severely disorganized at day 5 ...................................... 53	
Chapter 4. Gcn5-/- EBs have impaired capacities in differentiation ........ 56	
4.1 Gcn5-/- expresses lower levels of epiblast-specific marker genes at day 5
 .............................................................................................................................. 57	
4.2 Delineating heterogenic populations in day5 Gcn5-/- EBs by mass 
cytometry ............................................................................................................. 59	
4.3 Gcn5-/- EBs have impaired abilities to differentiate into germlayers ........ 66	
Chapter 5. Gene expression profiling points to a regulatory role of Gcn5 
in FGF signaling pathway ........................................................................... 68	
5.1 Overview of differentially expressed genes upon Gcn5 loss at day 3 and 
day 5 ..................................................................................................................... 69	
5.2 Gene ontology and pathway analysis reveal deregulated FGF signaling in 
Gcn5-/- EBs at day5 .............................................................................................. 72	
5.3 Validating Changes in Expression of FGF pathway genes by qRT-PCR . 72	
Chapter 6. Deregulation of FGF signaling in Gcn5-/- EBs ........................ 83	
6.1 Abnormal FGF signaling in day5 Gcn5-/- EBs ............................................. 84	
6.2 Deficient activation of ERK and p38 is associated with crippled 
cytoskeletal networks in Gcn5-/- EBs at day 5 .................................................. 85	
Chapter 7. GCN5 regulates selective c-MYC target genes in early 
differentiation ............................................................................................... 89	
 xi 
7.1 Attempts of ChIPs for GCN5 in differentiating EBs not successful ......... 90	
7.2 H3K9ac ChIPs in Gcn5fx/fx and Gcn5-/- EBs at day5 .................................. 101	
7.3 GCN5 is required for activating c-MYC target genes in day 5 EBs ........ 101	
Chapter 8. Conclusions, Discussion and Future Directions ................. 113	
8.1 Conclusions ................................................................................................. 114	
8.2 Possible contributions to the observed EB phenotypes by non-
transcriptional targets of GCN5 ....................................................................... 122	
8.3 Potential compensatory effects from GCN5/ATAC or PCAF .................. 129	
8.4 Potential novel roles of GCN5 during early differentiation ..................... 130	
8.5 Concluding remarks and perspectives ..................................................... 132	
APPENDIXES .............................................................................................. 135	
BIBLIOGRAPHY ......................................................................................... 185	
VITA ............................................................................................................. 208	
 
  
 xii 
LIST OF FIGURES 
Figure 1 GCN5 containing complexes in mammalian systems ................ 5	
Figure 2 Creation of the pairing Gcn5fx/fx and Gcn5-/- ESCs ..................... 11	
Figure 3 GCN5 – MYC partnership to promote gene transcription in 
various developmental/differentiation contexts ....................................... 16	
Figure 4 Gcn5-/- EBs have abnormal morphology during early stages of 
differentiation ............................................................................................... 49	
Figure 5 Loss of Gcn5 does not inhibit proliferation or promote 
apoptosis at an early differentiation stage ................................................ 51	
Figure 6 Severely disorganized epiblast of Gcn5-/- EBs at day 5 ............ 55	
Figure 7 Epiblast marker genes are expressed at lower levels in Gcn5-/- 
EBs ................................................................................................................ 58	
Figure 8 Using mass cytometry to delineate heterogeneous cell 
populations in differentiating ESCs ........................................................... 63	
Figure 9 Changes in cell population composition in Gcn5-/- EBs at the 
epiblast stage ............................................................................................... 65	
Figure 10 Impaired differentiation abilities of Gcn5-/- EBs ....................... 67	
Figure 11 Overview of altered gene expression profiles in early stage 
Gcn5-/- EBs ................................................................................................... 71	
Figure 12 Top enriched processes identified by GSEA in the control EBs 
compared to Gcn5-/- EBs at day 5 .............................................................. 74	
 xiii 
Figure 13 Altered gene expression profiles of FGF signaling pathway 
components in Gcn5-/- EBs at day 5 .......................................................... 82	
Figure 14 Deficient activation of the FGF pathway in the day 5 Gcn5-/- 
EBs ................................................................................................................ 88	
Figure 15 Attempts of GCN5 ChIPs for EBs are not successful ............. 93	
Figure 16 Creation of Flag-HA-GCN5 expressing J1 ESCs using targeted 
insertion mediated by CRISPR/CAS9 ........................................................ 97	
Figure 17 FLAG-HA-GCN5 interacts with subunits of SAGA complex in 
ESCs ............................................................................................................. 99	
Figure 18 Putative target genes of GCN5 during early EB differentiation
 ..................................................................................................................... 112	
Figure 19 GCN5 impacts multiple components of the FGF signaling 
pathway and activates MYC targets during early differentiation .......... 116	
Figure 20 Acetylation of tubulin is not overtly affected by Gcn5 loss in 
day 5 EBs ................................................................................................... 124	
Figure 21 GCN5 expression is regulated during early differentiation .. 128	
Figure 22 Increased immune response in day 5 Gcn5-/- EBs ................. 131	
 
  
 xiv 
LIST OF TABLES 
Table 1 Antibodies used in this study ....................................................... 38	
Table 2 Primers used for PCR analyses .................................................... 42	
Table 3 Lineage markers used for mass cytometry ................................. 62	
Table 4 Gene list of GSEA set Multicellular Organismal Development .. 76	
Table 5 Gene list of GSEA set Cell Surface Receptor Linked Signal 
Transduction ................................................................................................ 79	
Table 6 Mapping rates of the tags from the H3K9ac ChIPseq to mouse 
genome assembly mm10 .......................................................................... 102	
Table 7 Peak calling for differential test between Gcn5fx/fx and Gcn5-/- 
samples ...................................................................................................... 104	
Table 8 Comparison of H3K9ac peaks and associated genes in Gcn5fx/fx 
and Gcn5-/- EBs at day 5 ............................................................................ 107	
Table 9 Top ranked transcription factors or regulators reported to bind 
genes with decreased H3K9ac identified in Gcn5 null EBs at day 5 .... 108	
 
  
 xv 
LIST OF APPENDIXES 
Appendix 1 List of genes with altered expression levels upon Gcn5 loss 
in day 5 EBs identified by RNAseq (FDR 0.05, FC2)............................... 135	
Appendix 2 List of genes with altered expression levels upon Gcn5 loss 
in day 3 EBs identified by RNAseq (FDR 0.05, FC2)............................... 172	
Appendix 3 List of genes with decreased H3K9ac levels in promoter 
region upon Gcn5 loss in day 5 EBs (FDR0.05) ...................................... 180	
 
  
 1 
 
 
 
 
 
 
 
 
 
Chapter 1. Introduction 
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1.1 Chromatin and gene transcription: Histone acetylation 
In eukaryotes, genomic DNA is highly compacted to fit into the nucleus. To 
accomplish this, 146 base pairs (bps) of DNA wrap an octamer of core 
histone proteins (H2A, H2B, H3 and H4) to form a nucleosome, which is the 
basic unit of chromatin. Repeating arrays of nucleosomes interconnected by 
linker DNA and histone H1 are further packed into higher-order chromatin 
structures. The relaxation or condensation of chromatin exposes or limits the 
genetic information to be accessed by transcriptional machineries, which in 
turn control transcription from the DNA.  
 
At the center of chromatin structure are the highly conserved core histone 
proteins. Both the N-terminal tail domains and the globular domains of 
histones are subject to a variety of post-translational modifications, however 
the tail domains are more heavily modified, including acetylation, 
phosphorylation, methylation, ubiquitination, sumoylation and ADP-
ribosylation (1, 2). These modifications influence chromatin organization by 
affecting histone – DNA, nucleosome – nucleosome, and nucleosome – 
chromatin modifier interactions, and therefore provide multiple levels of 
chromatin state remodeling, and thus regulate gene transcription, DNA 
replication and DNA damage repair.  
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Histone acetylation has long been associated with open-states of chromatin 
and active gene transcription. The histone tail domains are rich in lysine (K) 
residues including H3K9, H3K14, H3K18, H4K5, H4K8 and H4K12, to name a 
few (3). The addition of the acetyl group effectively neutralizes the positive 
charge of histone tails, perturbing the histone-DNA interaction and the 
interactions between neighboring histones, which then lead to a more relaxed 
chromatin state, allowing for the access of transcriptional machineries. 
Acetylated lysines (K-ac) can also serve as docking sites for chromatin 
regulators to facilitate transcription (4). For instance, K-ac can be “read” by 
bromodomain containing chromatin modifiers, which often are HAT, 
methyltransferases, or chromatin remodeling complexes, to “open up” the 
chromatin for transcription (5, 6). K-ac can be bound by YEATS domain 
containing proteins like AF9 as shown in a recent report (7), which also 
promotes active transcription. 
 
The level of histone acetylation is dynamic, and is regulated by the opposing 
actions of two families of chromatin modifiers, histone acetyltransferases 
(HATs) and histone deacetylases (HDACs). Although many HATs and 
HDACs have been identified to date, we still know very little about the specific 
biological processes regulated by particular enzymes. This dissertation 
project focuses on one such enzyme, GCN5, and its functions during early 
differentiation stages of embryonic stem cells.  
 4 
 
1.2 GCN5 functions: from gene transcription to embryonic development 
GCN5 was the first HAT to be linked to active transcription, and it exerts the 
fullest enzymatic activity when incorporated into multimember complexes (8). 
The main subunits and structures of GCN5 containing complexes are highly 
conserved across evolution (9, 10). In yeast, Gcn5 is part of the SAGA (SPT-
ADA-GCN5 acetyltransferase) and ADA complexes. In mammalian systems, 
GCN5 is also a subunit of another complex called ATAC (ADA2A containing 
complex), although SAGA has until recently been the better defined GCN5 
containing complex in terms of its subunits, modular organization and 
functions in gene transcription (11) (Figure 1). GCN5 has a highly related 
homolog protein, PCAF, which is a subunit of another multimember complex 
similar to SAGA (11-13).  
 
The mammalian SAGA complex is organized into four functional submodules, 
including two enzymatic modules, a HAT module (including GCN5, the ADA 
proteins and SGF29) and a deubiquitinating (DUB) module containing USP22 
as the catalytic subunit, along with ENY2, ATXN7 and ATXN7L3. Several 
substrates have been defined for SAGA, including acetylation on K9, K14, 
and K18 of H3 and ubiquitination on K120 of H2B. SAGA has two other 
submodules, the SPT module and the TAF module, which are essential for 
SAGA integrity and its interactions with transcriptional machinery (11, 14).   
 5 
 
 
Figure 1 GCN5 containing complexes in mammalian systems 
(A) The SAGA complex is composed of four submodules: SPT (orange), TAF 
(grey), DUB (blue) and HAT (red). GCN5 is the enzymatic center of the HAT 
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module and ADA2B is specific to the SAGA complex. USP22 is the 
deubiquitinase of the DUB module. 
(B) ATAC complex has a similar GCN5 containing HAT module (red) with a 
unique ADA2A, and subunits (green) unique from SAGA. ATAC2 is a weak 
HAT that acetylates H4. YEATS2 is a reader for both acetylation and 
crontonylation of histones (7, 15).  
Text color codes: the enzymes are highlighted in colors corresponding to the 
modules to which they belong.  
This figure is adapted from my review in 2014 (11).  
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Both enzymatic activities of SAGA facilitate gene transcription. Although 
SAGA does not bind DNA directly, it is recruited by specific transcription 
factors (TFs), such as c-MYC, E2F and p53 (16-20), through the SPT module 
to their target gene promoters, allowing the GCN5/HAT-module to acetylate 
the nearby lysines on histone H3. Meanwhile, the TAF module interacts with 
the transcriptional machinery to promote the initiation of transcription. SAGA 
also facilitates transcript elongation after transcription is initiated, which is 
accomplished by actions of both HAT and DUB (USP22) modules (14).   
 
Growing evidence indicates that the mammalian SAGA acts as a gene-
specific co-activator (21, 22), but may also promote global gene transcription 
by recruiting RNA polymerase II (pol II) to all transcribed genes (23). Genetic 
studies of GCN5, however, support a selective role of GCN5/SAGA in gene 
regulation. For instance, both GCN5 and its catalytic activity are essential for 
normal development and survival of mouse embryos. Gcn5 null embryos die 
soon after gastrulation and exhibit increased apoptosis in mesodermal 
lineages (24). Gcn5 catalytic mutants, however, survive until mid-gestation, 
but develop cranial neural tube closure defects (NTDs) (25) due to abnormal 
retinoic acid (RA) signaling involving a non-histone substrate of GCN5 (26). 
These findings indicate that GCN5-containing complexes have both HAT 
dependent and independent functions during early development. The 
phenotypes of Gcn5 mutant mice also indicate specific requirement for this 
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HAT in gene regulation during development, as loss of general transcription 
factors often leads to very early, preimplantation, death (27). 
 
A conditional, “floxed” allele of Gcn5 was also generated by the Dent lab to 
aid investigations of GCN5 functions in specific tissues or cell populations, at 
particular developmental stages. The Gcn5-floxed allele behaves as wild 
type, and mice homozygous for this allele (Gcn5fx/fx) show no overt 
phenotypes (28). After exposure to Cre recombinase, exons 3-18 of Gcn5 are 
deleted, creating a null allele. By crossing Gcn5fx/fx mice with mice bearing 
Cre alleles driven by tissue specific promoters, Gcn5 can be deleted in the 
tissues of interest, providing the opportunities to define the tissue specific 
requirements of Gcn5 in gene regulation. For instance, a Nestin-Cre-
mediated Gcn5 deletion in neural stem cells (NSC) in the developing brain 
leads to reduced brain mass with microcephaly, a phenotype similar to that of 
c-Myc or n-Myc NSC conditional knockouts (29). Gene expression analysis 
shows that about 1/6 of genes impacted by Gcn5 loss are also N-MYC 
targets, suggesting that GCN5 is a co-activator for N-MYC target gene 
expression in NSCs of the developing brain (29). Another study from our lab 
also reported the requirement for Gcn5 in adipose tissue development. Myf5-
Cre-mediated Gcn5 deletion in precursors of brown adipose tissue of Pcaf-/- 
mice results in postnatal lethality due to impaired brown adipose tissue 
development. Furthermore, GCN5/PCAF facilitate adipogenesis through 
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regulation of PPARγ expression and regulate brown adipogenesis by 
influencing Prdm16 expression (30).   
 
Collectively, these findings indicated that GCN5 is essential for 
embryogenesis, and is required for normal development of neural tissues and 
brown adipose tissues by regulating the expression of specific gene 
programs. It was still unclear, though, what gene programs are regulated by 
GCN5 during early stages of development, as the early lethality of the Gcn5 
mutant embryos posed significant challenges for detailed molecular studies.  
 
1.3 Embryonic stem cells: in vitro model system for developmental gene 
expression studies 
Mouse embryonic stem cells (ESC) are derived from the inner cell mass 
(ICM) of a blastocyst, which is an early stage of a preimplantation embryo 
(31). ESCs are self-renewing and can be propagated in culture while retaining 
pluripotency. Pluripotency refers to the capacity of a single cell to differentiate 
into all cell lineages in the course of development, from a developing embryo 
to the fully developed organs in an adult. Self-renewal refers to the ability of a 
cell to proliferate and generate an identical daughter cell (31). Gene 
expression programs controlling pluripotency and self-renewal of ESCs in 
vitro are regulated by intricate networks of TFs (e.g. the OCT4-SOX2-NANOG 
network)(32, 33), growth factor or cytokine signaling (e.g. leukemia inhibitory 
 10 
factor, LIF) (34) and an array of cofactors including chromatin regulators (e.g. 
Polycomb group and TIP60-p400)(35). These regulatory events are executed 
in a manner proven to be largely similar to that observed in vivo, which make 
the ESCs an attractive in vitro system modeling self-renewal, pluripotency 
maintenance and differentiation.  
 
In light of these technical advances, Gcn5 null ES cells were created in order 
to define the roles of GCN5 in self-renewal and/or pluripotency/differentiation 
in vitro (36). To do so, Gcn5fx/fx ES cell isolates were derived from blastocysts 
of Gcn5fx/fx mouse intercrosses, and then were transiently exposed to an 
EGFP-Cre recombinase by transfection (36) (Figure 2A). The GFP+ cells 
were sorted and selected by flow cytometry, and individual colonies 
propagated from the GFP+ cells were collected to confirm Gcn5 deletion and 
to determine karyotypes (a term for the number and appearance of 
chromosomes in the nucleus of a eukaryotic cell). Two independent Gcn5-/- 
ES clones were generated by this means (Figure 2, B and C), and together 
with their parental Gcn5fxfx isolates, were confirmed to have normal 
karyotypes.  
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Figure 2 Creation of the pairing Gcn5fx/fx and Gcn5-/- ESCs 
(A) A diagram illustrating the creation of a Gcn5-/- allele after exposure of the 
Gcn5fx/fx to Cre recombinase. 
(B) and (C) RNA transcripts (B) and immunoblots (C) showing deletion of 
Gcn5 and loss of GCN5 protein in the two null isolates. 
This figure is adapted from an article (36) published in Genes & Development, 
for which I was an author.   
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Of note, these Gcn5-/- ES clones have the same genome as the parental 
Gcn5fx/fx ES cells, except for lack of exons 3-18 of Gcn5 gene. Such genomic 
match should reduce the individual variance between the control and null 
cells, as would have been observed in isolates from wild type and null mice, 
Thus, in theory any defect observed in these Gcn5-/- ES cells should be 
exclusively due to Gcn5 loss. 
 
In order to determine the genome wide association of GCN5 in wild type 
ESCs, AB1 mouse ESCs stably expressing in vivo biotinylated GCN5 
(BirAV5-FLBioGcn5) were generated (36, 37) with a control cell line (BirAV5-
FLBio) that stably expressed BirA and FLBio alone. This approach was used 
due to the absence of a suitable GCN5-specific antibody for efficient and 
specific chromatin immunoprecipitation (ChIP). The in vivo biotinylation 
system has two advantages; first, the biotinylated GCN5 can be 
immunoprecipitated by streptavidin, which is extremely efficient; second, the 
FLBioGCN5-stable-ESCs were selected for lower or equal protein level of 
FLBioGCN5 relative to that of endogenous GCN5, reducing potential artifacts 
due to exogenous protein expression.  
 
These resources made it possible to define the gene expression programs 
regulated by GCN5 in undifferentiated ESCs. 
 
 13 
1.4 GCN5 – MYC partnership in the stem cell state 
 Gcn5-/- ES cells could be maintained in media conditioned for stem cell 
growth, and did not exhibit overt abnormalities (28, 36), suggesting that Gcn5 
is not required for ESC survival in undifferentiated culture conditions.  
 
Streptavidin-ChIP coupled with deep sequencing (bioChIPseq) using the 
FLBioGCN5 ES cells showed that average binding profile of GCN5 strongly 
correlates that of RNA polymerase II (pol II), and that 59% of GCN5 binding 
sequences are active promoters, in keeping with its known co-activator role in 
transcription. Interestingly GCN5 also binds to a cluster of bivalent domains, 
which refer to promoter regions, largely of developmental genes, 
simultaneously marked by both activating (H3K4me3) and repressing 
(H3K27me3) histone modifications (38). Bivalent domains keep genes at a 
poised state, allowing for rapid activation by losing H3K27me3 or continued 
silencing by losing H3K4me3 upon appropriate developmental cues (39). The 
association of GCN5 with bivalent domains indicates that GCN5 maybe 
involved in regulating genes specific for pluripotency or differentiation in the 
ES cells. Comparison to published ChIP data in mouse ESCs revealed a 
striking correlation between GCN5 binding sites with those of MYC-E2F1, but 
not NANOG -OCT4-SOX2 TF network (33, 40). In addition, these sites 
primarily fell into the genes actively transcribed in the ESCs. These findings 
suggested that GCN5 co-activates MYC and E2F1 transcriptional networks in 
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pluripotent cells. Integration with the altered gene expression profiles 
generated from Gcn5fx/fx and Gcn5-/- ES cells further confirmed these findings, 
showing that a significant portion of the putative target genes directly 
activated by GCN5 (genes bound by GCN5, and with expression down 
regulated upon Gcn5 loss) are also MYC/E2F targets, which largely regulate 
cell cycle. These results strongly indicate that GCN5 is an important co-factor 
for MYC/E2F TF network to regulate proliferation/self-renewal in ESCs (36).   
 
The GCN5-MYC partnership defined in ESCs raised the possibility that GCN5 
might also engage MYC during somatic cell reprogramming to induce 
pluripotent stem cell state from differentiated adult cells. Indeed, a functional 
RNAi screen for the earliest epigenetic regulators required for reprogramming 
identified GCN5 and several other SAGA subunits as critical regulators of 
reprogramming initiation. Genome wide analysis of gene expression events 
upon reprogramming initiation in MEFs (mouse embryonic fibroblasts) 
showed that, GCN5 and MYC form a positive feed-forward loop that activates 
a distinct alternative splicing gene network, which promotes the acquisition of 
the alternative slicing events essential for establishing pluripotency in early 
steps of reprogramming (36).  
 
In concordance with the GCN5/N-MYC connection in NSC gene regulation 
(29), these collective studies highlight a GCN5 – MYC partnership in 
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regulating gene expression in self-renewal of the ESCs and in initiation steps 
of somatic cell reprogramming (Figure 3).  
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Figure 3 GCN5 – MYC partnership to promote gene transcription in 
various developmental/differentiation contexts 
A cartoon showing GCN5 interactions with MYC family or related (E2F) 
factors to promote gene transcription in ESCs, reprogramming of MEFs 
(mouse embryonic fibroblasts) and NSCs (neural stem cells) in the 
developing brain (29, 36).   
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1.5 Is GCN5 important in ESC differentiation? 
Our previous studies indicated the involvement of Gcn5 in early differentiation 
events of ESCs, as Gcn5 null ESCs (isolates derived from Gcn5-/- blastocysts, 
which are different from the isogenic Gcn5-/- ESCs made from Gcn5fx/fx ESCs) 
form smaller aggregates compared to the wild type at day 6 of differentiation, 
and prematurely down regulated select pluripotency genes such as Oct4 and 
Nodal in the absence of LIF. The expression of a mesoderm marker Flk1, but 
not the ectodermal markers tested, was lower in the Gcn5 null EBs relative to 
the wild type EBs (28). These observations indicate that loss of Gcn5 does 
not completely halt differentiation, but does affect the normal expression 
dynamics of specific genes during the process. The early loss of mesodermal 
lineages shortly after gastrulation in Gcn5 null embryos also suggested that 
Gcn5 might be important for specific lineage development. However, the early 
developmental processes and associated signaling pathways modulated by 
GCN5 have not yet been clearly defined. 
 
By the time of implantation during mammalian development, the blastocyst 
has formed distinct lineages, including the trophoblast cells outlining the 
blastocyst that will give rise to extra-embryonic tissues, and the ICM, which 
develops into the epiblast, a columnar epithelial structure in a shape of an 
egg cylinder. The epiblast further differentiates into three germ layers, 
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ectoderm, endoderm and mesoderm. The process by which germlayers are 
formed from the epiblast is termed gastrulation (34).  
 
Fibroblast growth factor (FGF) signaling is essential for these multiple stages 
during early embryonic development, from segregation of trophectoderm and 
primitive endoderm from the ICM (41-46) to specifications of primitive 
ectoderm and primitive streak (47), which in turn determine the fate of 
epiblast. ESC-based studies indicate that FGF signaling is involved in both 
pluripotency maintenance and neural ectodermal and mesodermal lineage 
specification (48-50) in vitro. However, how or if chromatin regulators 
contribute to FGF pathway regulation of gene expression programs during 
early developmental events is not yet clear. 
 
This dissertation project employed an embryoid body differentiation protocol 
to define the functions of GCN5 in ESC differentiation. Embryoid bodies are 
3-dimensional aggregates formed by ESCs in suspension upon withdrawal of 
LIF and inhibitors for ERK and GSK3β (2i-s), which block differentiation. 
Hallmark events of this process include endodermal differentiation (visceral 
endoderm, VE) and basement membrane (BM) assembly at days 2-3, 
followed by polarized epiblast formation from the inner cells and the clearance 
of a central cavity (days 4-6) (51). These sequential events recapitulate 
transitions from formation of the inner cell mass (ICM) through embryonic 
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gastrulation, thereby providing opportunities to define molecular events in 
vitro that might contribute to the death of Gcn5 null embryos shortly after 
gastrulation in vivo.   
 
Using the Gcn5fx/fx and Gcn5-/- ESCs aforementioned, we find that Gcn5 loss 
leads to severe disorganization of cytoskeletal networks in epiblasts. Gene 
expression profiling by RNA sequencing indicates that these phenotypes are 
associated with defective FGF signaling in the Gcn5 null EBs. Several genes 
in the FGF and ERK pathways that are down regulated in Gcn5 null EBs are 
known targets of c-MYC, consistent with our findings in undifferentiated 
ESCs. Disruption of these pathways in turn is associated with defective 
endoderm and mesoderm differentiation in Gcn5 null EBs.  
 
1.6 Significance 
This work provides evidence for a novel role for GCN5 in the regulation of 
FGF signaling during early stage differentiation of EBs. It builds on previous 
links between GCN5 and MYC in undifferentiated ES cells, during neural 
development in embryos, and during somatic cell reprogramming, and 
reinforces the GCN5-MYC partnership in regulating gene expression in yet 
another important developmental process.  
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As abnormal regulation of growth factor regulated pathways drive 
oncogenesis (52), and MYC has long been linked to malignant transformation 
and growth (53), our findings here predict that GCN5 may also be important in 
cancers associated with over-activation of FGFs and/or MYC. Future work will 
explore this possibility, as well as the therapeutic potential of targeting GCN5 
to inhibit growth or progression of these cancers. 
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Chapter 2. Materials and Methods 
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ES cell culture and differentiation 
Gcn5fx/fx and Gcn5-/- ES lines were generated and characterized previously 
(36). ESCs were routinely grown on gelatin-coated plates in DMEM/High 
glucose (HyClone™, SH3002201) medium supplemented with 15% (v/v) ES-
screened FBS (HyClone™, SH3007003E), 2mM L-glutamine (Hyclone, 
SH3003401), 0.1mM non-essential amino acids (Corning™, MT25025CI), 1% 
(v/v) penicillin/streptomycin (Hyclone, SV30010), 0.1 mM β-mercaptoethanol 
(Fisher, 03446I-100), 1000U/mL of LIF/ESGRO (Millipore, ESG1107), 1µM 
PD0325901 (Sigma, PZ0162) and 3 µM 1-Azakenpaullone (Sigma, A3734) 
(2i-s), and passaged with 0.25% Trypsin (HyClone™, SH3004201) every 2-3 
days.  
For EB differentiation, 3×105 cells were plated in a well of an ultra-low 
attachment 6-well plate (Corning, 07-200-601) in 3mL of differentiation media 
at 37°C with 5% CO2. Media were replaced every other day by settling the 
EBs at low speed centrifugation (100g for 1 minute). The differentiation 
medium is composed of DMEM/High glucose:F12 (Cellgro™, 
MT10080CV):Neurobasal media (Gibco™, 21103049) (1:1:2) supplemented 
with 10% KnockOut Serum Replacement medium (Gibco™, A3181502), 2mM 
L-glutamine, 1% (v/v) penicillin/streptomycin and 0.1 mM β-mercaptoethanol.  
 
Immunofluorescence and Confocal imaging 
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2-3 wells of EBs were collected in a 1.5mL tube, and 1.3mL of a given 
solution was used in the following steps of washes and sucrose incubation. 
EBs were washed once in PBS/1%BSA and fixed in 4% paraformaldehyde 
(PFA) for 30 minutes at room temperature. The fixed EBs were incubated in 
7.5% sucrose/PBS for at least one hour at room temperature, then in 15% 
sucrose/PBS at 4°C overnight. Afterward, the EBs were embedded in Tissue-
Tek® O.C.T. compound (Electron microscopy sciences, 62550-12) and 
incubated for 10 minutes at room temperature with agitation before frozen in 
liquid nitrogen (LN2). Frozen sections (8µM) were cut on a cryostat (Thermo) 
and mounted on glass slides. Air-dried sections were defined by drawing a 
square or circle around using a PAP-pen, and 200µL of a given solution was 
used the following steps of staining and washing. Sections were washed once 
with PBS, fixed in 2% PFA for 2 minutes then blocked with PBS containing 
0.1% Tween-20 (Fisher, BP337-500) (PBT) and 5% Normal donkey serum 
(Millipore, S30-100ML) for 30 minutes at room temperature. The blocked 
sections were incubated with primary antibodies diluted in blocking buffer 
overnight at 4°C. The slides then were washed with PBT 3 times for a total 15 
minutes, followed by incubations with fluorescence conjugated secondary 
antibodies for 40 minutes at room temperature. DAPI staining was performed 
after washing off the secondary antibodies. The slides then were washed with 
PBT 3 times, 5 minute each, and cover-slipped in a drop (8-12µL) of 
ProLong® Gold Antifade mounting media (Invitrogen™, P36930), then cured 
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overnight at room temperature. The slides were imaged on a Zeiss LSM 880 
laser-scanning microscope. Airyscan detector array was used to image the 
cytoskeletons. Standard pinhole was used to image the various markers for 
lineages, proliferation and apoptosis. Antibodies used here are listed in the 
Table 1. 
 
Expression analysis 
EBs were harvested and total RNA was isolated using an RNeasy mini plus 
kit (Qiagen, 74134) following the manufacturer’s instructions. 10-20 ng of total 
RNA was used per reaction, and quantitative RT-PCRs were performed on a 
7500 Fast Real-Time PCR System (Applied Biosystems™, 4351107) using 
the Power SYBR Green RNA-to-CT1-Step Kit (Life technologies, 4389986). 
Three technical replicates were performed for each gene target tested and 
quantification using Pbgd as a reference gene. A two-tailed Student t-test was 
used for pair-wise comparisons. The expression primer sequences are listed 
Table 2. 
 
RNA sequencing and data analysis 
Total RNA was isolated as described above. The libraries were prepared 
using the Illumina TruSeq stranded total RNA kit according to the 
manufacturer’s protocol, except that the PCR amplification cycle was reduced 
to 8. The libraries were loaded on cBot (Illumina) at final concentration of 10 
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pM to perform cluster generation, followed by 76 bp pair-ended sequencing 
on HiSeq 2500 (Illumina). Three independent experiments were included.  25-
41 million pairs of reads were generated per sample. Each pair of reads 
represents a cDNA fragment from the library. 
 
Data analysis 
Mapping: The reads were mapped to mouse genome (mm10) by TopHat 
(version 2.0.10) (54) with an overall mapping rate of 84-94%. 72-91% 
fragments have both ends mapped to mouse genome.  
Differential Expression: The number of fragments in each known gene from 
GENCODE Release M8 (55) was enumerated using htseq-count from HTSeq 
package (version 0.6.0) (56). Genes with less than 10 fragments in all the 
samples were removed before differential expression analysis. The 
differential expression between conditions was statistically assessed by 
R/Bioconductor package DESeq (57) (version 1.16.0). Genes with FDR (false 
discovery rate) ≤ 0.05, fold change ≥ 2 and length > 200bp were called as 
differentially expressed.  
Principle Component Analysis (PCA): PCA was performed by R function 
prcomp using cpm (count of fragments in each gene per million of fragments 
mapped to all exons) values. The scale option was set as TRUE.  
Heatmap: The normalized counts from DESeq were used to generate 
heatmap by Cluster 3.0 (58) and Java Treeview (59). The values in each 
 26 
gene were centered by median and rescaled so that the sum of the squares 
of the values is 1.0.  
Gene Function and Pathway Analysis: The differential genes called by DESeq 
were used for Ingenuity Pathway Analysis (IPA) and Gene Set Enrichment 
Analysis (GSEA) (60).  
 
Chromatin immunoprecipitation, qPCR and deep sequencing 
5×106 ESCs (Gcn5fx/fx and Gcn5-/-) were seeded in 15mL differentiation media 
in a 10cm ultra-low attachment plate (Corning, 5539101) for differentiation. 
Cells were fed every other day. At day 5, EBs were collected in a 15mL falcon 
tube and washed once with 5mL PBS, then incubated with 1mL Accutase™ 
cell dissociation reagent (Gibco™, A1110501) at 37°C for 10 minutes. EBs 
were dissociated by pipetting then diluted 1:4 by the differentiation media to 
stop digestion, and pelleted at 200g for 5 minutes. The pellets were washed 
once in 1mL PBS, and chromatin immunoprecipitation (ChIP) was performed 
as previously described (61) with some modifications. Briefly, for crosslinking, 
each EB cell pellet was resuspended in 1.5mL media, a small aliquot (10µL) 
was set aside for cell count, then 100µL of 16% formaldehyde (Thermo 
Scientific™, PI28906) was added to make a final concentration of 1%, and 
the mixture was incubated for 10 minutes at room temperature on a rotator. 
178µL of 125 mM glycine was added to quench the crosslinking for 5 minutes. 
Cells were washed with 1mL ice-cold PBS containing protease inhibitor 
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cocktail (PI, Sigma, P8340). The washed, cross-linked cells were 
resuspended in swelling buffer (5 mM PIPES pH 8.0, 85 mM KCl and 1% 
NP40) at a concentration of 106cell/mL, and incubated for 20 minutes on ice. 
The crude nuclei were pelleted and lysed in nuclei lysis buffer (50 mM Tris-
HCl pH 8.0, 10 mM EDTA and 1% SDS) at a concentration of 106cell-
nuclei/200µL and sonicated using a Bioruptor® Plus sonication device 
(Diagenode B01020001). Total 15 minutes of sonication (3 rounds of 10 
cycles with 30 seconds on and 30 seconds off per cycle on the high setting) 
were applied to obtain chromatin fragments in the size of 150-300 bps. 
Sonicated samples were centrifuged to remove insoluble debris. 30ug of 
chromatin fragments were diluted 1:10 in ChIP Dilution Buffer (0.01% SDS, 
1% TritonX-100, 1mM EDTA, 20mM Tris-HCl, pH8.0 and 150mM NaCl) and 
were precleared with Dynabeads Protein A (Invitrogen™, 10002D) for 1 hour 
at 4°C. Precleared lysates were incubated with 1µg of anti-H3 or 3µg of anti-
H3K9ac overnight, followed by incubation with Dynabeads™ Protein A for 1 
hour at 4°C. Immunoprecipitates were washed as previously described (61). 
All solutions used in steps above were supplemented with PI. DNA was 
eluted in elution buffer (50mM NaHCO3 and 1% SDS) at room temperature 
for 15 minutes, de-crosslinked at 65°C overnight, treated with RNaseA for 1 
hour at 37°C and purified using a PCR purification kit (Qiagen, 28104).  
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For qPCR analysis, 2µL of input (2% input diluted100 x in water) or ChIP DNA 
was used for each reaction using a SYBR green PCR master mix kit (Life 
technologies, 4367659). Primers used for qPCR analysis are listed in Table 2. 
 
ChIP DNA from 4 independent replicative experiments, including 2 replicates 
for each isogenic pair (Gcn5fx/fx and Gcn5-/-), were used for deep sequencing. 
ChIP libraries were prepared using Kapa Hyper Preparation kit (KAPA 
Biosystems, Wilmington, MA) protocol for Illumina Platforms. Briefly, for each 
library, 5ng of ChIP DNA was end-repaired and 3’ adenylated using a 
proprietary master mix, and ligated to the specific NexTflex adaptors from 
Bioo Scientific (Bioo Scientific, Austin, TX). The adaptor ligated DNA was 
enriched using a KAPA Hyper Library Preparation kit (KAPA Biosystems, 
KK8502) with 5 cycles of PCR (1 cycle at 98°C for 45 seconds; 4 cycles of 
98°C for 15 seconds, 60°C for 30 seconds, and 72°C for 30 seconds; 1 cycle 
at 72°C for 1 minute), and purified with AmpureXP beads (Beckman Coulter, 
A63881). The library quality was validated on a 2200 TapeStation from 
Agilent Technologies (Agilent, Santa Clara, CA). Libraries concentrations 
were determined using a Kapa Library Quantification Kit (KAPA Biosystems, 
KK4933) and loaded on cBOT (Illumina) at final concentration of 1.5nM for 
cluster generation, then sequenced with 50bp single-read on a HiSeq3000 
sequencer (Illumina). 
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Data analysis 
Mapping:  Sequenced DNA reads were mapped to mouse genome mm10 
using bowtie (version 1.1.2) (62) with at most 2 mismatches allowed and only 
the reads that were mapped to unique position were retained. 34-47 million 
reads were generated per sample. 90-94% reads were mapped to mouse 
genome, with 73-84% uniquely mapped. To avoid PCR bias, for multiple 
reads that were mapped to the same genomic position, only one copy was 
retained for further analysis. 19-29 million reads were used in the final 
analyses.  
Peak Calling: H3K9ac peaks were detected by MACS (version 1.4.2) (63). 
The window size was set as 500 bp and the p-value cutoff was 1e-5. H3K9Ac 
peaks were initially called by comparing to the corresponding total H3. Then 
the peaks that overlapped ENCODE blacklisted regions (64) or were not 
called by comparing to the corresponding total input were removed.  
Differential Peak Calling: The peaks of all H3K9ac samples were merged and 
the numbers of reads in these merged peaks were counted for each H3K9ac 
sample. The count table was used to call differential H3K9ac peaks between 
Gcn5fx/fx and Gcn5-/- by edgeR (65). Batch effect among the 4 replicates was 
corrected following edgeR user’s guide. Peaks with FDR (false discovery 
rate) ≤ 0.05 were called as changed between Gcn5fx/fx and Gcn5-/-. Genes 
with differential peaks in promoter (defined as -1000 bp to +500bp from TSS) 
were called as associated with changed H3K9Ac.  
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Signal Landscape: Each read was extended by 150bp to its 3’ end. The 
number of reads on each genomic position was rescaled to normalize the 
effective library size by edgeR to 10M and averaged over every 10bp window. 
The normalized values were displayed in UCSC genome browser (66).  
Transcription Factor Binding: ENCODE ChIP-Seq Significance Tool (67) was 
used to identify enriched ENCODE transcription factors in the promoters of 
the genes associated with changed H3K9Ac. The promoter was defined as -
5000 bp to +2000 bp from TSS.  
 
Mass cytometry 
Sample preparation for mass cytometry was performed as in (68). Briefly, 
EBs were dissociated using Accutase, stained with cisplatin for viability at 
25µM for 1 minute at room temperature and then quenched using PBS 
containing 1%BSA. The cells were fixed 1.5% PFA for 10 minutes at room 
temperature, then permeabilized with methanol (1mL per million cells) and 
incubated overnight at 4°C. Samples were barcoded according to (69), pooled 
and antibody stained with the panel of antibodies in Table 2. Cells were 
stained with 1:2000191/193 Iridium (Ir) DNA intercalator (Fluidigm), 62.5nM final, 
for 10 minutes at room temperature. Samples and EQ Four Element 
Calibration Beads (Fluidigm) were combined and diluted with water to a 
concentration of 5×105 cells/ml and run at 45ul/min a CyTOF 2 mass 
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cytometer (Fluidigm). Data were normalized on bead passport using CyTOF 
software (v6.0.626, Fluidigm).  
 
Initial data processing and gating was done with FlowJo vX10.0. EQ Four 
Element Calibration Beads were removed and data were gated on singlets by 
Ir193 and Event Length parameters. Removal of dead cells was done in the 
Pt198 channel. SPADE analysis of the data was performed using SPADE 
V3.0 in MATLAB r2015b (Mathworks). SPADE tree construction was 
performed using agglomerative clustering on all markers listed in Table 1. 
Annotation of SPADE tree regions was done according to marker distribution 
and cell percentages in each region were calculated for all samples. 
Percentages were normalized relative to mean Gcn5fx/fx and statistical 
significance was determined by the Wilcoxon rank sum test performed in 
MATLAB using the ranksum function. 
 
Whole cell lysates and Nuclear extracts preparation 
For preparation of whole cell lysates (WCL), 5-10 million cells (EB or ESCs) 
were lysed in 1mL RIPA buffer (150mM NaCl, 50mM Tris-HCl pH7.9, 1% 
Triton X-100 and 1% sodium deoxycholate) containing PI and phosphatase 
inhibitor cocktail (Roche, 04906845001) on ice for 20 minutes, then sonicated 
briefly in a Diagenode Bioruptor® for 2.5 minutes (5 cycles with 30 seconds 
on and 30 seconds off per cycle on the high setting). The lysates were then 
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centrifuged at 21000g for 10 minutes to clear insoluble debris. The 
supernatants were WCL and transferred to fresh tubes for further analysis.     
 
Nuclear extracts (NE) were prepared following the Dignam and Roeder 
method (70) modified for ESCs. Briefly, cell pellets were resuspended in 5 
pellet volumes of ice-cold buffer A and incubated on ice for 15 minutes. The 
swollen cells were pelleted at 1000rpm for 10 min at 4°C on soft brake. 
Pellets were resuspended again in 3 pellet volumes of buffer A, and then 
homogenized in a glass homogenizer (1 mL Wheaton) with 20 strokes by a 
tight pestle. The homogenized cell suspension was collected and nuclei were 
pelleted by centrifugation at 21000g on soft brake for 20 minutes at 4°C. The 
supernatant (cytoplasmic fraction) was carefully removed and nuclei were 
then resuspended in 2 pellet volumes of buffer C and incubated on a vibrator 
at 4°C for 45 min. The mixtures were then centrifuged at 21000g for at least 
30 min at 4°C on soft brake. The supernatants were nuclear extracts and 
were carefully transferred to fresh tubes for further analysis.  
 
Protein concentration was determined by Bradford assays (Bio-Rad, 500-
0006). 
 
Immunoprecipitation (IP)  
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0.5 or 1mg of protein from WCL or NE were incubated with anti-HA-agaorase 
(Roche cat. #11815016001, pre-equilibrated with wash buffer 
contatining10mM HEPES pH 7.9, 1.5mM MgCl2, 300mM NaCl, 10mM KCl, 
0.2% Triton X-100 and PI) overnight at 4 °C on a rotator. For each IP, 5-10% 
input was set aside and 20µl HA-beads (50% slurry) were used. Beads were 
then collected by centrifugation at 2000rpm for 2 min, followed by 3 washes 
for a total of 30 min in wash buffer at 4°C. Washed beads were collected, and 
the immunoprecipitates were eluted using HA peptide (Roche cat. 
#11666975001) (200 µg/mL in elution buffer containing 10mM HEPES pH 
7.9, 1.5mM MgCl2, 100mM NaCl, 0.05% Triton X-100 and PI) for 1-2 hours 
on a vibrator at RT. ¼ eluate volume of 5x SDS sample buffer was added to 
the eluted immunoprecipitates and inputs, then the mixtures were heated at 
95°C for 10 min.  
 
Immunoblotting 
10-20µg of protein from WCLs or ½ volume of NE/IP products were resolved 
on 4-12% Bis-Tris protein gels (Invitrogen™ WG1402BOX). Proteins were 
transferred to nitrocellulose membranes (Invitrogen™, IB23001) using the 
iBlot2™ gel transfer device (Life Technology, IB21001). Membranes were 
blocked and incubated with primary antibodies following standard procedures. 
Primary antibodies were detected using peroxidase-conjugated secondary 
antibodies (1:8000). Amersham ECL prime western blotting detection reagent 
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(GE Healthcare, RPN2232) was used according to the manufacturer's 
instructions. Antibodies used for Immunoblotting are listed in Table 2. 
 
Creation of J1ESCs expressing FHGCN5 
Generation of FHGCN5 expressing J1ESCs by CRISPR/CAS9 targeting  
The GCN5 guide RNA construct (gBlock-GCN5) targeting exon 1 of the 
mouse GCN5 gene were designed and generated as described in the MIT 
CRISPR tool (71). The cDNA  
(5’_TGTACAAAAAAGCAGGCTTTAAAGGAACCAATTCAGTCGACTGGATC
CGGTACCAAGGTCGGGCAGGAAGAGGGCCTATTTCCCATGATTCCTTCA
TATTTGCATATACGATACAAGGCTGTTAGAGAGATAATTAGAATTAATTTG
ACTGTAAACACAAAGATATTAGTACAAAATACGTGACGTAGAAAGTAATA
ATTTCTTGGGTAGTTTGCAGTTTTAAAATTATGTTTTAAAATGGACTATCA
TATGCTTACCGTAACTTGAAAGTATTTCGATTTCTTGGCTTTATATATCTT
GTGGAAAGGACGAAACACCGTGCGCTGCCGGGACCGGGTTGTTTTAGA
GCTAGAAATAGCAAGTTAAAATAAGGCTAGTCCGTTATCAACTTGAAAAA
GTGGCACCGAGTCGGTGCTTTTTTTCTAGACCCAGCTTTCTTGTACAAAG
TTGGCATTA) was synthesized by IDT and was subcloned into TOPO-TA 
cloning vectors (Invitrogen™ K452040) following the manufacturer’s 
instructions, and then verified by DNA sequencing at the MB Core at UT-MD 
Anderson Cancer Center (UTMDACC) Science Park before being used for 
ESC nucleofection.  
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A single stranded oligo template for homologous recombination/repair 
(ssDNA-N-FHGCN5-ex1) was synthesized by BioSynthesis. The sequence 
(5’_GTTGCCCATGCGGCCCTAGGGCTGGGAGCGCGGCGCCGCTCCGCT
GCGGGGGAGGCCATGGACTACAAGGACGACGATGACAAGTCGGCCGC
TGGAGGATATCCCTACGACGTGCCCGACTACGCCGCGGAACCTTCCCA
GGCCCCAAATCCGGTGCCGGCCGCGCAGCCCCGGCCCCTTCACTCCCC
AGCCCCTGCCCCAACTTCG) contains a FLAG-HA tag sequence (a silent 
mutation within to create a EcoRV site unique from the wild type sequence) 
placed in frame immediately after the ATG of Kat2a, and a silent mutation in 
the 3’ sequence to prevent targeting by the gBlock-GCN5/CAS9.  
 
J1 ESCs were electroporated with the gBlock-GCN5 and CAS9-GFP 
plasmids (a kind gift by the Chen Laboratory at UTMDACC Science Park) and 
ssDNA-N-FHGCN5-ex1 template using a Lonza Nucleofector™ following the 
manufacturer instructions. 48 hours after nucleofection, the GFP+ cells were 
sorted and seeded by FACS in 96-well plates. Single clones were expanded 
and genomic DNA extracted and screened by PCR using primers 
5’_GGCCCGTGACGCCTGCGC (forward) and 
5’_CTTCTTGGCACGCGGCAGACC (reverse). The targeted loci of positive 
clones were verified for correct, in-frame insertion by DNA sequencing at 
Molecular Biology Core Facility (MB Core) at UT-MD Anderson Science Park. 
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Southern blotting was performed to determine the correct homologous 
recombination using a DIG High Prime DNA Labeling and Detection Kit 
(Roche, 11585614910) following the manufacturer’s instructions. 6µg of 
genomic DNA was used for each reaction. Primers 
5’_CTCCTGGGTTTCTGGGACTG (forward) and 
5’_ACAGCGACTTGAGTGTTTTTGC (reverse) were used to generate 5’-
probe, and 5’_GCAAGTGTAATGGCTGGAAAAAC (forward) and 
5’_GGGCTGGGAAGAACAGAAGAG (reverse) were used to generate 3’-
probe by standard PCR. The PCR products (4µL for each reaction) were 
subcloned into TOPO-TA cloning vectors (Invitrogen™ K452040) following 
the manufacturer’s instructions, and then verified by DNA sequencing at the 
MB Core. 
 
Ectopic expression of Flag-HA-GCN5 (FHGCN5) in J1 ESCs 
cDNA of mouse Kat2a from our lab (36) was subcloned into pCDH-EF1a-FH-
IRES-puro vectors that were kindly provided by Dr. Junya Tomida from the 
Wood Laboratory. The plasmids (FH-vector or FHGCN5 construct) were 
introduced to J1ESCs by lenti-viral infection and FHGCN5 expressing cells 
selected following the previously described procedures (72), with 
modifications in the following: 1) the infection time was reduced to 48 hours to 
meet the ESC media refreshment schedule (every two days), and 2) the 
puromycin concentration was reduced to 1µg/mL to allow speed selection 
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(50% killing in 2 days) without affecting normal growth of puromycin resistant 
ESCs .   
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Table 1 Antibodies used in this study 
Antibodies Manufacturers Catalog No. Applications 
Anti-GCN5 Cell Signaling 
Technology 
3305 Westerns, 1:500 
ChIP, various 
amounts 
Anti-phospho-ERK Cell Signaling 
Technology 
4370 Westerns, 1:1000 
Anti-ERK Cell Signaling 
Technology 
4695 Westerns, 1:2000 
Anti-phospho-AKT Cell Signaling 
Technology 
4060 Westerns, 1:1000 
Anti-AKT Cell Signaling 
Technology 
4691 Westerns, 1:2000 
Anti-phospho-p38 Cell Signaling 
Technology 
4511 Westerns, 1:1000 
Anti-p38 Cell Signaling 
Technology 
9212 Westerns, 1:2000 
Anti-phospho-c-RAF 
(S259) 
Cell Signaling 
Technology 
9421 Westerns, 1:1000 
Anti-c-RAF Cell Signaling 
Technology 
53745 Westerns, 1:2000 
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Anti-FGFR1 Cell Signaling 
Technology 
9740 Westerns, 1:500 
Anti-TRRAP Cell Signaling 
Technology 
3967 Westerns, 1:300 
Anti-ADA2B Abcam ab57953 Westerns, 1:500 
Anti-H3 Abcam ab1791 ChIP,  
1µg/30µg 
Chromatin 
Anti-H3K9ac Millipore 07-352 ChIP,  
3µg/30µg 
Chromatin 
Anti-SOX1 BD Biosciences 560749 IF, 1:100 
Mass Cytometry, 
10µL 
Anti-GATA4 Abcam ab84593 IF, 1:100 
Anti-Laminin Millipore AB2034 IF, 1:100 
Anti-Vimentin Abcam ab92547 IF, 1:300 
Alexa Fluor 568 
Phalloidin 
ThermoFisher 
Scienctific 
A12380 IF, 1:300 
Donkey anti-rabbit IgG 
Alexa Fluor® 488 
ThermoFisher 
Scienctific 
A21206 IF, 1:500 
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Donkey anti-rabbit IgG 
Alexa Fluor® 555 
ThermoFisher 
Scienctific 
A31572 IF, 1:500 
Donkey anti-rabbit IgG 
Alexa Fluor® 647 
ThermoFisher 
Scienctific 
A31573 IF, 1:500 
Donkey anti-mouse 
IgG Alexa Fluor® 488 
ThermoFisher 
Scienctific 
A21202 IF, 1:500 
Goat Anti-mouse IgG 
Alexa Fluor® 568 
ThermoFisher 
Scienctific 
A11004 IF, 1:500 
Donkey anti-mouse 
IgG Alexa Fluor® 647 
ThermoFisher 
Scienctific 
A31571 IF, 1:500 
Anti-NANOG Cell Signaling 
Technology 
3580 Mass Cytometry, 
5µL 
Anti-OCT4 Santa Cruz sc-5279 Mass Cytometry, 
10µL 
Anti-SOX2 R&D Systems MAB2018 Mass Cytometry, 
10µL 
Anti-GATA6 R&D Systems AF1700 Mass Cytometry, 
10µL 
Anti-PAX3 R&D Systems MAB2457 Mass Cytometry, 
10µL 
Anti-PAX6 R&D Systems AF8510 Mass Cytometry, 
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10µL 
Anti-BRACHYURY R&D Systems AF2085 Mass Cytometry, 
10µL 
Anti-HAND1 R&D Systems AF3168 Mass Cytometry, 
10µL 
Anti-FOXA2 BD Biosciences 561580 Mass Cytometry, 
10µL 
Anti-GATA4 BD Biosciences 560327 Mass Cytometry, 
10µL 
Anti-SOX17 BD Biosciences 561590 Mass Cytometry, 
10µL 
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Table 2 Primers used for PCR analyses 
qRT-PCR Primers for expression analysis 
Oligo name Sequences (5’-3’) Source 
Cdh2 fwd CAGGGTGGACGTCATTGTAG  (73) 
Cdh2 rev AGGGTCTCCACCACTGATTC 
Fgf3 fwd ACAGGCGGGAAGCATATGTA Originally 
designed Fgf3 rev GGCCATGAACAAGAGAGGAC 
Fgf4 fwd CGTTGTAGTTGTTGGGCAGA Originally 
designed Fgf4 rev TTCTTCGTGGCTATGAGCAG 
Fgf5 fwd GCGATCCACAGAACTGAAAA  (73) 
Fgf5 rev ACTGCTTGAACCTGGGTAGG 
Foxa2 fwd GAGCAGCAACATCACCACAG Originally 
designed Foxa2 rev CGTAGGCCTTGAGGTCCAT 
Gata6 fwd CAAAAGCTTGCTCCGGTAAC  (73) 
Gata6 rev TGAGGTGGTCGCTTGTGTAG 
Grb10 fwd ATCTTCCGTTTCCCATTTCC Originally 
designed Grb10 rev CTCCTTACCTCCTCCTCCGA 
Otx2 fwd CTTCATGAGGGAAGAGGTGG Originally 
designed Otx2 rev GGCCTCACTTTGTTCTGACC 
Pbgd fwd CAGGGTACAAGGCTTTCAGC Originally 
designed Pbgd rev CGGAGTCATGTCCGGTAAC 
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Prcka fwd AACGAACTCATGGCACCTCT Originally 
designed Prcka rev CACTGCACCGACTTCATCTG 
Sox1 fwd CCTCGGATCTCTGGTCAAGT  (73) 
Sox1 rev GCAGGTACATGCTGATCATCTC 
Spry4 fwd AGGTCCTGAACTGCACCAAG Originally 
designed Spry4 rev GGGGATTTACACAGACGTGG 
Stat3 fwd CTGCTCCAGGTAGCGTGTGT Originally 
designed Stat3 rev CTCAGCCCCGGAGACAGT 
T fwd CTGGGAGCTCAGTTCTTTCG  (73) 
T rev CCCCTTCATACATCGGAGAA 
qPCR primers for ChIP analysis 
Oligo name Sequences (5’-3’) Source 
Asf1b fwd CAGCCTTCTTTCTGCCTTTC Dr. Calley Hirsch 
Asf1b rev GGGAGGTGTATGAGATCGACA 
Alcam fwd AACGAGTGTCCAAAGCCAAG Dr. Calley Hirsch 
Alcam rev GAGGATGCGGAGAGCCTAT 
Havcr2 fwd CCTGACCTGACCAAGAAACC Dr. Calley Hirsch 
Havcr2 rev GGCTACCAAGGCTGTCCTAT 
Meg3 fwd AGGGAAGGGCTGCATTATTT Dr. Calley Hirsch 
Meg3 rev CTTACTCGCGTGATCCCATT 
Tbx3 fwd TTGGATGGCTGAGGCCTTTCA Dr. Calley Hirsch 
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Tbx3 rev AAAGTCGCCTCTAGGTGGCTGAT 
Dicer fwd CGAGTTCCCACTTCAACAATGC Dr. Calley Hirsch 
Dicer rev TTAGCCTCTCTGACACCACA 
Usp10 fwd TGGAAGAGCAGTCAGTGCTCTT Dr. Calley Hirsch 
Usp10 rev TTCTCTTTGTAGCCCTGGCT 
Intergenic fwd AAGGGGCCTCTGCTTAAAAA Dr. Calley Hirsch 
Intergenic rev AGAGCTCCATGGCAGGTAGA 
Grb10_2 fwd CCCAACTCCTACCTGACGTG Originally 
designed Grb10_2 rev TTTCTCCGTTGTGACTCGTG 
Grb10_3 fwd GAAGACCGACCGGACCTG Originally 
designed Grb10_3 rev CAGCCCAGGAAGAGTTTGAA 
Spry4_1 fwd AGCTTAACCCGTGATTGCTG Originally 
designed Spry4_1 rev AACAACCTCCACCCCTCTTT 
Spry4_2 fwd ATGAATGGGTGGGCACAAGT Originally 
designed Spry4_2 rev AGCAATCACGGGTTAAGCTC 
Fmn2 fwd CCTACTTGGTTGCAGGAGGA Originally 
designed Fmn2 rev ATGGCTGCACAGGACTCAG 
Etv5 fwd AGCACACACGTCCCCATT Originally 
designed Etv5 rev AGCTGGATTTGCCTGAAGAC 
Pcna fwd CGGAGTTGTGGCGACTAGAT Originally 
designed Pcna rev GCTTCTGCATCGTGAATCG 
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Neg. Chr1 fwd ATTCAGGCCATCAAGAGGAC Originally 
designed Neg. Chr1 rev GGGGGCTTTGTAAAAAGTTAATG 
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Chapter 3. Gcn5 loss leads to defective morphogenesis of EBs at 
epiblast stage  
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3.1 Embryoid body (EB) assay models embryogenesis leading to 
gastrulation 
As aforementioned, ES cells form distinct 3-D structures (EBs) in suspension 
culture upon LIF and 2i removal. In a day or two into the differentiation 
course, ES cells readily aggregate, followed by the first lineage segregation 
that gives rise to the visceral endoderm (VE), a single layer of cuboidal 
epithelial like cells surrounding the ICM like inner cells. The basement 
membrane (BM) is then deposited in between the VE and the inner cells 
around day 3. During day 4-6, the inner cells undergo morphogenesis to 
become a columnar epithelial layer termed epiblast, lining up along the 
interior side of the BM, and the center cells that do not contact the BM are 
cleared by apoptosis to form a cystic cavity. The epiblast cells then further 
differentiate into lineages expressing marker genes for germlayers parallel to 
those that arise from embryonic gastrulation (51). This differentiation course 
progresses in a manner that recapitulates embryonic transitions from 
formation of the ICM through gastrulation, allowing us to define the molecular 
events that might contribute to the death of Gcn5-/- embryos shortly after 
gastrulation in vitro.   
 
3.2 Gcn5-/- EBs do not exhibit defective proliferation or apoptosis at day5 
We used isogenic ES cells (Gcn5fx/fx and Gcn5-/-) for EB differentiation, and 
observed that Gcn5-/- EBs were much smaller than Gcn5fx/fx control EBs at 
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day 9, when all three germ layer cells should be formed. To define the time of 
onset of abnormalities in the null EBs, we examined earlier time points.  At 
day 3, Gcn5-/- EBs were not obviously different from control EBs. They 
appeared to be in similar size as the controls, and to have similar density 
under the bright field lighting, indicating the aggregate structures were not 
different from those of the controls at day 3. However, by day 5, Gcn5-/- EBs 
appeared to suffer more breakage than control EBs (Figure 4), as indicated 
by the increased smaller, irregularly shaped pieces evident in the Gcn5-/- EB 
culture.  Either or both of the following possibilities may contribute to these 
morphological defects observed in the Gcn5-/- EBs. One is that the null EBs 
were more structurally fragile, which leads to increased collapse of EB 
populations. Alternatively these defects could reflect increased cell death 
and/or proliferation arrest.  
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Figure 4 Gcn5-/- EBs have abnormal morphology during early stages of 
differentiation  
Bright field images showing differentiating EBs at days 3, 5, and 9, comparing 
EB morphology between Gcn5fx/fx and Gcn5-/- EBs. Scale bar, 200µM.  
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To better define the origin of the defects, we first examined expression of 
markers for proliferation and apoptosis by immunostaining and immunoblots. 
No increase was observed in the number of cleaved Caspase-3 (CC3) 
positive cells at day 5 in Gcn5-/- EBs, nor was the expression of active Lamin 
A (C-LMNA) increased, as determined by immunostaining  (CC3) and 
immunoblots (C-LMNA), indicating that Gcn5 loss does not lead to increased 
apoptosis during early EB differentiation. Levels of H3S10p, a marker for 
mitotic cells, also did not change in the Gcn5-/- EBs at day 5 compared to the 
control EBs, indicating that deletion of Gcn5 does not lead to decreased cell 
proliferation in day 5 EBs (Figure 5, A and B).  
 
We also examined the levels of H3K9ac in day5 EBs by immunoblotting, as it 
is one of the primary substrates of GCN5, but observed no decrease (Figure 
5C) in Gcn5-/- EBs. This observation is consistent with the presence of other 
HATs in the EBs, for example, PCAF, which is a highly similar homolog of 
GCN5 in mammals.  
 
Altogether these data indicate that Gcn5 is required for normal morphology, 
but not proliferation or survival, of EBs during the early stages of 
differentiation. In addition, loss of Gcn5 alone does not cause decreases in 
global levels of H3K9ac much likely due to presence of other HATs. 
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Figure 5 Loss of Gcn5 does not inhibit proliferation or promote 
apoptosis at an early differentiation stage 
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(A and B) Immunoblots and immunostaining of mitotic marker (H3S10p) and 
apoptosis markers (cleaved-Caspase3, CCP3; cleaved-Lamin A) showed no 
differences between Gcn5fx/fx and Gcn5-/- EBs at day 5. Scale bars, 200mM. 
(C) Immunoblots of H3K9ac and H3 in day 5 EBs demonstrated no global 
changes upon loss of Gcn5 at early stage of differentiation. 
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3.3 Gcn5-/- epiblast is severely disorganized at day 5 
The unaffected proliferation or apoptosis observed in the Gcn5-/- EBs at day 5 
pointed to the possible defective structures in the null EBs. By day 5, the VE 
and the BM are already formed, while inner cells undergo morphogenesis to 
give rise to epiblast with a distinct columnar epithelial like organization. To 
investigate whether the abnormal morphology of Gcn5-/- EBs observed under 
the bright field microscope reflects defective formation of these structures, we 
performed immunostaining with markers well characterized in the literature.  
 
GATA4 is a transcription factor that marks the endodermal populations during 
early development (74) and was used as a marker for the VE. Laminin was 
used as a marker for the BM, as it is an integral component of basement 
membrane (75). Since a majority of the inner cells express early 
neuroectodermal markers by day 5, we used immunostaining for SOX1 to 
visualize the organization of epiblast cells. All sections were counterstained 
with DAPI to visualize the nuclei. Laminin staining of the BM showed little 
difference between the null and control EBs (Figure 6A). GATA4 staining was 
also very similar in Gcn5fx/fx and Gcn5-/- EBs. These observations indicated 
normal formation and organization of the BM and VE in Gcn5-/- EBs. In sharp 
contrast, SOX1 staining revealed severe disorganization of the columnar 
epithelial morphology of the epiblast in Gcn5-/- EBs (Figure 6B). Altogether, 
 54 
these data clearly indicate that Gcn5 is required for normal formation and 
organization of the epiblast during early differentiation.  
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Figure 6 Severely disorganized epiblast of Gcn5-/- EBs at day 5 
Representative immunofluorescence (IF)/confocal images of EB architecture 
in day 5 Gcn5fx/fx and Gcn5-/- EBs, with Laminin (red) staining for BM (A), 
GATA4 (green) staining for VE, and SOX1 (magenta) and DAPI (blue) 
staining for nuclei of the epiblast (B). Scale bars, 100μM in (A) and 50μM in 
(B).  
 56 
 
 
 
 
 
 
 
 
 
Chapter 4. Gcn5-/- EBs have impaired capacities in differentiation 
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4.1 Gcn5-/- expresses lower levels of epiblast-specific marker genes at 
day 5 
The epiblast expresses specific genes, including Fgf5 and Otx2, and 
expression levels of these genes usually peaks around day 5 in EBs or the 
equivalent embryonic stage (46, 73, 76, 77). The severe disorganization of 
the epiblast cells in the Gcn5-/- EBs indicated that they might express these 
markers abnormally. To test this possibility, we used qRT-PCR to measure 
expression levels of Fgf5 and Otx2 in the Gcn5-/- EBs at day 5, compared to 
the Gcn5fx/fx EBs, and observed lower expression of both genes (Figure 7). 
These results suggested that the Gcn5-/- epiblasts may have impaired 
functions, which might compromise subsequent formation of the three germ 
layers (34, 78).  
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Figure 7 Epiblast marker genes are expressed at lower levels in Gcn5-/- 
EBs 
Gene expression analysis by qRT-PCR for epiblast marker genes, Fgf5 and 
Otx2, normalized to a house-keeping gene Pbgd. 
Data are presented as Mean ± SD from 3 independent experiments. 
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4.2 Delineating heterogenic populations in day5 Gcn5-/- EBs by mass 
cytometry  
To more fully assess the composition of cell populations within the control and 
null EBs at day 5, when the epiblast cells have begun to adopt fates toward 
germlayers, we utilized state-of-the-art mass cytometry. Mass cytometry 
fuses two advanced technologies, flow cytometry and mass spectrometry, to 
provide measurement of over 40 simultaneous cellular parameters at single-
cell resolution, significantly augmenting the ability of cytometry to evaluate 
complex cellular systems and processes that, at the same time, leverages 
precision from mass spectrometry (79). As such, mass cytometry offers 
unique and powerful abilities to investigate the cellular identities at the level of 
proteins and properties of proteins (e.g. posttranslational modifications of 
proteins), and monitor behavior of cells in response to intrinsic or 
environmental cues, such as differentiation of ESCs. The high dimensionality 
of mass cytometry is afforded by antibodies labeled with non-radioactive 
isotopes of rare earth metals with distinct atomic masses, which can be 
distinguished by mass cytometry and serve as reporters for the labeled cells 
(79). This approach allowed us to delineate and compare the compositions of 
heterogeneous populations in day 5 EBs. Application of SPADE analytic tool 
(80) then allowed us to visualize, delineate and quantify each lineage 
population in EBs and assess how loss of Gcn5 affects a given population 
during differentiation.  
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We first tested an array of antibodies against each germlayer and pluripotent 
cells using differentiated and undifferentiated wild type ESCs, and selected 
those that specifically identify their intended cell populations (Table 3 and 
Figure 8) for day 5 EBs. Subsequent mass cytometry data from Gcn5fx/fx and 
Gcn5-/- EBs were analyzed with SPADE and represented as a comparative 
graphical tree plot (Figure 9A, Gcn5fx/fx vs. Gcn5-/-, blue represents 
subpopulations decreased in the nulls, and red represents subpopulations 
increased in the nulls), allowing us to visualize the cell populations impacted 
by Gcn5 loss. Each population of Gcn5-/- EBs was also quantified using 
SPADE in fold change relative to that of Gcn5fx/fx EBs (Figure 9B). The results 
indicated that the Gcn5-/- EBs contained significantly lower numbers of 
endodermal and mesodermal cells relative to the control EBs, as shown by 
the blue nodes in the endoderm and mesoderm regions in Figure 9A and the 
P-Value (<0.05) in Figure 9B. However, only one or two blue nodes were 
evident in the mesoderm region of the tree plot (Figure 9A), in contrast to the 
significant decreased population in Gcn5 null EBs as shown by the 
quantification (Figure 9B). This discrepancy may be explained by the small 
size of the mesodermal population relative to the other lineage populations at 
day 5, which may make this population more sensitive to expression changes 
of the markers (Brachyury and HAND1) in the statistical test for significance. 
For the ectoderm population, although there was no difference between 
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Gcn5fx/fx and Gcn5-/- EBs for the entire lineages population (Figure 9B), there 
were indeed decreased SOX1+ (Figure 9A, blue nodes in ectoderm region) 
and increased SOX1- subpopulations (Figure 9A, red nodes in ectoderm 
region) in the null EBs. However, because the overall percentile of the 
ectodermal cells (labeled by SOX1, PAX3 and PAX6, Table 3) was quantified 
altogether in SPADE, the changes in SOX1 subpopulations of the null EBs 
were not reflected in the comparison of the overall ectodermal populations 
(Figure 9B).  
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Table 3 Lineage markers used for mass cytometry 
  Antibodies Expression Isotope Label 
Anti-NANOG Pluripotency 163Dy 
Anti-OCT4 Pluripotency 146Nd 
Anti-SOX2 Pluripotency 147Sm 
Anti-SOX1 Ectoderm 176Yb 
Anti-PAX3 Ectoderm 170Er 
Anti-PAX6 Ectoderm 153Eu 
Anti-FOXA2 Endoderm 150Nd 
Anti-GATA6 Endoderm 142Nd 
Anti-GATA4 Endoderm 171Yb 
Anti-SOX17 Endoderm 175Lu 
Anti-Brachyury (T) Mesoderm 156Gd 
Anti-HAND1 Mesoderm 158Gd 
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Figure 8 Using mass cytometry to delineate heterogeneous cell 
populations in differentiating ESCs 
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Proof-of-principle experiment showing lineage markers are enriched for 
corresponding cell populations.  
Upper panels: ES cells, NANOG, OCT4, and SOX2 enriched in pluripotent 
region defined in red.  
Middle panels: differentiated EBs, SOX1, PAX6 and PAX3 enriched in 
ectoderm region (blue).  
Lower panels: differentiated EBs, SOX17, GATA4, GATA6 enriched for 
endoderm region (green) and Brachyury enriched in mesoderm region 
(purple). 
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Figure 9 Changes in cell population composition in Gcn5-/- EBs at the 
epiblast stage 
(A) SPADE plot showing decreased endoderm and mesoderm populations in 
the Gcn5-/- EBs at day 5; (B) Quantitation of fold changes in cell numbers of a 
given population in Gcn5-/- EBs relative to control. 
Data are presented as Mean ± SD from 4 independent experiments. 
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4.3 Gcn5-/- EBs have impaired abilities to differentiate into germlayers 
Both the population analysis and the epiblast marker mRNA analysis 
indicated clearly that the Gcn5-/- EBs likely have impaired ability to 
differentiate further into mature germlayer cells. To test this idea, we analyzed 
expression of germlayer marker genes in late-stage (days 9 and 12) EBs 
using qRT-PCR. We observed decreased expression of all germlayer 
markers analyzed in null EBs in both day 9 and day 12, including ectoderm 
(Sox1, Cdh2), endoderm (Gata6, Foxa2) and mesoderm (T) (Figure 10). 
These findings validated our prediction that the Gcn5-/- EBs have 
compromised potentials in differentiation, indicating that Gcn5 is required for 
normal differentiation of the germlayer lineages during EB formation.   
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Figure 10 Impaired differentiation abilities of Gcn5-/- EBs 
qRT-PCR plots showing decreased expression of marker genes for ectoderm 
(Sox1, Cdh2), endoderm (Foxa2, Gata6), and Mesoderm (T) in late stage 
EBs (days 9 and 12), normalized to Pbgd. 
Data are presented as Mean ± SD from 3 independent experiments. 
 
  
 68 
 
 
 
 
 
 
 
 
 
 
Chapter 5. Gene expression profiling points to a regulatory role of Gcn5 
in FGF signaling pathway 
  
 69 
5.1 Overview of differentially expressed genes upon Gcn5 loss at day 3 
and day 5 
GCN5 is characterized primarily as a transcriptional co-activator in the context 
of the SAGA and ATAC complexes (14, 81, 82), so to better understand the 
molecular basis underlying the defects in structures and differentiation 
capacity caused by Gcn5 loss in early EBs, we compared gene expression 
profiles in day 3 and day 5 control and null EBs using RNA-seq. Total RNA 
was isolated from three technical replicates of Gcn5fx/fx and Gcn5-/- EBs, and 
key gene expression changes were confirmed using a second biological 
replicate by quantitative real-time polymerase chain reaction (qRT-PCR). 
These time points were chosen to define both early events (day 3) and events 
that coincide with the onset of the abnormal phenotype of Gcn5-/- EBs (day 5).  
Principle-component analysis (PCA) revealed significant differences in gene 
expression profiles for all EBs between day 3 and day 5, consistent with 
developmental progression over time. However, gene expression profiles of 
null and control EBs were much more similar at day 3 than at day 5 (Figure 
11A). Further, more genes (754 genes) exhibited altered expression at day 5 
in mutant EBs than at day 3 (158 genes) (Figure 11, B and C). These data 
indicate that Gcn5 loss impacts more significantly on gene expression at day 
5, consistent with the timing of the onset of null morphological phenotype. 
Therefore, we focused further detailed analyses on differences in gene 
expression observed at day 5.   
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Figure 11 Overview of altered gene expression profiles in early stage 
Gcn5-/- EBs 
(A) Principle component analysis (PCA) plots showing variance of expression 
profiles among replicative samples, and increased differences in profiles 
between Gcn5fx/fx and Gcn5-/- EBs at day 5 (D5, Appendix 1) compared to day 
3 (D3, Appendix 2), (n=3).  
(B) Break down of the numbers of down or up regulated genes upon Gcn5 
loss at days 3 and 5. 
(C) A Venn diagram view of (B). 
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5.2 Gene ontology and pathway analysis reveal deregulated FGF 
signaling in Gcn5-/- EBs at day5 
Gene set enrichment analysis (GSEA) revealed significant down regulation of 
several biological processes in the null EBs at day 5, with multicellular 
organismal development (MOD) and cell surface receptor linked signal 
transduction (CSRLST) among the most affected (Figure 12).  In the MOD 
category, 15 out of 50 genes were among the core enrichment group in the 
mutant EBs, including Pax5, Msx2, Gli1, Spry2 and Mest, which are all 
important for early development (83-87) (Figure 12 A and B, and Table 4). In 
the CSRLST category, 7 out of 30 genes are in the core enrichment group, 
including Grb10, the most down regulated gene in the null EBs (Figure 12 C 
and D, and Table 5). Consistent with these results, Ingenuity Pathway 
Analysis (IPA) identified a number of signaling pathways to be significantly 
altered in the Gcn5 null EBs. Interestingly, 4 of the 7 top ranked affected 
pathways were intimately linked to FGF signaling, including Regulation of 
epithelial-to-mesenchymal transition (EMT), STAT3, FGF and Growth 
Hormone Signaling pathways (Figure 13A).  
 
5.3 Validating Changes in Expression of FGF pathway genes by qRT-
PCR 
FGF ligands and their receptor tyrosine kinases (RTKs) exert control of 
multiple developmental processes including proliferation, survival, 
 73 
differentiation and migration (88). Expression of key genes in these pathways 
was markedly altered in the Gcn5-/- EBs as identified by the RNAseq. Using 
qRT-PCR with a second pair of isogenic cells, we validated several key genes 
of the FGF pathway from the RNAseq. For example, expression of Fgf3 and 
Fgf4 was significantly downregulated in the Gcn5-/- EBs, as was expression of 
a negative regulator of these pathways, Spry4 (89).  Grb10, which is a 
negative regulator of insulin-AKT signaling (90, 91), was also downregulated 
in the Gcn5-/- EBs.  Conversely, effector genes such as Stat3 and Prkca were 
markedly up regulated (Figure 13B). Together, these data strongly indicate 
that FGF signaling is abnormal in the Gcn5-/- EBs at day 5.  
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Figure 12 Top enriched processes identified by GSEA in the control EBs 
compared to Gcn5-/- EBs at day 5 
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(A and B) GSEA enrichment profile (A) and heatmap (B) showing the 
multicellular organismal development gene set is enriched in the control EBs 
comparing to Gcn5-/- EBs at day 5.  
(C and D) GSEA enrichment profile (A) and heatmap (B) showing the cell 
surface receptor linked signal transduction gene set is enriched in the control 
EBs comparing to Gcn5-/- EBs at day 5.  
Color code: Red, positively correlated with Gcn5fx/fx, Blue, negatively 
correlated with Gcn5-/-.  
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Table 4 Gene list of GSEA set Multicellular Organismal Development 
GENE 
SYMBOL 
RANK 
IN 
GENE 
LIST 
RANK 
METRIC 
SCORE 
RUNNING 
ES 
CORE 
ENRICHMENT 
PAX5 2 3.143970966 0.026952207 Yes 
MSX2 6 2.793720722 0.048327506 Yes 
HMGA2 10 2.60679245 0.067849986 Yes 
ZIC1 13 2.445233583 0.08787638 Yes 
SLIT2 14 2.438150406 0.11204308 Yes 
COL2A1 20 2.313369513 0.12444666 Yes 
KIRREL3 23 2.268698215 0.14272325 Yes 
GLI1 25 2.187872887 0.16230397 Yes 
TGM3 27 2.169377327 0.18170136 Yes 
SPRY2 31 2.100628138 0.1962068 Yes 
DPYSL5 33 2.077706337 0.21469556 Yes 
MEST 44 1.956736565 0.21303791 Yes 
MAB21L2 54 1.908952236 0.21301188 Yes 
TWIST1 55 1.892674208 0.23177189 Yes 
FABP5 57 1.876633048 0.24826762 Yes 
OTX2 74 1.794868827 0.23237398 No 
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PTCH2 81 1.774591208 0.23733197 No 
NDP 101 1.670649171 0.21389128 No 
FGF17 117 1.568956375 0.19786368 No 
EPHA2 127 1.409094691 0.19288312 No 
NR0B1 134 1.361806631 0.19374964 No 
FGF5 160 1.005194783 0.15108146 No 
LRMP 162 1.003890395 0.15892665 No 
TDGF1 166 0.946586847 0.16199334 No 
ALOX12B 174 -1.041075826 0.15757555 No 
TRIM14 181 -1.18687892 0.1567082 No 
ANXA2 198 -1.373691678 0.13663988 No 
SGCD 201 -1.397668123 0.1462829 No 
ETS1 217 -1.476131439 0.12933522 No 
ERG 222 -1.50989151 0.13588007 No 
RAPGEFL1 227 -1.535297155 0.14267674 No 
IGFBP3 249 -1.666120291 0.11498063 No 
SGCE 251 -1.675953865 0.12948726 No 
JAG2 253 -1.683297992 0.14406668 No 
SGCG 282 -1.763670683 0.10260065 No 
MYH3 290 -1.779546738 0.10550249 No 
IGFBP4 301 -1.796701074 0.10225859 No 
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CACNA1H 311 -1.824573159 0.10139622 No 
SHOX2 315 -1.830768824 0.11322682 No 
AEBP1 340 -1.907915235 0.08161158 No 
RASGRP4 376 -2.075456142 0.028499093 No 
NEUROG3 385 -2.098732948 0.032459423 No 
FGF11 389 -2.107631922 0.04703428 No 
ALDH3A2 397 -2.13826108 0.05349167 No 
MEF2C 398 -2.148215771 0.07478458 No 
STAT3 401 -2.162971735 0.09201321 No 
CRIM1 429 -2.307478189 0.05804261 No 
NMUR2 462 -2.529047012 0.015741859 No 
DMRT1 474 -2.65857625 0.01893551 No 
EVPL 485 -2.816974878 0.02580446 No 
GFRA3 486 -2.819857836 0.053754613 No 
SNAI2 492 -2.860271454 0.07157903 No 
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Table 5 Gene list of GSEA set Cell Surface Receptor Linked Signal 
Transduction 
GENE 
SYMBOL 
RANK 
IN 
GENE 
LIST 
RANK 
METRIC 
SCORE RUNNING ES 
CORE 
ENRICHMENT 
GRB10 0 4.903269768 0.07419716 Yes 
CDKN1C 1 3.456902027 0.12650761 Yes 
LGR5 11 2.555413246 0.14706793 Yes 
ZIC1 13 2.445233583 0.18205757 Yes 
GLI1 25 2.187872887 0.19303207 Yes 
ADAMTS1 36 2.065867424 0.20417242 Yes 
HRH3 37 2.059562922 0.23533809 Yes 
IRS1 53 1.913015485 0.2341051 No 
OTX2 74 1.794868827 0.22102393 No 
HIPK2 106 1.659950376 0.18376835 No 
RGS2 115 1.601378202 0.19190411 No 
FGF5 160 1.005194783 0.11858372 No 
TDGF1 166 0.946586847 0.12284728 No 
STC1 186 -1.224491358 0.10314713 No 
FLT4 191 -1.312462449 0.114959255 No 
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RAPGEFL1 227 -1.535297155 0.06776911 No 
TBXA2R 256 -1.689142942 0.0369915 No 
RAMP1 285 -1.764481425 0.007353922 No 
GPR20 295 -1.789713264 0.016327534 No 
IL13RA1 356 -1.987249494 -0.07432539 No 
BDKRB2 360 -2.004709721 -0.050025985 No 
SOCS1 381 -2.084973097 -0.058717243 No 
OPRD1 394 -2.121104479 -0.05076518 No 
RASD1 439 -2.354247332 -0.10367147 No 
GABRA4 442 -2.365311384 -0.071903296 No 
NMUR2 462 -2.529047012 -0.07186268 No 
CD274 463 -2.539172888 -0.03343946 No 
LAT 500 -2.93972373 -0.06138964 No 
IL12RB1 521 -3.552495718 -0.04787409 No 
CLEC1A 524 -3.695590973 0.004024112 No 
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Figure 13 Altered gene expression profiles of FGF signaling pathway 
components in Gcn5-/- EBs at day 5 
(A) Significantly altered pathways in day 5 Gcn5-/- EBs identified by IPA 
canonical pathway analysis.  
(B) qRT-PCR validating expression changes of key genes encoding FGF 
signaling pathway components identified by RNAseq, using a second 
biological sample, normalized to Pbgd. Data are presented as Mean ± SD 
from 3 independent experiments. 
 
  
 83 
 
 
 
 
 
 
 
 
 
Chapter 6. Deregulation of FGF signaling in Gcn5-/- EBs 
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6.1 Abnormal FGF signaling in day5 Gcn5-/- EBs 
Mammalian FGF signaling involves several secreted FGF ligands that interact 
with four types of tyrosine receptor kinases (FGFRs). Upon binding of the 
ligands, FGF receptors are activated and phosphorylated at specific tyrosine 
residues that mediate interactions with cytosolic adaptor proteins and 
intracellular signaling pathways including RAS-MAPK, PI3K-AKT, PLC-γ and 
STAT pathways (92). To further define the status of FGF signaling 
intermediates in Gcn5-/- EBs, we examined expression of FGFR1 and 
phosphorylation of downstream signaling intermediates, including ERK, p38, 
c-RAF, and AKT, by immunoblotting (Figure 14, A and B). FGFR1 protein 
levels were notably decreased in the null EBs, as were the activated, 
phosphorylated forms of both ERK and p38 (P-ERK and P-p38, respectively), 
indicating deficient activation of the RAS/MAPK pathway. In contrast, levels of 
activated AKT (P-AKT) and P-c-RAF-Ser259 were not decreased, and might 
even be slightly increased, suggesting the AKT pathway downstream of FGF 
signaling is affected to a lesser degree. Levels of PLC-γ did not change 
(Figure 14C), even though Prkca mRNA was up regulated in the null EBs. We 
also attempted to examine phosphorylated STAT3 levels by immunoblotting 
to determine if STAT pathway activities were altered in the null EBs, as the 
Stat3 gene was significantly upregulated. However we could not assess the 
status of STAT3 activation because the antibody did not work in our hands. 
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6.2 Deficient activation of ERK and p38 is associated with crippled 
cytoskeletal networks in Gcn5-/- EBs at day 5 
To relate these molecular changes back to the morphological phenotypes of 
the Gcn5-/- EBs, we examined organization of cytoskeletal networks regulated 
by ERK and p38 signaling (93) using Airyscan confocal microscopy. Airyscan 
uses a revolutionary area detector that enables light-efficient imaging with 
super-resolution and significantly improved signal-to-noise ratio (94), which 
allows us to visualize and examine detailed intracellular structures. 
 
We first assessed the actin cytoskeletons of day 5 EBs using phalloidin, 
which specifically stains filamentous actin (F-actin). In the epiblast of EBs or 
in early embryonic epithelial structures, F-actin localizes to the periphery of 
epithelial cells and is particularly enriched at apical sites of columnar epithelial 
cells (95, 96).  This staining pattern was observed as expected in the 
Airyscan images of phalloidin staining of Gcn5fx/fx EBs. In contrast, Gcn5-/- 
EBs displayed disarrayed F-actin, primarily in the inner cells (epiblast) with 
reduced apical distribution (Figure 14E, left panels). Airyscan images of an 
intermediate filament protein, vimentin, also showed disrupted staining 
patterns in the null EBs with notable reduction in fluorescent intensity (Figure 
14E, right panels). Decreased vimentin expression was confirmed by 
immunoblotting (Figure 14D). Conversely, E-cadherin staining showed little 
difference in localization or expression levels between Gcn5fx/fx and Gcn5-/- 
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EBs (Figure 14F). These observations suggest that insufficient activation of 
ERK and p38 upon Gcn5 loss affects primarily the F-actin and vimentin 
networks during early differentiation, in concordance with disorganized 
epithelial architectures observed in the null epiblasts (Figure 6B), whereas E-
cadherin mediated cellular adhesion is not affected by Gcn5 loss.  
 
Of note, defective ERK signaling is also consistent with decreased mesoderm 
differentiation (97) in the null EBs (Figure 9 and Figure 10), as well as 
mesodermal defects previously observed in Gcn5-/- embryos (24). 
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Figure 14 Deficient activation of the FGF pathway in the day 5 Gcn5-/- 
EBs 
(A) Representative immunoblots showing decreased phosphorylated forms of 
ERK and p38 in the Gcn5-/- EBs at day 5. 
(B) Representative immunoblots showing AKT pathway is affected to a lesser 
degree in the Gcn5-/- EBs at day 5. 
(C) Representative immunoblots showing PLCγ is not changed in the Gcn5-/- 
EBs at day 5. 
(D) Representative immunoblots showing vimentin expression is decreased in 
the Gcn5-/- EBs at day 5. 
(E) Confocal Airyscan (Zeiss LSM880) image showing disarray of F-actin 
(red) and vimentin (green) cytoskeleton networks in day 5 null EBs. Scale 
bars, 10µM. 
(F) Confocal images showing E-cadherin is not overtly affected in the day 5 
null EBs. Scale bars, 20µM. 
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Chapter 7. GCN5 regulates selective c-MYC target genes in early 
differentiation 
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7.1 Attempts of ChIPs for GCN5 in differentiating EBs not successful 
To identify the gene targets directly regulated by GCN5 at the epiblast stage, I 
attempted ChIP-Seq for GCN5 in the control EBs, but was not successful 
using either a commercially available antibody or tagging systems in 
differentiating cells.   
 
I first attempted ChIP using a GCN5 antibody (Cell Signaling #3305), which 
works well for immunoprecipitation (IP), in the Gcn5fx/fx and Gcn5-/- ES cells. 
However there were non-specific ChIP-qPCR signals in the Gcn5-/- cells when 
using Asf1b gene promoter (36) for GCN5 antibody titration ChIPs (Figure 
15A). The enrichment of GCN5 at Asf1b in the Gcn5fx/fx ESCs was also very 
low (<0.001%) and was not augmented as the antibody amount increased 
(Figure 15A). As Asf1b gene promoter is a validated binding region for 
bioGCN5 (36), these observations suggested the GCN5 antibody is likely not 
suitable for ChIPs. However, qPCRs results of additional validated GCN5 
binding genes/loci are needed to confirm this conclusion and rule out this Cell 
Signaling GCN5 antibody for ChIPs.   
 
I then tried streptavidin ChIP in day 5 EBs differentiated from bioGCN5 ES 
cells and vector control cells. Although I was able to see enrichment of 
bioGCN5 at promoter regions of few target genes (e.g. Asf1b, Alcam) 
identified by the ESC-ChIPseq (36) in bioGCN5 ESCs, I was unsuccessful in 
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optimizing the streptavidin ChIP conditions (Asf1b, Usp10, Tbx3, Dicer) for 
EBs (Figure 15, B and C).   
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Figure 15 Attempts of GCN5 ChIPs for EBs are not successful 
(A) Anti-GCN5 (Cell Signaling 3305) ChIPs with Gcn5fx/fx and Gcn5-/- ESCs. 
For each IP, 25ug of sheared chromatin was incubated with increasing 
amounts of anti-GCN5 (2.5, 5, 7.5 and 10µL) in order to determine the 
appropriate antibody/chromatin ratio. Asf1b gene promoter and an intergenic 
region were used as positive and negative controls (36). 
(B) Streptavidin ChIPs in FlBioGCN5 ESCs. IP was performed as previously 
reported, Asf1b and Alcam promoter regions were used as positive loci or 
qPCR and the intergenic region was used as negative (non-binding) locus 
(36).  
(C) Streptavidin ChIPs in day 5 EBs differentiated from FlBioGCN5 ESCs. IPs 
were performed as previously reported with adjusted chromatin/streptavidin-
beads ratio (2 x chromatin) as Gcn5 level in ESCs is higher that in 
differentiated cells (36). Since direct target genes of GCN5 in EBs were not 
defined at the time, we selected genes strongly bound by bioGCN5 in ESCs 
(36) that are known to be important for development or essential cellular 
functions (98-100) for qPCR tests.  
(D) HA ChIPs in FHGCN5 (N6 clone) ESCs. For each IP, 25µg of sheared 
chromatin were incubated with 3µg of HA antibody per manufacturer’s 
instructions. Bound HA-DNA mixtures were eluted by HA peptide following 
standard procedures. qPCR results showed strong enrichment of FHGCN5 
over Vec at gene promoters (36) tested, compared to the intergenic region.   
 94 
(E) HA ChIPs in day 5 EBs differentiated from FHGCN5 ESCs. IPs were 
performed with adjusted chromatin amount similar to (C). At that time, the 
H3K9ac ChIPseq results were obtained, and genomic loci with decreased 
K9ac peaks in Gcn5-/- EBs were selected for qPCR tests; genes associated 
with these loci (promoters) were also downregulated upon Gcn5 loss as 
indicated by our RNAseq data.    
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Next I sought to create ES cells expressing GCN5 that contains a different 
tag. To do so, I employed two strategies. One was to introduce a Flag-HA 
dual tag to the N-terminus of the endogenous GCN5 allele using 
CRISPR/CAS9 mediated targeting, and the other method was to ectopically 
express FLAG-HA tagged GCN5 using a lenti-viral vector. For CRISPR/CAS9 
targeting strategy (Figure 16A), small guide RNA (sgRNA) and a template 
single strand oligo were introduced to the J1 ESCs together with the CAS9-
EGFP expression vector using nucleoporation. The GFP positive cells were 
sorted after 48 hours, and seeded one cell per well in a 96-well plate. The ES 
clones that survived were screened for targeted insertion of the tags by 
junction PCRs, and positive clones were sequenced to verify the insertion. A 
total of 666 such clones were analyzed and 3 were confirmed by to have only 
HA targeted to the intended locus (clones 140, 616, and 666). The flag tag 
was lost for reasons unknown, and the HA tag inserted in the clone 666 
caused a frame shift. The homology arms were examined by Southern 
blotting, and clone 140 was confirmed to have one allele targeted correctly. 
For clone 616, one allele was correctly targeted, but the other was abnormal 
(Figure 16, B and C). Westerns using an anti-GCN5 antibody could not detect 
GCN5 in the HA-IP products from clones 140 and 616, suggesting that either 
the HA-GCN5 is not expressed or the HA tag might be hidden due to protein 
folding, which could render it undetectable (Figure 16D). 
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Figure 16 Creation of Flag-HA-GCN5 expressing J1 ESCs using targeted 
insertion mediated by CRISPR/CAS9  
(A) Targeting strategy to create Flag-HA-GCN5 allele. The excision site (blue 
triangle) was recognized and targeted by the small guide RNA (sgRNA) 
bound CAS9-GFP. A single strand oligo containing a dual Flag-HA tag placed 
directly downstream of ATG in frame is used as the template for homologues 
recombination (HR).  
(B) and (C) Southern blots of clones 140, 616, and 666 using probes 
upstream (B) or downstream (C) of the targeted site. Clone 140 had a 
correctly targeted allele (2.3kb bands in B, 4.3kb bands in C) and an intact 
wild type allele (6.6kb bands). Clone 616 had a correctly targeted allele, but 
the other allele showed abnormal recombination (starred bands). Clone 666 
appeared to have similar targeting pattern as 140, however the DNA 
sequencing showed frame-shift downstream of the tag.  
(D) Immunoblots showing HA-IP products from clones 140 and 616 blotted 
with antiGCN5. The J1 wild-type ESCs were used as a negative control. The 
Flag-HA-GCN5 expressing 293T cells and their control cells (vec) were used 
as a positive control for HA-IP/GCN5 western. The positions of FHGCN5 
(upper band) and endogenous GCN5 (lower band) are indicated.  
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In parallel, I also created the Flag-HA-GCN5 (FHGCN5) expressing J1 ESCs, 
and control cells that express only the dual tag (FH), by lenti-viral infection. 
This work was done in collaboration with a talented scientist, Dr. Junya 
Tomida, who is an instructor in the laboratory of Dr. Rick Wood. We verified 
that the FHGCN5 is expressed and interacts with the SAGA subunits TRRAP 
and ADA2B, indicating that addition of the tags did not interfere with 
incorporation of the FHGCN5 into SAGA complex (Figure 17). Next, I used 
these FHGCN5 ESCs (N6 clone) and their vector control cells for HA-
ChIP/qPCR at several ES target genes (e.g. Asf1b, Alcam, Meg3, Havcr) 
(36), and I was able to see enrichment of FHGCN5 at these targets (Figure 
15D). However I could not detect enrichment of FHGCN5 at selective 
promoters when using the EBs generated from these ESCs for HA-ChIPs 
(Figure 15E), even though these regions are likely to be bound by GCN5 as 
indicated by our H3K9ac ChIPseq and RNAseq data. 
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Figure 17 FLAG-HA-GCN5 interacts with subunits of SAGA complex in 
ESCs 
(A) Illustration of the vector of pCDH-EF1alpha-FH-GCN5 (N-terminus tag, 
N6). 
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(B) Illustration of the vector of pCDH-EF1alpha-GCN5-FH (C-terminus tag, 
C3). The original empty pCDH-EF1alpha-FH vector used to generate (A) and 
(B) was a kind gift from the Wood laboratory at UTMDACC Science Park.  
 (C) HA immunoprecipitation of the J1 FHGCN5 ESC nuclear extracts 
immunoblotted with TRRAP, GCN5 and ADA2B. Vec: J1 FH vector, N6: J1 
ESCs expressing GCN5 tagged with FH at N-terminus, C3: J1 ESCs 
expressing GCN5 tagged with FH at C-terminus.  
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7.2 H3K9ac ChIPs in Gcn5fx/fx and Gcn5-/- EBs at day5 
Since histone H3 lysine 9 (H3K9) is a well-characterized substrate for GCN5 
(101), we performed H3K9ac ChIP, using the same control and Gcn5-/- EBs 
as used for RNAseq. We reasoned that localized decreases in H3K9ac in the 
Gcn5-/- EBs might identify genes that uniquely require the presence of this 
HAT for proper regulation. As global levels of H3K9ac were not affected by 
Gcn5 loss (Figure 5C), regions identified by this approach will likely provide 
an underestimate of GCN5 targets due to redundancies with PCAF and 
possibly other HATs.   
 
7.3 GCN5 is required for activating c-MYC target genes in day 5 EBs  
Coupled with deep sequencing, we identified 12000 – 21000 peaks in each 
sample with good mapping rates (Table 6 and Table 7). Peaks were called at 
P value of 1e-5 and merged for replicative samples of a given genotype. A 
total of 26031 peaks were used for differential analysis between the control 
and null samples (Table 7).  
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Table 6 Mapping rates of the tags from the H3K9ac ChIPseq to mouse 
genome assembly mm10 
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Table 7 Peak calling for differential test between Gcn5fx/fx and Gcn5-/- 
samples 
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Differential peak analysis identified 173 peaks that were decreased in the 
Gcn5-/- EBs, the majority (154) of which were located near gene promoters 
(Table 8). Gene annotation identified 238 genes likely driven by these 
promoters, with occasions where an H3K9ac peak falls in a putative promoter 
region driving more than one gene. We also uncovered 144 H3K9ac peaks 
that increased upon Gcn5 loss, yet only 30 of those peaks were near 
promoters, associated with 31 genes. These data are consistent with the co-
activator role of GCN5 in gene transcription (Table 8). 
 
Comparison of genes identified in our analyses as having decreased H3K9ac 
peaks in their promoters with ENCODE ChIPseq data identified candidate 
transcription factors that might recruit GCN5 to these regions (Table 9). Top 
TFs identified by this approach include HCFC1, a nuclear protein known to 
associate with GCN5 containing complexes (102), as well as TBP and CTCF. 
Strikingly, a number of MYC family members, including MAX, MXI1 and c-
MYC, were also identified by this approach, consistent with our previous work 
connecting GCN5 to MYC functions in both ESCs and during somatic cell 
reprogramming (36).  
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Table 8 Comparison of H3K9ac peaks and associated genes in Gcn5fx/fx 
and Gcn5-/- EBs at day 5 
Gcn5-/- vs Gcn5fx/fx Decreased Increased 
Number of peaks 173 144 
Number of peaks in 
promoters 
154 30 
Genes associated 238 31 
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Table 9 Top ranked transcription factors or regulators reported to bind 
genes with decreased H3K9ac identified in Gcn5 null EBs at day 5 
Rank TFs or regulators 
Number of genes with 
H3K9ac decrease 
Q-value 
1 HCFC1 205 1.25E-77 
2 MAX 204 4.43E-72 
3 MXI1 199 4.25E-66 
4 GCN5 172 2.65E-61 
5 NELFE 192 2.65E-61 
6 TBP 192 1.69E-59 
7 CTCF 210 3.77E-59 
8 SIN3A 192 9.08E-59 
9 P300 188 1.14E-58 
10 C-MYC 164 2.44E-57 
11 E2F4 99 1.40E-48 
12 ZNF 145 1.69E-43 
13 POL2 218 4.62E-43 
14 FLI1 103 1.48E-42 
15 CHD2 143 5.48E-35 
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To better determine which of these regions might reflect genes directly 
activated by GCN5, we compared genes with decreased H3K9ac at their 
promoters (Appendix 3) with genes identified as down regulated more than 2 
fold by RNAseq. Only 7 genes (P=0.0096, one-sided hyper geometric test) 
were both downregulated and decreased in H3K9ac, and 4 of these genes 
are reported to be regulated by c-MYC in different cellular systems (103-106). 
Myc is induced by most mitogenic factors including FGFs to exert the 
immediate early cellular responses through its transcriptional targets (107). 
Specifically, Rps6ka2 encodes RSK3 that belongs to the 90kDa ribosomal S6 
kinase (RSK) family. RSK kinases are directly activated by ERK and p38 
cascades downstream of mitogen and stress mediated stimuli, by which 
regulate diverse cellular processes including cell growth and migration. 
Transcriptional regulation of RSK genes is much less defined compared to 
RSK activation mechanisms mediated by protein phosphorylation. Our 
findings here suggested that GCN5 is required for normal transcription of 
Rps6ka2 during early differentiation (Figure 18A, and Figure 18B, middle 
panels). Mthfd2, also a c-MYC target, regulates vimentin expression in breast 
cancer cells (108). As it is markedly downregulated upon Gcn5 loss in the 
developing EBs (Figure 18A and Figure 18B lower panels), downregulation of 
this gene might contribute to the vimentin loss observed in the Gcn5 null EBs. 
Additional experiments are needed to explore this possibility. The other two c-
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MYC targets, Bcat1 and Srm (Figure 18A) both promote cancerous growth in 
a c-Myc dependent manner (103, 109). Whether such connection holds true 
in the developing EBs or early embryonic development is an interesting area 
for further investigation. 
 
The most significantly downregulated gene, Grb10 (Figure 18A and Figure 18 
B upper panels), as well as Nmnat2 (Figure 18A), are also involved in 
regulation of insulin/AKT signaling and MAPK signaling, respectively, as 
implicated in studies done in different cellular contexts (90, 110-112). These 
implications reinforce the potential roles of GCN5 in regulation of signaling 
events during early differentiation.  
 
Collectively, these data suggest that GCN5 directly activates selective genes, 
including several MYC targets, during early differentiation of EBs. The 
literature-implicated involvement of these genes in signaling events, 
particularly related to MAPK and AKT pathways, supported the link between 
GCN5 and FGF signaling identified in gene expression analysis in early EB 
differentiation.    
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Figure 18 Putative target genes of GCN5 during early EB differentiation 
(A) Putative target genes directly regulated by GCN5. Venn diagram showing 
overlap between H3K9ac decreased genes and GCN5 induced genes. 
Overlapping genes are listed in the table with a general description of the 
reported functions.   
(B) Examples of H3K9ac peak profiles (n=4) and RNA transcripts (n=3) for 
top targets of GCN5 in day 5 EBs. 
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Chapter 8. Conclusions, Discussion and Future Directions 
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8.1 Conclusions  
Previous studies showed that Gcn5 is essential for embryo development and 
survival, but the functions of this HAT in regulating differentiation are not well 
defined (24, 25). Our findings reveal a new role of Gcn5 in regulation of FGF 
signaling during early differentiation (Figure 19). FGF signaling regulates both 
migration and patterning of mesoderm during gastrulation (88). We report 
here that Gcn5 is required for proper expression of Fgf3, Fgf4, and Fgfr1, as 
well as for activation of downstream pathway effectors including ERK and 
p38. Failures in the execution of these pathways result in defective mesoderm 
differentiation and cytoskeletal networks (93, 97, 113) as reported by others 
using mouse models and cellular systems. Consistently, we show that Gcn5-/- 
EBs have abnormal cytoskeletal organization and defective mesoderm and 
endoderm formation during early differentiation. Loss of Gcn5 also leads to 
significant downregulation of Grb10, which is characterized as a negative 
regulator for insulin/IGF mediated AKT signaling (90, 91, 110), indicating that 
Gcn5 may be also required for normal insulin signaling during early 
differentiation.   
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Figure 19 GCN5 impacts multiple components of the FGF signaling 
pathway and activates MYC targets during early differentiation 
Upper illustration: 
The abnormal phenotype of Gcn5-/- EBs becomes evident early during EB 
differentiation  (day 5). Loss of Gcn5 leads to disorganization of the epiblast 
architecture that is associated with defective cytoskeleton, including F-actin 
and vimentin networks, and decrease in progenitors fated for endoderm and 
mesoderm.  
At later stages of differentiation (days 9 and 12), Gcn5 null EBs are smaller in 
size and express lower levels of germlayer marker genes, compared to the 
controls. Color codes: Blue represents ectoderm, green represents 
endoderm, and magenta represents mesoderm. Lighter shades in the Gcn5-/- 
EBs indicate decreased expression levels of marker genes for each 
population. 
 
Middle illustration: 
At day 5 of differentiation, GCN5 impacts expression of multiple genes 
encoding critical components in FGF signaling pathway and for proper 
activation of ERK and p38 pathways.  
Solid diamond: altered level of transcripts 
Open diamond: altered level of protein expression 
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Double open diamond: altered level of protein phosphorylation 
 
Bottom illustration: 
At day 5 of differentiation, GCN5 is required for activating genes important for 
signaling through promoter associated H3K9ac, including 4 c-MYC targets 
(blue).   
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Further, we identified Grb10, Nmnat2, Gldc, Bcat1, Rps6ka2, Mthfd2, and 
Srm as likely direct targets of GCN5, which exhibit both decreased acetylation 
at H3K9 and decreased expression upon Gcn5 loss. Four of these genes 
(Bcat1, Rps6ka2, Mthfd2, and Srm) are reportedly MYC targets (103, 104, 
106, 109) in various tumorous cell lines. These findings point to a co-activator 
role of GCN5 for these MYC targets during early differentiation. Such 
partnership between GCN5 and MYC in gene regulation is also consistent 
with previous observations in ESCs, during somatic cell reprogramming and 
during neural development (29, 36), once again, highlighting the significant 
relationship of GCN5-MYC in gene regulation in diverse physiological and 
pathological contexts.  
 
Myc itself is targeted by RAS/ERK and AKT pathways through both 
transcription dependent and independent mechanisms, as shown by studies 
using cellular models (114), and its induction is an immediate early response 
to most mitogenic factors including FGFs (107). Myc deletion in ESCs 
induces a dormant pluripotent state that mimics embryonic diapause, and 
promotes primitive endoderm formation in vitro (115, 116). C-Myc-/- mice die 
by E10.5 with growth retardation, defective cardiac and neural development, 
and defects in vasculogenesis, angiogenesis, and primitive erythropoiesis in 
the yolk sac and in the embryo proper (117, 118). Whereas n-Myc-/- mice die 
by E12.5, exhibiting developmental delay and a decrease in size/cellularity of 
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certain organs, for instance, nervous system, lung, and heart (119-121). 
These phenotypes are different from what we observed here in Gcn5-/- ESCs 
and previously reported in Gcn5 null mice (24, 36), indicating Myc 
independent requirement for Gcn5 during early development or differentiation, 
or that GCN5 may be required for selective genes targeted by MYC, as 
supported by our data.  
 
We previously reported that in mouse ESCs, GCN5 also has shared 
transcriptional targets with E2F1, as GCN5 binding sites are highly enriched 
of E2F1 motif and GCN5 induced genes significantly overlap with E2F1 
targets in the ESCs (36). Our study in differentiating ESCs identified E2F4 as 
a TF likely to recruit GCN5/SAGA to a subset of its target genes to acetylate 
H3K9 (Table 9).  However we did not observe changes in expression of direct 
E2F4 gene targets in Gcn5-/- EBs. The best-characterized function of E2F 
family TFs is cell cycle regulation (122). Individual E2F family members are 
dispensable in mouse development, but compound deletions of E2F3 in 
combination with E2F1 and/or E2F2 lead to embryonic lethality after E9.5, 
with evident growth retardation largely attributed by proliferation arrest (123).  
Our EB studies probe for differentiation events that parallel embryonic stages 
prior to gastrulation, much earlier than E9.5 when E2F1-3 become essential 
for embryonic survival, and we did not observe overt proliferation defect at 
such early stage of differentiation in the absence of Gcn5. This timing 
 120 
difference could explain the absence of E2F targets affected by loss of Gcn5 
in our data set. Further, roles of E2F family TFs in ESC differentiation remain 
an understudied area. Of interest, E2F4 has been implicated in cell lineage 
differentiation during mouse development by regulating cell-cycle exit (122), 
which is essential for controlling differentiation dynamics. Knowledge of 
GCN5 genomic locations during differentiation will help us gain insights on 
coinciding TFs that are specifically required for GCN5 target gene expression 
in such developmental context.  A GCN5-ChIP or tag-mediated GCN5 ChIP in 
differentiating ESCs will help to achieve this goal. 
 
In addition, some of the putative gene targets of GCN5 identified in this study 
have been shown to function in specific lineages or cell migration, though in 
different cellular systems. For example, the paternally expressed Grb10 
isoform is specifically important for neuronal tissue development in mice, 
while the maternal, major isoform of Grb10 is required for growth inhibition 
involving insulin/AKT pathway regulation (124). NMNAT2 is required for 
MAPK signaling mediated axon degeneration in response to injury as a 
survival mechanism, as shown in a mouse dorsal root ganglia culture based 
study (112). Mthfd2 is a regulator of vimentin expression in breast cancer 
cells and might promote migration and invasion of these cells (108). These 
findings provide clues for us to further clarify if these genes may indeed 
contribute to the phenotypes in Gcn5-/- EBs, with additional experiments to 
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assess if lineage specific Grb10 expression is associated with defective 
germlayer differentiation, or if decreased expression of Nmnat2 or Mthfd2 
may be directly related to the cytoskeletal defects upon Gcn5 loss. 
 
Another notable common function of GCN5 targets identified here is that they 
regulate metabolism and growth, either positively (Nmnat2, Bcat1, Gldc, 
Mthfd2 and Srm) or negatively (Grb10, Bcat1 and Rps6ka2) (90, 91, 103, 
105, 111, 125-127). Altered carbon metabolism induced by these gene 
expression changes could further derail differentiation (128). Some of these 
genes are also directly regulated by ERK/MAPK pathway (Rps6ka2, Nmnat2) 
(111, 112, 129) or AKT pathway (Grb10) (90), indicating their metabolic 
impacts could be part of the signaling outputs and may lead to the 
phenotypes observed in the Gcn5 null EBs. However, additional studies are 
needed to establish such direct links.   
 
Finally, some of the FGF pathway components did not appear to be directly 
regulated by GCN5 at the level of transcription. For instance, transcripts of 
Fgf3 and Fgf4 are downregulated in Gcn5-/- EBs at day 5, but H3K9ac levels 
were not altered in their promoters. Phosphorylation of ERK and p38 is 
decreased in the day 5 Gcn5-/- EBs without overt alterations in their transcript 
levels. Perhaps the best-characterized mechanism by which FGF signaling is 
regulated involves protein-protein interactions and the resulting post-
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translational modifications (phosphorylation) of these proteins. However, 
transcriptional regulation of FGF pathway genes themselves seems a much 
less investigated area. It has been suggested that microRNAs can target 
multiple FGF signaling genes including Fgfr2, Stat3 and Mapk14 to influence 
cellular differentiation during development (92). In addition, SOX2 and OCT4 
regulate Fgf4 transcription in early development by binding to a downstream 
enhancer of the Fgf4 gene in a cooperative manner. Interestingly, Oct4 
mRNA is decreased 2 fold in Gcn5-/- EBs, suggesting this event might 
contribute to the downregulation of Fgf4 observed in the null EBs. How loss of 
Gcn5 leads to deregulation of the other FGF signaling genes observed 
remains an open question. Future work will address these questions, and the 
answers will enrich our understandings in regulatory mechanisms controlling 
FGF signaling pathway and the biological consequences it confers.  
 
8.2 Possible contributions to the observed EB phenotypes by non-
transcriptional targets of GCN5 
Our study primarily focused on transcriptional changes caused by Gcn5 loss 
at the epiblast stage of EB differentiation, as abnormal phenotypes were first 
observed in day 5 EBs. However, among 240 genes downregulated upon 
Gcn5 loss, only 7 genes were identified as likely to be directly regulated by 
GCN5 transcriptionally, as they have decreased H3K9ac peaks in the 
promoter region. Such small proportion pointed to alternative mechanisms by 
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which loss of Gcn5 contributes to altered gene expression and/or the cellular 
phenotypes observed in day 5 Gcn5-/- EBs. One possible explanation is that 
PCAF, the highly related homolog of GCN5, largely compensates for 
transcriptional activation of GCN5 target genes in absence of Gcn5, and we 
will discuss this possibility in the next section. Another possibility might be 
that Gcn5 loss impacts gene expression by its ability to modify non-histone 
proteins (26, 30, 130). For example, GCN5 pairs with MYC-nick, a CALPAIN-
cleaved cytoplasmic derivative of MYC, to acetylate alpha-tubulin (ac-alpha-
TUB) and regulate cytoskeleton organization and differentiation of myoblasts. 
We examined the ac-alpha-TUB using immunostaining and immunoblotting in 
the day 5 EBs. The levels of alpha-tubulin appeared to be similar between 
Gcn5fx/fx and Gcn5-/- EBs, as indicated by both confocal images and the 
immunoblot (Figure 20A, upper panels and Figure 20B). However, the 
acetylate alpha-tubulin showed cytoplasmic diffusion in the null EBs, 
compared to the distinctive apical distribution in the controls, as in the 
confocal images, even though the changes in ac-alpha-TUB protein level 
were minimum as indicated by the immunoblot (Figure 20A, lower panels and 
Figure 20B). These findings suggested that loss of Gcn5 indeed affected 
subcellular localization of the acetylated alpha-tubulin, even though the level 
of this modification appeared to be maintained by other HATs. The altered 
staining pattern of acetylated alpha-tubulin is also consistent with the 
disorganized epiblast architecture observed in the absence of Gcn5.  
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Figure 20 Acetylation of tubulin is not overtly affected by Gcn5 loss in 
day 5 EBs 
(A) Confocal images of alpha-tubulin (green, cytoplasmic) and acetylated-
alpha tubulin (green, apical distribution in control epiblast cells, but 
cytoplasmic diffusion and less well organized fibers in the null epiblast cells) 
in day 5 EBs. Scale bar, 20µM. 
(B) Representative immunoblots for acetylated-alpha tubulin levels in day 5 
EBs.  
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GCN5 can also acetylate transcription factors, such as E2F, c-MYC and p53 
(25, 131, 132). Such acetylation event can increase DNA-binding ability, 
facilitate activation or prolong half-life of these TFs, thereby modulate their 
abilities in gene regulation and in carrying out cellular functions. IPA analysis 
can predict upstream regulators based on the overall gene expression 
changes in a given gene set. In the day 5 Gcn5-/- EBs, we did identify c-MYC 
(z= -1.613, P=1.11E-06) and p53 (z=0.917, P=5.66E-07) as potential 
regulators for genes changed in absence of Gcn5, but not E2F family factors. 
A positive z score indicates upregulation of the predicted regulator, and a 
negative z score indicates downregulation. So these results suggested 
downregulation of c-MYC, consistent with decreased c-MYC targets 
transcription observed earlier, and slight upregulation of p53. We did not 
observe direct targets of p53 with altered promoter H3K9ac levels in the 
absence of Gcn5 by our genomic sequencing data, so it is possible that Gcn5 
loss may alter p53 acetylation levels to affect the transcription of p53 target 
genes. More interestingly, the most downregulated upstream transcriptional 
regulators in the absence of Gcn5 predicted by IPA include TRIM24 (z=-
5.255, P=2.07E-20), NKX2-3 (z=-3.539, P=7.60E-12), IRF4 (z=-2.360, 
P=3.63E-04) and CTNNB1 (z=-2.346, P=2.90E-07). GCN5 interacts with 
beta-catenin (CTNNB1) in colon cancer cell lines (133, 134), yet it is unclear 
whether such interaction occurs during early differentiation, nor is known if the 
interaction leads to acetylation and functional consequences in early 
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differentiation. Little is known about relations of GCN5 with the other TFs 
identified here and about other non-histone targets of GCN5 during early 
differentiation, and we cannot exclude the contributions of such targets to 
developmental processes that require GCN5. 
 
The FHGCN5 expressing ES cells created during this project, together with 
the previously generated bioGCN5 expressing ES cells will be useful tools for 
identifying new substrates of GCN5 in both ES cells and lineages generated 
thereof. However, successfully tagging endogenous GCN5 remains the best 
strategy in studying GCN5 binding partners and genomic distribution in vivo 
and during various developmental stages. My attempts to use exogenously 
tagged GCN5 for ChIP experiments proved to be fruitless. One explanation is 
that GCN5 expression level is regulated during differentiation, with lower 
expression in day 5 EB compared to day 0 (ESC) (36) (Figure 21). Also our 
data from this study suggest that GCN5 regulates specific sets of genes that 
may not be large in number. All of these factors could increase the difficulty in 
optimizing ChIP conditions in differentiating cells, even for tag proteins/beads 
proven to be efficient for ChIP in ESCs. In addition, a tagged GCN5 
expressed from its own promoter, is most likely to be regulated as the wild 
type protein. If such tagged GCN5 is normally expressed and functions as the 
wild type protein, for instance, to acetylate H3K9/14, to be incorporated into 
SAGA or ATAC complexes and to be loaded onto the chromatin at reported 
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GCN5 target genes, then the biochemical or functional analysis performed 
through the tag will give reliable information as to what GCN5 interacts with, 
where in the genome it binds, and how these interactions may confer cellular 
consequences.     
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Figure 21 GCN5 expression is regulated during early differentiation 
(A) qRT-PCR plot showing Gcn5 mRNA levels in Gcn5fx/fx cells during 
differentiation, normalized to Pbgd gene. Data from 4 independent 
experiments represented as Mean±SD. 2-way ANOVA was used to test the 
statistical difference in Gcn5 mRNA level between EBs and ES. 
(B) Representative immunoblots showing GCN5 protein levels in Gcn5fx/fx 
WCLs during differentiation. 
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8.3 Potential compensatory effects from GCN5/ATAC or PCAF  
GCN5 is most active in vivo when incorporated into modular complexes, 
including SAGA and ATAC in mammals (14). Our studies do not differentiate 
the functions of the two complexes, and the phenotypes we observe may 
reflect loss of activity of both. However, knockout of Atac2, a component of 
ATAC but not SAGA, did not cause defects in lineage differentiation (135), as 
was observed in Gcn5-/- embryos, suggesting SAGA may be more important 
for these early developmental events.  Nonetheless, future studies disrupting 
subunits specific to SAGA or ATAC will aid in differentiating the overlapping 
or distinct gene sets regulated by these two GCN5 containing complexes 
during early differentiation stage or embryogenesis.  
 
Our previous genetic studies showed Gcn5-/-;Pcaf-/- embryos die earlier than 
do Gcn5-/- embryos, even though Pcaf deletion on its own exhibits no overt 
abnormal phenotype (24, 136). These findings indicate that Gcn5 and Pcaf 
have shared functions during early development. The phenotypes of Gcn5-/- 
EBs at day 5 despite the presence of PCAF suggested non-redundant 
function of GCN5 during early differentiation. However, generation of ES cells 
lacking Gcn5 in different Pcaf allelic background will provide opportunities to 
identify common or unique gene targets regulated by these two sister proteins 
in stem cell state or during differentiation processes. 
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8.4 Potential novel roles of GCN5 during early differentiation 
Interestingly, more genes were up regulated upon loss of Gcn5 (at both day 3 
and day 5) than were down regulated, in contrast to the role of GCN5 as a co-
activator of transcription. Many of these events are likely indirect effects upon 
Gcn5 loss, although we cannot exclude the possibility that GCN5 may be 
involved in gene repression during early differentiation. Indeed, a recent study 
revealed that another HAT, TIP60, acts as a transcriptional repressor in ES 
cells by a HAT independent mechanism (137).  Notably, many of the genes 
up regulated upon Gcn5 loss are involved in acute phase response and 
interferon signaling, as indicated by both IPA and GSEA (Figure 22).  
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Figure 22 Increased immune response in day 5 Gcn5-/- EBs  
(A) Top ranked immune response related pathways (IPA) in the Gcn5-/- EBs at 
day 5. 
(B) Top one gene set enriched in the null EBs at day 5 identified by GSEA. 
Red: positively correlated to Gcn5fx/fx. Blue: positively correlated to Gcn5-/-.  
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These findings are in line with our previous work in fibroblasts that indicated 
GCN5 and PCAF repress IFNβ expression by targeting a non-histone 
substrate, TBK1 (138). The links between interferon signaling and early 
embryonic development or ESCs remain an understudied area. Apart from its 
important roles in immune response, this pathway may be also involved in cell 
adhesion, proliferation and early development. A recent report shows 
Interferon-induced trans-membrane protein 3 (IFITM3) is expressed at 
relatively high levels at primitive streak region, and marks the stem/progenitor 
cell pool for the allantois (139). Future work will help determine how GCN5 
regulates the interferon-signaling pathway during early development. 
 
8.5 Concluding remarks and perspectives 
In summary, our study identified a novel role of an epigenetic factor, GCN5, in 
regulating FGF signaling pathways, particularly through ERK and p38 
activation, in early differentiating embryoid bodies that are equivalent to the 
embryonic stage leading to gastrulation in vivo. This work built up on our 
previous discovery of an essential requirement of Gcn5 for embryonic survival 
shortly after gastrulation, presented multiple points of action of GCN5 within 
the FGF signaling pathway, that are accomplished through transcription 
dependent and independent mechanisms.   
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This work also brings forth new areas to be investigated as discussed in the 
above chapter. For instance, how is FGF signaling pathway modulated by 
GCN5, if GCN5-mediated H3K9ac is not a major regulatory event in the 
expression of multiple genes within the pathway? What genes are directly 
bound by GCN5 at early differentiation stage, and what TFs recruit GCN5 to 
its targets, other than MYC family TFs? Another important area that needs 
more investigation is that how GCN5 is distributed between SAGA and ATAC 
in gene regulation during early differentiation, and further, how are GCN5 and 
PCAF differentially required for the early differentiation processes? And 
finally, in addition to its co-activator role in gene regulation, does GCN5 
repress gene transcription during early differentiation, and if yes, is such 
repressive role unique to the developmental context or also applicable to 
terminally differentiated somatic cells? Answers to these questions will 
expand the roles of GCN5 in more specific, intercalated developmental 
processes. As the full functions of GCN5 unveil, they will inspire in-depth 
research to add more epigenetic regulators to the blueprint of developmental 
pathways.  
 
Since many human diseases thrive on deregulation of signaling pathways 
essential for development, understanding fully how these pathways function 
in physiological contexts will allow us to identify and alleviate or correct 
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deregulated components/processes in pathological conditions, eventually 
equip us to win the battles against those diseases. 
  
 135 
APPENDIXES 
Appendix 1 List of genes with altered expression levels upon Gcn5 loss 
in day 5 EBs identified by RNAseq (FDR 0.05, FC2) 
Gene name 
Normalized expression 
Log2ratio P-value FDR 
Gcn5fx/fx  Gcn5-/- 
Grb10 22128.0674 216.1360 -6.6778 1.77E-72 3.23E-68 
Gm26709 26.4121 0.6739 -5.2926 8.81E-05 1.81E-03 
Nccrp1 33.3149 1.0622 -4.9710 2.00E-09 2.33E-07 
Zic4 37.2170 2.2623 -4.0401 1.85E-03 1.91E-02 
Mirg 97.1816 6.0881 -3.9966 6.05E-14 1.94E-11 
Gm26945 14.4247 1.0622 -3.7634 9.73E-05 1.97E-03 
Rian 1190.6757 87.9964 -3.7582 1.10E-07 7.26E-06 
Meg3 155.5578 13.3514 -3.5424 4.09E-08 3.14E-06 
Tfap2e 9.9507 0.8914 -3.4807 6.04E-03 4.48E-02 
Gm37899 33.6802 3.1751 -3.4070 3.54E-05 8.64E-04 
Zic1 990.8949 97.3476 -3.3475 5.60E-05 1.25E-03 
Accsl 26.6962 2.6275 -3.3449 2.65E-05 6.79E-04 
Krt42 22.5114 2.3420 -3.2649 5.96E-04 8.00E-03 
Nlrc4 38.9378 4.0763 -3.2558 1.70E-04 3.06E-03 
Cdkn1c 2457.2057 283.9797 -3.1132 5.97E-54 5.45E-50 
Tgm3 16.4238 1.9420 -3.0802 6.42E-03 4.66E-02 
 136 
Chrna9 19.4325 2.3420 -3.0527 7.85E-04 9.86E-03 
Aox3 19.6486 2.5479 -2.9471 5.94E-03 4.42E-02 
H19 4233.7052 568.4079 -2.8969 3.26E-04 5.10E-03 
Gm26793 31.2848 4.2373 -2.8842 2.28E-04 3.85E-03 
Tril 399.3314 54.8963 -2.8628 5.33E-03 4.10E-02 
Hrh3 18.8222 2.8099 -2.7438 9.07E-05 1.85E-03 
Fgf15 1205.6433 180.9974 -2.7358 4.89E-07 2.53E-05 
Pax5 198.2041 31.2130 -2.6668 1.26E-14 4.91E-12 
Timp4 60.6949 9.7428 -2.6392 4.56E-06 1.63E-04 
Crisp1 26.9425 4.3520 -2.6301 1.15E-03 1.33E-02 
Irs4 460.6010 74.7667 -2.6230 1.16E-04 2.27E-03 
Vtn 71.7713 11.7078 -2.6159 1.54E-03 1.66E-02 
1700097N02Rik 64.4900 10.6577 -2.5972 1.03E-05 3.14E-04 
A730089K16Rik 48.3558 8.0765 -2.5819 1.47E-05 4.18E-04 
Gli1 139.7209 24.0668 -2.5374 2.36E-07 1.36E-05 
Rspo3 67.4786 12.1410 -2.4745 1.37E-06 5.90E-05 
Aoah 68.1841 12.8017 -2.4131 2.47E-05 6.40E-04 
Cp 220.3961 42.9131 -2.3606 2.57E-04 4.20E-03 
Nr0b1 329.1974 64.8138 -2.3446 8.58E-04 1.06E-02 
Lonrf2 314.2172 63.4280 -2.3086 4.72E-07 2.47E-05 
Pcdh8 898.8077 182.0427 -2.3037 3.67E-03 3.12E-02 
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Foxd3 108.3497 23.0282 -2.2342 1.21E-03 1.38E-02 
Ndp 48.6021 10.6105 -2.1955 1.49E-03 1.62E-02 
Ism1 103.6340 23.2081 -2.1588 3.16E-08 2.52E-06 
4930519F16Rik 28.4236 6.3969 -2.1517 6.59E-04 8.69E-03 
Etv4 287.3084 66.9886 -2.1006 1.85E-07 1.12E-05 
Sytl2 157.4214 37.1883 -2.0817 4.70E-03 3.73E-02 
Car14 552.6317 132.7884 -2.0572 2.89E-07 1.63E-05 
Rassf9 31.1592 7.7078 -2.0153 2.27E-03 2.19E-02 
Tdh 2292.4677 567.6737 -2.0138 1.17E-05 3.46E-04 
Grrp1 49.1450 12.6906 -1.9533 3.77E-04 5.68E-03 
Pllp 17.3060 4.5461 -1.9286 1.51E-03 1.64E-02 
Wfikkn1 113.2081 30.5876 -1.8880 5.11E-07 2.60E-05 
Klhl14 26.7804 7.3114 -1.8730 6.17E-03 4.55E-02 
Sfrp2 6661.6870 1818.9214 -1.8728 1.65E-04 2.99E-03 
Gm7325 120.9587 33.0427 -1.8721 6.93E-09 7.04E-07 
A730017C20Rik 65.5780 18.0253 -1.8632 4.94E-04 6.95E-03 
Gm6792 47.9732 13.2501 -1.8562 1.93E-04 3.37E-03 
Ajap1 188.1074 52.2570 -1.8479 5.19E-09 5.51E-07 
Scube3 852.2563 238.6717 -1.8363 2.81E-04 4.50E-03 
Msx2 162.7654 46.0763 -1.8207 7.13E-08 4.97E-06 
Nkx1-2 145.2421 41.2793 -1.8150 1.80E-03 1.87E-02 
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Lgr5 67.3983 19.6001 -1.7819 2.74E-04 4.42E-03 
Cyp26b1 1217.3294 357.7910 -1.7665 1.37E-03 1.52E-02 
Enox1 390.1685 114.7678 -1.7654 3.18E-03 2.80E-02 
Slc8a1 393.8127 116.7655 -1.7539 8.98E-05 1.84E-03 
Myc 375.7351 111.8573 -1.7481 4.47E-06 1.60E-04 
Tcerg1l 40.1714 12.0497 -1.7372 1.17E-04 2.29E-03 
Tdgf1 2619.9410 788.2355 -1.7328 1.54E-03 1.66E-02 
Dkk1 165.1393 49.7782 -1.7301 2.11E-06 8.56E-05 
Tcl1 120.4452 36.6087 -1.7181 2.36E-04 3.92E-03 
Tmem132c 1185.8459 363.6488 -1.7053 1.41E-13 4.16E-11 
Slc44a5 559.7664 172.0509 -1.7020 2.14E-08 1.82E-06 
Mab21l2 73.1490 22.6736 -1.6898 4.56E-04 6.52E-03 
Spred3 449.0330 139.5566 -1.6860 1.04E-06 4.65E-05 
Pdzd4 1000.2840 310.9493 -1.6857 2.33E-06 9.22E-05 
Hmga2 3485.0433 1096.4454 -1.6683 1.36E-34 4.15E-31 
Platr10 394.8537 124.5546 -1.6645 2.83E-03 2.58E-02 
Phlda2 267.5180 84.6624 -1.6598 2.63E-12 6.09E-10 
Cdh11 843.0047 267.8497 -1.6541 3.28E-03 2.87E-02 
Rprm 609.4064 198.1424 -1.6209 2.32E-03 2.23E-02 
Wnt3a 366.1002 119.3479 -1.6171 2.51E-03 2.37E-02 
Kirrel3 122.9077 40.3085 -1.6084 2.44E-05 6.36E-04 
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Sdc3 413.7918 135.8707 -1.6067 2.21E-05 5.87E-04 
Nsg1 742.2702 245.6103 -1.5956 9.00E-04 1.10E-02 
Mylk 994.7025 331.8835 -1.5836 4.81E-04 6.80E-03 
Tspan7 710.8583 241.4018 -1.5581 8.37E-04 1.04E-02 
Fam184b 26.7121 9.1037 -1.5530 4.49E-03 3.60E-02 
Nr4a3 121.8141 41.5743 -1.5509 2.76E-03 2.54E-02 
Dpysl5 1903.2606 650.2402 -1.5494 1.70E-06 7.16E-05 
Ckb 3284.3390 1124.9350 -1.5458 4.06E-03 3.35E-02 
Epha2 1322.7012 453.0738 -1.5457 4.56E-07 2.40E-05 
Frem1 399.3119 136.9355 -1.5440 2.46E-05 6.39E-04 
Slit2 725.9245 250.0231 -1.5378 5.35E-07 2.69E-05 
Mfsd2a 129.9173 44.9747 -1.5304 3.94E-04 5.86E-03 
Trh 4207.8256 1458.4873 -1.5286 6.75E-10 9.28E-08 
Lypd1 36.8998 12.7932 -1.5282 3.28E-03 2.87E-02 
Adamts20 61.6139 21.6681 -1.5077 4.66E-04 6.63E-03 
Fgf3 146.6152 51.7094 -1.5035 3.58E-06 1.34E-04 
Fgf4 781.2407 276.4722 -1.4986 6.19E-03 4.55E-02 
Mfsd7b 638.1105 226.4205 -1.4948 1.69E-18 1.24E-15 
Vcan 2020.1769 717.4804 -1.4935 1.61E-20 1.40E-17 
Mcf2 486.4079 172.9397 -1.4919 1.61E-05 4.51E-04 
Ptch2 150.0112 54.3304 -1.4652 2.34E-09 2.69E-07 
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Zfp819 137.8092 49.9740 -1.4634 3.17E-06 1.20E-04 
Fndc3c1 2829.4600 1027.3070 -1.4617 5.93E-22 5.70E-19 
Spry4 339.6938 124.0294 -1.4536 2.66E-04 4.31E-03 
Calcoco2 166.7671 60.9530 -1.4521 1.77E-04 3.15E-03 
Tmem40 51.5239 18.8721 -1.4490 6.05E-04 8.08E-03 
Col2a1 6973.2614 2555.8359 -1.4480 8.02E-10 1.07E-07 
Fgf17 111.8676 41.0625 -1.4459 1.21E-04 2.34E-03 
Gareml 188.4349 69.2764 -1.4436 1.63E-03 1.73E-02 
Kirrel2 25.2922 9.3194 -1.4404 3.57E-03 3.06E-02 
Kat2a 2207.4250 817.0114 -1.4339 1.42E-25 2.35E-22 
Foxa2 228.7116 84.9930 -1.4281 3.70E-04 5.62E-03 
Etv5 3291.7605 1226.4589 -1.4244 8.09E-06 2.60E-04 
Hsd17b14 45.4036 17.2019 -1.4002 3.02E-03 2.71E-02 
Pde8b 40.7985 15.5820 -1.3886 2.20E-03 2.15E-02 
Klf15 167.0599 64.3376 -1.3766 2.00E-07 1.18E-05 
Fgd3 63.3471 24.4427 -1.3739 5.44E-03 4.15E-02 
Nedd9 783.3409 304.5100 -1.3632 2.72E-04 4.39E-03 
Plch1 3921.6363 1532.1270 -1.3559 1.47E-10 2.33E-08 
Ccdc96 89.2425 35.2148 -1.3415 6.57E-04 8.67E-03 
 Sep1 244.8066 96.8499 -1.3378 1.83E-03 1.89E-02 
Stmn2 1208.6429 480.9150 -1.3295 7.69E-15 3.12E-12 
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Rarb 134.1129 53.3687 -1.3294 5.59E-04 7.61E-03 
Plxnc1 315.5200 125.7499 -1.3272 2.87E-05 7.23E-04 
Trim67 98.6861 39.4710 -1.3221 6.19E-03 4.55E-02 
A830082K12Rik 97.9611 39.3184 -1.3170 1.49E-03 1.62E-02 
Scube1 830.8794 334.3613 -1.3132 5.66E-04 7.68E-03 
Esrrb 1188.7064 479.3134 -1.3104 1.42E-05 4.08E-04 
Ctnnd2 491.2564 198.6209 -1.3065 1.25E-04 2.41E-03 
Nodal 562.6321 227.4994 -1.3063 2.93E-07 1.64E-05 
Ncald 480.5016 194.3429 -1.3059 1.73E-03 1.82E-02 
Emilin2 1133.1554 459.8020 -1.3013 1.99E-03 2.01E-02 
Dppa2 330.0419 134.3557 -1.2966 8.71E-06 2.74E-04 
Lrp3 951.1686 387.2976 -1.2963 4.28E-08 3.27E-06 
Spry2 2668.9097 1089.7856 -1.2922 4.51E-14 1.47E-11 
C77370 290.6548 119.6264 -1.2808 2.05E-03 2.04E-02 
Hsd11b2 142.9096 59.2543 -1.2701 4.26E-05 1.00E-03 
Adamts1 384.3574 159.6061 -1.2679 3.61E-10 5.35E-08 
Nmnat2 264.8970 110.5387 -1.2609 1.87E-03 1.93E-02 
Trabd2b 99.0198 41.7142 -1.2472 4.37E-04 6.32E-03 
Ccno 34.3156 14.4731 -1.2455 2.18E-03 2.13E-02 
Adgrv1 2773.3252 1173.3112 -1.2410 3.07E-05 7.67E-04 
Plxna2 1815.4866 768.4387 -1.2404 4.55E-04 6.52E-03 
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Il17rd 4567.8114 1937.7115 -1.2371 3.15E-03 2.79E-02 
Megf6 1655.8588 702.7732 -1.2364 1.51E-08 1.40E-06 
Mapk11 466.1863 198.0744 -1.2349 1.14E-04 2.25E-03 
Slc6a15 264.1292 112.3220 -1.2336 4.10E-06 1.49E-04 
Dppa5a 3806.0278 1622.5131 -1.2301 3.77E-08 2.92E-06 
Ass1 1103.2782 476.0740 -1.2125 6.61E-06 2.17E-04 
Rpl34-ps2 43.5779 18.8813 -1.2066 4.98E-03 3.90E-02 
Slc4a5 128.7386 55.9204 -1.2030 2.18E-04 3.73E-03 
Slc28a1 105.6846 45.9183 -1.2026 9.56E-04 1.16E-02 
Cdh2 4676.2733 2033.2732 -1.2016 6.10E-04 8.13E-03 
Gm4430 97.6676 42.4873 -1.2008 2.21E-04 3.78E-03 
Sema3d 86.1518 37.5429 -1.1983 1.47E-03 1.60E-02 
Vegfc 205.8726 90.0057 -1.1937 6.10E-06 2.03E-04 
Mest 29226.9679 12785.5010 -1.1928 4.70E-05 1.09E-03 
Zik1 960.5538 420.8368 -1.1906 3.19E-06 1.20E-04 
Nr2f1 1213.0883 532.0365 -1.1891 7.60E-05 1.61E-03 
Cbs 89.5502 39.3006 -1.1881 1.53E-03 1.66E-02 
Snora26 66.4027 29.1506 -1.1877 5.96E-04 8.00E-03 
Scube2 309.7533 136.2751 -1.1846 2.38E-03 2.27E-02 
Agpat3 1116.3188 491.3896 -1.1838 1.44E-07 9.09E-06 
Fam78b 139.7806 61.6117 -1.1819 1.86E-04 3.29E-03 
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H13 1428.7179 629.8178 -1.1817 1.19E-16 6.21E-14 
Gm3531 82.7837 36.6229 -1.1766 4.11E-04 6.07E-03 
Bcl2 394.6888 174.7148 -1.1757 5.66E-07 2.81E-05 
Crb2 1217.8694 540.1290 -1.1730 3.25E-14 1.12E-11 
Cdh6 800.8449 356.6617 -1.1670 1.02E-03 1.21E-02 
Rex2 447.0485 199.1438 -1.1666 9.84E-04 1.18E-02 
Irs1 1693.7849 756.3541 -1.1631 6.50E-16 3.04E-13 
Slco3a1 180.5684 80.6976 -1.1619 1.57E-04 2.88E-03 
Zfp459 357.6479 160.2568 -1.1582 5.47E-04 7.47E-03 
Fabp5 1746.0709 785.5523 -1.1523 1.87E-08 1.63E-06 
Exoc3l 63.4773 28.6108 -1.1497 1.27E-03 1.43E-02 
Twist1 76.3181 34.4054 -1.1494 7.62E-04 9.68E-03 
Etv1 407.1285 183.6976 -1.1482 3.11E-08 2.50E-06 
P3h2 337.6349 153.2041 -1.1400 1.34E-07 8.56E-06 
Gm37065 75.2258 34.1552 -1.1391 2.78E-04 4.47E-03 
Zfp600 403.0853 183.2855 -1.1370 7.81E-04 9.82E-03 
Zfp296 115.6875 52.6626 -1.1354 2.12E-03 2.09E-02 
Adamts6 160.7424 73.2262 -1.1343 3.57E-05 8.67E-04 
Aldh1l2 136.0960 62.1846 -1.1300 4.23E-04 6.19E-03 
Gm13461 81.9653 37.4674 -1.1294 6.37E-04 8.44E-03 
Igf2r 9292.7014 4260.7296 -1.1250 8.24E-20 6.27E-17 
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Lrmp 59.1559 27.1290 -1.1247 2.13E-03 2.10E-02 
Tshz3 228.6931 105.1169 -1.1214 2.22E-03 2.16E-02 
Megf9 906.7817 416.8409 -1.1213 3.50E-04 5.39E-03 
Amer2 103.7563 47.7130 -1.1207 2.41E-03 2.29E-02 
Gm13225 238.3780 109.7908 -1.1185 1.02E-03 1.21E-02 
Sfxn2 331.3617 152.8832 -1.1160 5.91E-09 6.17E-07 
AI504432 72.4162 33.5019 -1.1121 1.89E-03 1.94E-02 
Lrrc17 1079.8847 499.6516 -1.1119 2.66E-04 4.32E-03 
Siglec1 84.4393 39.1476 -1.1090 2.39E-03 2.28E-02 
Cachd1 2012.8475 937.0510 -1.1030 1.89E-16 9.59E-14 
Rab11fip5 489.5926 227.9935 -1.1026 3.73E-03 3.16E-02 
Tst 110.3775 51.6380 -1.0959 5.63E-05 1.26E-03 
Gpa33 169.9918 79.6341 -1.0940 1.19E-04 2.31E-03 
Wnt3 85.4388 40.0858 -1.0918 3.37E-04 5.23E-03 
Zhx2 431.6440 202.7086 -1.0904 3.08E-08 2.49E-06 
Spry1 887.9858 417.4841 -1.0888 1.48E-11 2.79E-09 
Slc7a3 1334.5146 627.8050 -1.0879 1.12E-03 1.30E-02 
Dnajc6 235.6596 111.0981 -1.0849 1.37E-03 1.52E-02 
Otx2 624.1963 294.4326 -1.0841 1.27E-04 2.43E-03 
Bcat1 3085.0929 1456.8619 -1.0824 2.45E-05 6.37E-04 
Apcdd1 404.4224 191.3827 -1.0794 9.28E-08 6.28E-06 
 145 
Mppe1 93.7328 44.4242 -1.0772 2.55E-03 2.40E-02 
Sp8 1271.3243 602.7558 -1.0767 2.15E-03 2.11E-02 
Gldc 5076.5395 2409.8249 -1.0749 1.95E-17 1.19E-14 
Tfcp2l1 1532.2853 731.1865 -1.0674 2.94E-03 2.65E-02 
Ooep 194.0437 92.8414 -1.0635 6.20E-04 8.24E-03 
Pcsk5 146.5803 70.1366 -1.0635 4.16E-04 6.11E-03 
Fam167a 175.8964 84.2116 -1.0626 1.72E-04 3.09E-03 
Hipk2 1233.9159 591.0208 -1.0620 8.38E-06 2.67E-04 
Gm6180 60.5278 29.0223 -1.0604 4.33E-03 3.51E-02 
Gm13154 450.9449 216.4462 -1.0589 2.53E-03 2.38E-02 
Trim2 1909.2769 916.4267 -1.0589 3.89E-14 1.32E-11 
Pou5f1 3780.2337 1819.8995 -1.0546 1.53E-03 1.65E-02 
Cerk 431.0249 207.6804 -1.0534 5.34E-04 7.35E-03 
Fut9 568.2209 273.9605 -1.0525 1.61E-07 9.91E-06 
2610318N02Rik 693.0175 334.5087 -1.0508 1.44E-10 2.30E-08 
 Sep3 1148.5513 555.8546 -1.0470 2.13E-03 2.10E-02 
Dgat2 292.5788 141.7787 -1.0452 4.85E-07 2.51E-05 
Ppp4r4 180.9182 87.6996 -1.0447 4.35E-04 6.30E-03 
Pkdcc 1831.2646 888.8444 -1.0428 2.30E-06 9.14E-05 
Fgf5 223.8867 108.7134 -1.0422 3.04E-03 2.72E-02 
Pkia 690.2532 335.3060 -1.0416 1.94E-06 7.96E-05 
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Rgs2 488.7387 237.8183 -1.0392 1.48E-03 1.61E-02 
Sparcl1 161.7817 78.8366 -1.0371 6.34E-04 8.41E-03 
Rps6ka2 1601.7214 783.2298 -1.0321 2.27E-14 8.11E-12 
Phf2 625.8573 306.3095 -1.0308 7.33E-04 9.42E-03 
Tmem229a 97.5618 48.1562 -1.0186 1.44E-03 1.57E-02 
Lad1 262.5589 129.7457 -1.0170 4.34E-05 1.02E-03 
Map6 366.1999 181.9378 -1.0092 1.32E-03 1.48E-02 
Myb 232.8799 115.8400 -1.0075 2.84E-03 2.59E-02 
BC064078 149.5282 74.4598 -1.0059 4.14E-03 3.40E-02 
Adgrl3 380.9406 189.7584 -1.0054 3.51E-03 3.02E-02 
Adamts7 462.6814 230.5014 -1.0052 9.37E-05 1.91E-03 
Mthfd2 1197.3426 597.1456 -1.0037 1.50E-03 1.63E-02 
Vash2 811.2325 405.2200 -1.0014 5.41E-10 7.72E-08 
Prob1 131.0078 262.2272 1.0012 1.36E-04 2.57E-03 
Hpn 111.9873 224.2406 1.0017 1.68E-07 1.03E-05 
Pld6 58.1154 116.5129 1.0035 3.47E-05 8.51E-04 
Shisa8 68.5369 137.5728 1.0052 2.74E-06 1.06E-04 
Sgce 583.6004 1172.0925 1.0060 1.12E-09 1.42E-07 
Fam161a 43.4289 87.2430 1.0064 1.08E-03 1.27E-02 
Calr3 46.3571 93.3138 1.0093 1.02E-03 1.21E-02 
Jag2 320.7101 646.2447 1.0108 6.75E-10 9.28E-08 
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Ypel2 176.1140 355.2591 1.0124 1.71E-07 1.05E-05 
Trim21 282.8989 571.2565 1.0139 1.42E-05 4.08E-04 
Ankrd37 69.8897 141.2213 1.0148 6.06E-04 8.09E-03 
Tnik 124.9679 253.0258 1.0177 1.36E-05 3.94E-04 
Gatm 189.9437 384.8729 1.0188 5.10E-08 3.79E-06 
Fbxl8 37.6645 76.5067 1.0224 4.42E-03 3.56E-02 
Gm43597 74.1591 150.7637 1.0236 8.08E-05 1.70E-03 
Phldb3 43.4643 88.3856 1.0240 2.01E-03 2.02E-02 
Psme1 1561.8508 3176.3498 1.0241 1.33E-08 1.27E-06 
Tmem220 31.4002 63.8606 1.0242 6.06E-03 4.49E-02 
Synpo 75.1128 152.9660 1.0261 9.24E-04 1.12E-02 
Car12 119.7580 243.9981 1.0267 8.26E-07 3.85E-05 
Cbx4 163.3112 332.8440 1.0272 1.33E-05 3.85E-04 
Chpt1 481.2397 982.2217 1.0293 7.64E-12 1.62E-09 
Hrc 158.7639 324.5373 1.0315 4.14E-03 3.40E-02 
Parp9 483.9018 989.7124 1.0323 2.05E-06 8.37E-05 
Rrad 116.4774 238.5323 1.0341 5.19E-04 7.22E-03 
Zfp750 33.2537 68.1665 1.0355 3.14E-03 2.78E-02 
Neurl1b 42.0078 86.1619 1.0364 4.88E-04 6.89E-03 
Ttc25 49.3097 101.3803 1.0398 2.07E-03 2.06E-02 
Cyb5d2 132.6106 272.8612 1.0410 8.01E-07 3.75E-05 
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Ets1 895.9082 1843.8147 1.0413 3.23E-07 1.77E-05 
Kat2b 851.1111 1754.2415 1.0434 1.24E-14 4.91E-12 
Nab1 440.1994 907.8816 1.0443 1.64E-04 2.99E-03 
Brdt 44.8196 92.5631 1.0463 1.92E-03 1.96E-02 
D330045A20Rik 104.5146 216.3352 1.0496 3.81E-04 5.73E-03 
Ampd3 36.0659 74.7922 1.0523 2.38E-04 3.96E-03 
Slc13a4 109.5769 227.5871 1.0545 5.09E-04 7.13E-03 
Egflam 177.9292 369.5558 1.0545 5.92E-05 1.31E-03 
Mmel1 23.9390 49.8124 1.0571 3.12E-03 2.78E-02 
Kcnab3 34.3806 71.7704 1.0618 1.17E-03 1.34E-02 
Pde11a 32.8473 68.6360 1.0632 1.94E-03 1.97E-02 
Crym 39.5045 82.5515 1.0633 3.91E-04 5.84E-03 
2810408A11Rik 220.7593 462.0095 1.0654 1.23E-03 1.40E-02 
Gca 104.0192 217.7193 1.0656 5.21E-07 2.63E-05 
Amigo2 131.6653 275.6869 1.0662 5.57E-05 1.25E-03 
Taf7l 29.8063 62.5464 1.0693 5.79E-03 4.35E-02 
Il33 34.5568 72.5394 1.0698 2.78E-03 2.55E-02 
Efhc1 41.5037 87.1288 1.0699 1.70E-03 1.79E-02 
Slc16a3 2393.9230 5029.7354 1.0711 8.82E-18 6.19E-15 
Gm11423 29.4688 61.9261 1.0714 6.79E-03 4.86E-02 
Slc16a4 40.3450 84.8765 1.0730 5.61E-03 4.24E-02 
 149 
Atp2a3 154.0728 324.4829 1.0745 9.73E-09 9.66E-07 
Flt4 101.1528 213.2430 1.0760 3.94E-06 1.45E-04 
P4ha1 1339.7264 2829.2422 1.0785 1.48E-04 2.77E-03 
Mtl5 41.1533 86.9896 1.0798 3.27E-03 2.87E-02 
Gpr20 36.3525 76.8850 1.0806 3.05E-04 4.82E-03 
P3h4 432.3480 915.4230 1.0822 8.84E-08 6.00E-06 
Dkk3 309.3824 655.4901 1.0832 8.46E-05 1.75E-03 
Slc50a1 169.6146 359.4506 1.0835 2.45E-08 2.03E-06 
Cyb561 235.0551 498.6183 1.0849 7.13E-11 1.19E-08 
Inf2 228.5933 486.2688 1.0890 4.40E-04 6.35E-03 
Eps8l1 132.4285 281.8443 1.0897 2.90E-04 4.63E-03 
Trap1a 908.6037 1935.3587 1.0909 1.60E-08 1.45E-06 
Gngt2 45.7121 97.5489 1.0935 1.25E-04 2.41E-03 
BC026585 175.9901 376.5348 1.0973 1.46E-08 1.37E-06 
Nfatc2 86.1391 184.4727 1.0987 2.06E-03 2.05E-02 
Lmntd2 47.6173 102.1715 1.1014 3.02E-04 4.79E-03 
Gm12758 36.9528 79.3143 1.1019 1.07E-03 1.26E-02 
Klhl10 23.9768 51.5524 1.1044 5.28E-03 4.08E-02 
Myh3 40.4427 86.9597 1.1045 1.65E-04 2.99E-03 
Sema3e 962.8070 2070.4302 1.1046 1.32E-06 5.74E-05 
Chrnb1 113.6280 244.6372 1.1063 7.48E-07 3.56E-05 
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Nrg4 23.9575 51.6091 1.1071 5.53E-04 7.54E-03 
Nr3c1 231.0857 497.8996 1.1074 7.52E-12 1.62E-09 
Ezh1 741.9629 1601.0540 1.1096 1.83E-09 2.18E-07 
4632428N05Rik 59.3387 128.0653 1.1098 1.94E-03 1.97E-02 
Aifm2 60.1259 130.0617 1.1131 1.71E-06 7.17E-05 
Adssl1 241.7634 523.4435 1.1144 3.35E-04 5.21E-03 
Atg10 96.2186 208.4947 1.1156 4.43E-06 1.59E-04 
Dmc1 241.3049 523.7430 1.1180 4.23E-13 1.17E-10 
Pygl 194.7303 422.8381 1.1186 3.13E-04 4.93E-03 
Adcy2 84.0482 182.9711 1.1223 1.58E-05 4.44E-04 
Cox7a1 55.9473 121.8228 1.1226 2.77E-05 7.07E-04 
Gstm6 100.8593 219.6616 1.1229 1.98E-06 8.11E-05 
Des 552.9723 1207.0696 1.1262 2.14E-04 3.68E-03 
Lgals9 33.7515 73.6967 1.1266 2.98E-03 2.68E-02 
Syne1 129.1445 283.1264 1.1325 1.25E-07 8.11E-06 
Padi3 57.3445 125.8573 1.1341 5.10E-06 1.76E-04 
Rras 201.3204 442.7093 1.1369 3.46E-08 2.73E-06 
Galnt12 149.9222 329.7356 1.1371 1.62E-08 1.45E-06 
Cyp4f13 173.5500 382.1771 1.1389 4.68E-09 5.03E-07 
Platr14 233.5314 514.5256 1.1396 1.64E-09 1.98E-07 
Aifm3 88.4641 194.9165 1.1397 1.11E-08 1.08E-06 
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Rapgef5 431.7828 951.6675 1.1402 1.36E-14 5.17E-12 
Igfbp4 1712.9685 3783.8160 1.1433 8.13E-05 1.70E-03 
Neat1 444.9396 983.4956 1.1443 4.06E-04 6.02E-03 
1810011O10Rik 101.4409 224.4117 1.1455 5.40E-03 4.12E-02 
Nmi 111.3087 246.4445 1.1467 1.25E-04 2.41E-03 
Oas1c 53.3562 118.2923 1.1486 7.13E-05 1.53E-03 
Stat5a 152.6822 338.5577 1.1489 5.50E-09 5.80E-07 
Shox2 36.7677 81.5896 1.1499 4.81E-03 3.80E-02 
Psmb10 537.7742 1193.9891 1.1507 2.12E-04 3.65E-03 
Rassf6 36.5446 81.1553 1.1510 2.93E-04 4.68E-03 
Elmo3 151.9440 338.2652 1.1546 6.77E-09 6.94E-07 
Rbm44 292.7688 652.4125 1.1560 1.85E-09 2.18E-07 
Myo1h 16.2671 36.2660 1.1567 4.33E-03 3.51E-02 
Susd2 76.5772 170.8675 1.1579 1.02E-04 2.05E-03 
Adgre5 124.5779 278.1937 1.1590 1.51E-08 1.40E-06 
Plekhd1 30.0761 67.3210 1.1624 1.23E-04 2.37E-03 
Cep112 82.4597 184.7758 1.1640 5.45E-04 7.46E-03 
Thra 754.1833 1690.5729 1.1645 2.51E-16 1.24E-13 
Pde4b 285.0702 639.5426 1.1657 1.10E-11 2.16E-09 
Carns1 28.6357 64.3534 1.1682 4.06E-03 3.35E-02 
Anxa2 1117.3788 2512.3936 1.1689 5.17E-07 2.62E-05 
 152 
Ybx2 45.5383 102.4967 1.1704 8.75E-06 2.75E-04 
Cyp2j9 20.9745 47.3032 1.1733 6.78E-03 4.86E-02 
Dhx58 19.8504 44.8123 1.1747 2.80E-03 2.56E-02 
Zrsr1 235.4355 532.1963 1.1766 1.17E-11 2.28E-09 
Sec11c 180.1998 407.8163 1.1783 6.45E-10 9.04E-08 
Syne3 83.4225 188.8382 1.1786 1.29E-03 1.45E-02 
Slc26a10 44.6496 101.2329 1.1810 1.80E-04 3.20E-03 
Bik 67.7784 153.9069 1.1832 2.66E-04 4.32E-03 
N4bp2l1 37.9123 86.2993 1.1867 1.14E-04 2.24E-03 
Rbakdn 13.6407 31.1952 1.1934 3.26E-03 2.86E-02 
Pde4a 82.0765 187.8452 1.1945 1.93E-06 7.93E-05 
Plekhn1 56.7969 130.2063 1.1969 1.57E-05 4.43E-04 
Faah 46.7281 107.3610 1.2001 8.43E-07 3.92E-05 
Zcchc24 267.6080 615.0488 1.2006 7.99E-07 3.75E-05 
Unc5a 90.5073 208.0177 1.2006 1.01E-06 4.58E-05 
Sohlh2 180.6396 415.3628 1.2013 3.75E-03 3.17E-02 
Dcxr 307.2823 706.6574 1.2014 5.67E-13 1.48E-10 
Acsf2 283.0399 651.7198 1.2032 3.92E-10 5.73E-08 
Igfbp3 604.8068 1393.1117 1.2038 3.84E-05 9.20E-04 
C130074G19Rik 85.8001 197.8819 1.2056 5.10E-04 7.14E-03 
Kank3 355.0133 819.4889 1.2069 1.14E-06 5.05E-05 
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Mr1 42.7577 98.8170 1.2086 1.59E-03 1.70E-02 
Agbl2 34.2427 79.2916 1.2114 4.28E-04 6.23E-03 
Bnip3 1226.1206 2843.0872 1.2134 1.49E-04 2.77E-03 
Bcas1 17.1401 39.7514 1.2136 3.42E-03 2.96E-02 
Cacna1h 191.4933 444.8348 1.2160 7.39E-10 9.92E-08 
Gm2a 553.6214 1286.5082 1.2165 3.07E-09 3.44E-07 
Klc3 297.8823 693.6161 1.2194 1.57E-09 1.91E-07 
Ngfr 252.3736 588.2520 1.2209 2.22E-03 2.16E-02 
Kif19a 54.9329 128.5452 1.2265 5.31E-03 4.09E-02 
Slc7a4 77.7602 181.9865 1.2267 3.81E-07 2.05E-05 
Gnat2 27.2693 63.9204 1.2290 7.76E-04 9.79E-03 
Lrrn4cl 40.3331 94.5541 1.2292 2.26E-04 3.84E-03 
Lrrc51 51.1807 120.0955 1.2305 1.51E-03 1.64E-02 
Rnf135 125.9822 295.9356 1.2321 6.27E-09 6.47E-07 
Rell1 778.6661 1829.2434 1.2322 9.03E-10 1.18E-07 
Ugt8a 51.1276 120.1421 1.2326 2.67E-08 2.20E-06 
Trim12a 125.8894 296.3314 1.2351 2.41E-09 2.75E-07 
Il13ra1 98.9678 233.5487 1.2387 6.44E-08 4.58E-06 
Dhdh 216.0011 511.1760 1.2428 9.74E-14 2.92E-11 
Prkca 160.4162 380.3879 1.2457 1.57E-04 2.88E-03 
Cmpk2 82.9617 196.7794 1.2461 1.61E-06 6.81E-05 
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Trf 19.4986 46.2611 1.2464 6.35E-03 4.63E-02 
Alpk1 70.8724 168.9188 1.2530 4.25E-06 1.53E-04 
BC022960 45.2550 107.9692 1.2545 2.39E-05 6.26E-04 
Podn 24.3385 58.0786 1.2548 6.79E-03 4.86E-02 
Susd5 24.6694 58.8698 1.2548 2.22E-04 3.78E-03 
Fbxo47 36.2580 86.5247 1.2548 2.79E-05 7.09E-04 
Fam83b 83.2569 198.9160 1.2565 1.54E-07 9.57E-06 
Pla2g16 220.9291 530.2184 1.2630 1.96E-13 5.60E-11 
Sh2d5 32.4518 77.8947 1.2632 1.93E-03 1.97E-02 
Fetub 67.8254 162.8652 1.2638 2.63E-03 2.45E-02 
Ptpn18 36.2862 87.1345 1.2638 1.01E-04 2.04E-03 
Ly6a 98.0719 235.7541 1.2654 2.26E-06 9.02E-05 
Sfi1 477.0708 1148.6086 1.2676 7.21E-04 9.30E-03 
Slc15a2 107.7285 259.3998 1.2678 5.97E-04 8.02E-03 
Scarf1 68.1303 164.6011 1.2726 5.05E-06 1.75E-04 
Myh7b 21.6080 52.2482 1.2738 2.73E-04 4.41E-03 
C1qtnf4 26.0488 62.9870 1.2738 1.84E-04 3.26E-03 
Rasgrp4 159.0005 384.6757 1.2746 5.47E-13 1.47E-10 
Sez6 92.9482 225.2304 1.2769 3.18E-04 5.00E-03 
Slc43a3 295.0410 715.7006 1.2784 1.80E-14 6.73E-12 
Sec14l4 45.2586 109.8199 1.2789 4.38E-05 1.03E-03 
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Pgm2 1152.3591 2798.4633 1.2800 3.19E-23 3.64E-20 
Socs1 51.2319 124.5191 1.2813 6.45E-06 2.13E-04 
Lgals3bp 36.3054 88.4206 1.2842 6.65E-04 8.75E-03 
Ddit4 1403.6826 3422.7783 1.2860 1.61E-04 2.95E-03 
Tbxa2r 12.1833 29.7663 1.2888 5.17E-03 4.01E-02 
Irs3 19.8719 48.5891 1.2899 1.67E-03 1.77E-02 
Rab20 69.6206 170.6238 1.2932 1.47E-07 9.22E-06 
Lrriq3 20.8694 51.1522 1.2934 5.60E-03 4.24E-02 
Pear1 23.5493 57.7537 1.2942 2.60E-03 2.43E-02 
Ddx4 195.6295 480.9106 1.2976 2.14E-14 7.81E-12 
Ndufa4l2 26.9131 66.2245 1.2991 1.27E-03 1.43E-02 
Art1 17.5815 43.2702 1.2993 1.95E-03 1.98E-02 
Rapgefl1 59.4853 146.4776 1.3001 2.04E-04 3.53E-03 
Tm6sf1 88.5548 218.1561 1.3007 1.42E-09 1.74E-07 
Acadvl 846.8413 2087.9641 1.3019 5.40E-12 1.20E-09 
Baiap3 46.4757 114.6325 1.3025 1.02E-05 3.14E-04 
Irf1 929.1760 2295.5461 1.3048 3.82E-06 1.42E-04 
Oprd1 20.0407 49.5717 1.3066 2.56E-03 2.40E-02 
Tmem176a 99.5315 246.5251 1.3085 6.04E-07 2.94E-05 
Ccdc73 42.6307 105.5973 1.3086 1.53E-06 6.52E-05 
Lmod1 84.8749 210.7086 1.3118 7.91E-05 1.67E-03 
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Crlf1 11.1503 27.7114 1.3134 1.35E-03 1.50E-02 
Gmfg 68.9871 171.6705 1.3152 1.68E-08 1.47E-06 
Mov10l1 36.1944 90.1029 1.3158 4.92E-03 3.87E-02 
Gm11532 18.1326 45.1757 1.3170 4.57E-03 3.66E-02 
Prkg2 54.6984 136.3323 1.3176 1.17E-05 3.46E-04 
Aldh3a2 1455.4729 3630.5007 1.3187 2.80E-10 4.30E-08 
Olfr1372-ps1 32.7261 81.6800 1.3195 3.45E-05 8.49E-04 
Nfe2l3 58.4043 146.1699 1.3235 1.99E-07 1.18E-05 
Nol4l 399.9905 1001.3654 1.3239 5.87E-12 1.29E-09 
Kcp 21.2631 53.3241 1.3264 2.61E-04 4.26E-03 
Procr 42.8366 108.1258 1.3358 4.87E-06 1.71E-04 
Tmem173 55.9971 141.3484 1.3358 3.51E-05 8.59E-04 
Stat3 1315.7981 3322.1471 1.3362 1.24E-23 1.54E-20 
Gadd45b 246.5319 624.3039 1.3405 1.63E-03 1.73E-02 
Sertad4 238.3019 604.1226 1.3421 1.42E-08 1.35E-06 
Slfn5 28.1643 71.4040 1.3421 4.59E-03 3.67E-02 
Stc1 28.5793 72.6708 1.3464 3.74E-03 3.17E-02 
Clic5 196.9318 500.7982 1.3465 7.96E-13 1.96E-10 
Lrp8os2 115.7099 294.5424 1.3480 9.81E-06 3.03E-04 
Tnnt1 194.4448 495.0678 1.3483 4.23E-04 6.19E-03 
1700029J07Rik 25.5091 64.9543 1.3484 1.31E-03 1.47E-02 
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Snhg14 465.0178 1186.0800 1.3508 5.11E-17 2.92E-14 
Tubg2 19.8013 50.5760 1.3529 1.38E-03 1.52E-02 
Ccdc155 34.6269 88.5157 1.3540 1.34E-05 3.87E-04 
Trim7 15.0719 38.5397 1.3545 1.82E-03 1.89E-02 
Mef2c 136.5361 349.1658 1.3546 4.16E-09 4.53E-07 
Tex19.2 23.0513 58.9574 1.3548 2.68E-03 2.49E-02 
Afap1l2 296.4360 758.3341 1.3551 6.46E-04 8.54E-03 
Aebp1 194.6547 498.8102 1.3576 3.32E-09 3.70E-07 
Coro2a 119.0473 306.1414 1.3627 2.23E-12 5.29E-10 
Tap2 100.9896 260.1466 1.3651 3.64E-04 5.55E-03 
Wdr93 26.3734 68.0957 1.3685 5.28E-04 7.29E-03 
Tmem59l 60.5859 156.5779 1.3698 1.33E-10 2.14E-08 
Parp10 271.3902 702.7218 1.3726 7.99E-06 2.57E-04 
G0s2 57.3950 148.8977 1.3753 2.92E-06 1.12E-04 
Tapbp 1201.9029 3119.1896 1.3759 1.02E-11 2.03E-09 
Gstt3 65.4622 169.9045 1.3760 2.68E-08 2.20E-06 
Tlcd2 145.3326 379.8753 1.3862 7.26E-13 1.84E-10 
Tmod1 22.0402 57.6148 1.3863 1.21E-03 1.38E-02 
Gramd1c 64.1076 167.8579 1.3887 3.39E-07 1.85E-05 
C3 8.8574 23.2102 1.3898 4.74E-03 3.76E-02 
Emp3 40.1201 105.1875 1.3906 3.55E-05 8.64E-04 
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AU022751 22.6715 59.5751 1.3938 6.70E-04 8.79E-03 
Rec8 634.8332 1670.7360 1.3960 8.88E-05 1.82E-03 
H2-T23 68.1957 179.5453 1.3966 2.74E-06 1.06E-04 
Tex14 297.1768 782.8015 1.3973 3.23E-15 1.37E-12 
Neurod1 149.5025 395.2576 1.4026 6.22E-03 4.57E-02 
Echdc3 39.0445 103.7143 1.4094 3.47E-05 8.52E-04 
Mlxipl 15.9263 42.3211 1.4100 7.86E-04 9.86E-03 
Mycbpap 51.8690 137.9226 1.4109 2.62E-03 2.44E-02 
CN725425 41.1493 109.7996 1.4159 6.17E-08 4.42E-06 
BB218582 17.8300 47.6122 1.4170 2.25E-03 2.18E-02 
Coch 95.7929 255.8283 1.4172 1.98E-07 1.17E-05 
Cd68 95.1475 254.3947 1.4188 3.02E-10 4.56E-08 
Guca1a 14.1079 37.7434 1.4197 9.29E-04 1.13E-02 
A2m 35.6867 95.7462 1.4238 1.33E-04 2.52E-03 
Gbp10 23.1910 62.2583 1.4247 5.98E-04 8.02E-03 
Gm4779 32.8596 88.2150 1.4247 2.33E-04 3.90E-03 
Smc1b 138.1400 372.0931 1.4295 6.57E-08 4.65E-06 
Capn12 13.3775 36.0642 1.4308 5.03E-03 3.92E-02 
Lrrc18 23.5120 63.4640 1.4325 4.98E-04 7.00E-03 
Stx11 22.1439 59.8078 1.4334 3.95E-04 5.87E-03 
Crim1 673.4911 1827.8483 1.4404 1.11E-23 1.54E-20 
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Dennd2d 31.3768 85.3514 1.4437 4.18E-06 1.51E-04 
Pomc 36.3267 98.8407 1.4441 6.83E-05 1.47E-03 
Plekhg1 842.5648 2297.8430 1.4474 1.32E-24 2.01E-21 
Best1 17.2363 47.1499 1.4518 1.34E-03 1.49E-02 
Fmo5 18.9025 51.7318 1.4525 3.15E-03 2.79E-02 
Ctso 69.3127 190.0267 1.4550 2.17E-07 1.27E-05 
Bin2 73.4192 201.6352 1.4575 1.29E-12 3.13E-10 
Phyhip 60.0957 165.6012 1.4624 4.43E-07 2.35E-05 
Psmb9 38.3846 106.2119 1.4683 3.36E-06 1.26E-04 
Zmat1 51.1781 142.0068 1.4724 1.30E-06 5.69E-05 
Gm807 25.9127 72.0367 1.4751 2.25E-03 2.18E-02 
Gm11837 11.6316 32.3721 1.4767 1.73E-03 1.82E-02 
Dlec1 25.4386 70.8651 1.4781 5.48E-04 7.49E-03 
Nrk 1371.8020 3841.5138 1.4856 6.12E-08 4.42E-06 
Airn 38.5382 108.2488 1.4900 1.15E-04 2.26E-03 
Myo15 8.6792 24.4667 1.4952 5.88E-03 4.40E-02 
Rdm1 302.5323 853.5434 1.4964 1.97E-05 5.32E-04 
Fgl1 30.4290 86.1578 1.5015 5.63E-05 1.26E-03 
Ppp1r3g 10.8504 30.7368 1.5022 6.27E-03 4.59E-02 
H2-K1 643.4523 1829.4098 1.5075 7.79E-29 1.78E-25 
Slc47a2 9.2398 26.3309 1.5108 2.15E-03 2.11E-02 
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Slc41a2 15.8627 45.2684 1.5129 8.02E-05 1.69E-03 
Sowaha 20.4636 58.5389 1.5163 8.56E-05 1.77E-03 
Fmnl1 10.3123 29.5253 1.5176 1.27E-03 1.43E-02 
Cd74 32.8159 93.9795 1.5180 2.13E-05 5.68E-04 
Tfr2 10.9322 31.3568 1.5202 6.00E-04 8.03E-03 
Adamtsl4 35.3812 101.4973 1.5204 1.70E-05 4.74E-04 
Ndrg1 314.0184 905.2255 1.5274 7.50E-04 9.57E-03 
Espn 77.2468 223.9492 1.5356 7.21E-12 1.57E-09 
Fgf11 35.8035 103.9357 1.5375 1.61E-08 1.45E-06 
Egr1 109.9002 319.9696 1.5417 1.30E-09 1.62E-07 
1810010H24Rik 31.8293 93.0381 1.5475 3.15E-06 1.20E-04 
Sgcd 23.2656 68.0467 1.5483 5.77E-03 4.35E-02 
Lrrc8e 14.7978 43.3032 1.5491 1.56E-03 1.67E-02 
Tmem106a 91.5503 268.2538 1.5510 2.88E-11 5.26E-09 
Tex11 109.6107 323.9817 1.5635 1.08E-04 2.14E-03 
2010300C02Rik 57.5807 170.3895 1.5652 2.21E-08 1.87E-06 
Tdrd5 215.4523 637.7114 1.5655 8.30E-17 4.60E-14 
Lgr6 26.9717 79.8790 1.5664 5.29E-05 1.20E-03 
Arg1 27.7105 82.3121 1.5707 4.26E-04 6.21E-03 
Gm13032 9.7940 29.1604 1.5740 6.97E-03 4.95E-02 
Selplg 11.9085 35.5029 1.5759 2.83E-03 2.58E-02 
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8030474K03Rik 56.7760 169.4069 1.5771 4.36E-03 3.52E-02 
Fkbp7 45.3390 135.2932 1.5773 5.94E-07 2.91E-05 
Usp18 20.5880 61.4854 1.5784 1.44E-03 1.58E-02 
Cyp2s1 21.8175 65.2885 1.5813 1.00E-06 4.56E-05 
Smoc2 48.0060 144.2187 1.5870 4.52E-04 6.50E-03 
Gm42875 12.2748 36.8948 1.5877 5.32E-03 4.10E-02 
Itga2b 22.7369 68.8497 1.5984 5.10E-05 1.16E-03 
Got1l1 108.2364 328.2837 1.6008 3.98E-11 7.05E-09 
Pik3ap1 29.3725 89.3040 1.6043 4.44E-05 1.04E-03 
Gabra4 39.8208 121.1466 1.6052 2.46E-07 1.41E-05 
Amhr2 22.2889 67.8457 1.6059 2.86E-06 1.11E-04 
Ace 28.5789 87.2020 1.6094 2.62E-05 6.76E-04 
Gm13261 16.8305 51.5073 1.6137 1.02E-04 2.04E-03 
Ppp1r14a 107.4669 329.0723 1.6145 1.10E-05 3.30E-04 
Unc93b1 138.9831 430.1786 1.6300 1.41E-17 8.89E-15 
Ocln 405.0820 1255.8874 1.6324 7.66E-27 1.56E-23 
Padi2 38.5120 119.4937 1.6336 5.37E-07 2.70E-05 
Gm1564 143.8182 446.3871 1.6340 2.23E-03 2.16E-02 
Prss50 15.1094 47.0728 1.6395 2.53E-06 9.93E-05 
Gbp9 117.5802 366.4245 1.6399 9.71E-14 2.92E-11 
Abcd2 440.2904 1376.0000 1.6440 4.50E-05 1.05E-03 
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Abcc3 22.6884 71.1285 1.6485 6.60E-06 2.17E-04 
Bcl3 27.4150 86.1482 1.6519 2.55E-06 9.99E-05 
Scn7a 25.9852 81.6607 1.6520 1.52E-04 2.82E-03 
Trim12c 217.3670 683.4468 1.6527 9.12E-14 2.82E-11 
Gsap 59.0266 185.7533 1.6540 2.70E-10 4.18E-08 
Rnf112 13.7531 43.4426 1.6594 5.20E-04 7.22E-03 
Parp4 226.2777 714.9850 1.6598 2.22E-04 3.78E-03 
Tmem140 60.7659 192.7629 1.6655 3.53E-07 1.92E-05 
Ldb3 24.0169 76.2446 1.6666 1.12E-05 3.35E-04 
Cyct 187.9921 598.8772 1.6716 1.26E-23 1.54E-20 
Pramef12 530.7252 1690.7487 1.6716 1.31E-08 1.27E-06 
Cpxm2 23.8546 76.2073 1.6757 1.89E-03 1.94E-02 
Sox30 7.4306 23.8624 1.6832 3.37E-03 2.94E-02 
Pgam2 27.3781 87.9307 1.6833 5.49E-06 1.86E-04 
Dnah10 36.6451 117.9424 1.6864 2.20E-07 1.28E-05 
Zbtb7c 16.8676 54.3472 1.6879 4.33E-04 6.29E-03 
Wt1 81.9033 264.9011 1.6935 1.21E-17 7.87E-15 
Sycp1 14.3892 46.6417 1.6966 4.38E-06 1.58E-04 
4930447C04Rik 190.0210 618.4815 1.7026 1.64E-11 3.05E-09 
Dlgap1 32.4896 105.7816 1.7030 2.24E-04 3.81E-03 
Rnf180 112.7086 367.3762 1.7047 8.87E-14 2.79E-11 
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Fbxo40 50.0988 163.5486 1.7069 2.22E-03 2.16E-02 
Dmrt1 503.2347 1646.0333 1.7097 2.30E-13 6.48E-11 
Trim14 10.1200 33.1617 1.7123 2.42E-03 2.30E-02 
Hpse 52.0954 171.0412 1.7151 3.04E-07 1.69E-05 
Cacng6 75.4822 247.8513 1.7153 3.43E-17 2.02E-14 
Elf4 155.8689 514.3941 1.7225 1.58E-06 6.69E-05 
Rgs22 28.2553 93.8887 1.7324 1.27E-06 5.55E-05 
Skap1 12.8588 43.0239 1.7424 7.73E-04 9.77E-03 
Gm15286 7.4915 25.1192 1.7455 2.26E-03 2.18E-02 
Helt 19.6683 65.9861 1.7463 4.28E-03 3.48E-02 
Dmrta1 40.8700 137.1443 1.7466 3.19E-06 1.20E-04 
Fam65c 25.3599 85.1906 1.7481 4.93E-05 1.13E-03 
Icam5 8.6324 29.0806 1.7522 2.35E-03 2.25E-02 
Bdkrb2 12.6364 42.5824 1.7527 3.28E-03 2.87E-02 
Aipl1 12.6320 42.6371 1.7550 1.11E-03 1.29E-02 
Rasd1 12.6334 42.7090 1.7573 2.45E-04 4.05E-03 
Cyp2d22 15.7570 53.5550 1.7650 5.42E-04 7.42E-03 
Gpr155 60.6368 206.9286 1.7709 7.23E-11 1.20E-08 
Ifih1 120.9784 412.9371 1.7712 5.55E-13 1.47E-10 
Nmnat3 5.5858 19.0857 1.7727 5.52E-03 4.18E-02 
Dnaja4 150.0869 513.1397 1.7736 4.68E-08 3.51E-06 
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Gng13 9.2614 31.6975 1.7751 2.76E-03 2.54E-02 
Paqr5 6.4121 21.9655 1.7764 4.72E-03 3.74E-02 
Mcoln2 12.1618 41.9013 1.7846 1.99E-03 2.01E-02 
Zc3h6 119.4633 415.1793 1.7972 9.15E-18 6.19E-15 
Cox4i2 8.0879 28.1889 1.8013 4.87E-03 3.83E-02 
Trim30a 9.3480 32.5976 1.8020 5.38E-03 4.12E-02 
Sptbn5 13.8214 48.3175 1.8056 8.02E-06 2.58E-04 
Pnma5 83.8672 294.4904 1.8120 1.35E-04 2.55E-03 
9530082P21Rik 17.0226 59.8346 1.8135 5.54E-05 1.25E-03 
Fbxo2 80.7816 284.0876 1.8142 1.84E-09 2.18E-07 
Psmb8 107.7042 379.2427 1.8160 2.07E-05 5.57E-04 
Dnah11 82.5439 291.3954 1.8197 4.26E-11 7.48E-09 
Adam2 11.8076 42.2096 1.8379 8.50E-05 1.76E-03 
Evpl 81.8040 294.4664 1.8479 1.20E-21 1.10E-18 
Asah2 60.7828 219.1670 1.8503 4.12E-12 9.30E-10 
Rtp4 19.9585 72.1918 1.8548 3.17E-05 7.87E-04 
Syt17 25.5605 92.6454 1.8578 2.36E-08 1.97E-06 
Txnip 3165.2228 11520.0925 1.8638 4.32E-04 6.28E-03 
Ier3 71.0148 260.0723 1.8727 1.92E-03 1.96E-02 
Lox 17.1449 62.8973 1.8752 9.18E-05 1.87E-03 
Sphkap 33.9468 126.2096 1.8945 5.62E-07 2.81E-05 
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Isg15 24.1103 89.6640 1.8949 9.00E-06 2.82E-04 
Dhrs7 207.0718 772.3037 1.8990 1.01E-34 3.70E-31 
Slc6a13 14.1055 53.0192 1.9103 3.91E-05 9.30E-04 
C920025E04Rik 14.5326 54.9855 1.9198 2.30E-04 3.87E-03 
Sycp2 17.1026 65.0339 1.9270 3.19E-07 1.75E-05 
H2-T10 54.1102 206.7339 1.9338 1.88E-08 1.63E-06 
Trim5 12.7533 48.7525 1.9346 3.89E-05 9.30E-04 
Kcnn4 3.9240 15.0442 1.9388 1.47E-03 1.60E-02 
Rhbdl3 91.1471 350.9383 1.9449 4.97E-20 3.95E-17 
4933427D06Rik 13.7317 52.8937 1.9456 2.73E-03 2.51E-02 
Sp140 16.1356 62.2683 1.9483 8.31E-05 1.73E-03 
Gm9112 78.5342 303.5714 1.9506 2.31E-14 8.11E-12 
H2-M3 23.1739 89.8534 1.9551 1.18E-07 7.74E-06 
Gm42637 10.5917 41.1081 1.9565 8.09E-04 1.01E-02 
Ifi27 26.7647 104.1312 1.9600 5.45E-06 1.85E-04 
Lat 25.6801 100.2235 1.9645 8.84E-12 1.81E-09 
Nxnl2 5.8393 22.8355 1.9674 2.71E-03 2.51E-02 
Lpar3 31.4491 123.0933 1.9687 1.08E-08 1.07E-06 
Catsperg1 26.0305 102.0202 1.9706 1.02E-10 1.66E-08 
Gcnt4 111.3340 437.5631 1.9746 2.48E-03 2.35E-02 
Dmkn 12.7041 50.1178 1.9800 4.81E-04 6.81E-03 
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Irf6 461.7431 1823.5981 1.9816 6.48E-10 9.04E-08 
Proca1 16.6519 65.9908 1.9866 4.10E-06 1.49E-04 
Ighm 59.3574 236.5316 1.9945 3.24E-04 5.09E-03 
Cerkl 14.5511 58.4832 2.0069 4.25E-05 1.00E-03 
Aldoc 215.6836 867.6424 2.0082 1.69E-15 7.71E-13 
1700024P16Rik 5.5765 22.4680 2.0104 5.38E-03 4.12E-02 
Shcbp1l 7.8388 31.6050 2.0114 1.52E-03 1.64E-02 
Ifi35 104.6149 424.3176 2.0201 2.25E-05 5.96E-04 
Tns4 22.1813 90.3173 2.0257 6.48E-07 3.13E-05 
Neurog3 83.0923 341.6931 2.0399 9.85E-06 3.03E-04 
Gbp4 138.2273 570.4679 2.0451 1.85E-15 8.24E-13 
Atp1b2 122.2184 505.9941 2.0497 1.20E-04 2.34E-03 
Cntnap1 20.0997 83.2184 2.0497 1.10E-06 4.89E-05 
Slc17a7 57.7501 240.0947 2.0557 2.21E-15 9.60E-13 
Uba7 16.6261 69.5880 2.0654 1.89E-05 5.15E-04 
Tgfbi 520.8911 2180.3083 2.0655 1.52E-13 4.41E-11 
Ltk 11.2558 47.3135 2.0716 4.03E-06 1.48E-04 
Spink2 6.3931 26.9344 2.0749 6.91E-04 9.01E-03 
Izumo1 20.5900 86.9188 2.0777 3.67E-08 2.86E-06 
Oasl2 223.0380 941.7511 2.0781 5.22E-11 8.99E-09 
Abcg3 4.4569 18.8252 2.0786 2.39E-03 2.28E-02 
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Gal3st1 24.9507 105.4646 2.0796 4.80E-07 2.50E-05 
Nmur2 12.6664 53.5625 2.0802 3.65E-04 5.55E-03 
Nxf3 115.1203 487.2829 2.0816 1.93E-26 3.52E-23 
Mgarp 165.9103 705.5638 2.0884 1.45E-35 6.64E-32 
Izumo1r 6.9493 29.8709 2.1038 5.28E-04 7.29E-03 
Parp14 246.5764 1061.3226 2.1058 1.89E-22 2.03E-19 
Stra8 87.5600 377.2841 2.1073 6.48E-03 4.69E-02 
Tgm2 298.4437 1297.0796 2.1197 1.88E-05 5.13E-04 
Nfix 19.3604 84.5951 2.1275 3.29E-08 2.61E-06 
Gm15283 8.9702 39.4527 2.1369 1.41E-03 1.55E-02 
1810041L15Rik 155.0780 684.4664 2.1420 2.89E-06 1.11E-04 
Snai2 16.6801 73.6261 2.1421 5.14E-06 1.77E-04 
Fstl4 41.9548 185.6131 2.1454 2.62E-12 6.09E-10 
Stk31 11.5873 51.4926 2.1518 7.99E-06 2.57E-04 
Cd274 36.4580 162.7085 2.1580 1.33E-06 5.76E-05 
Gbp3 239.5297 1074.5647 2.1655 1.73E-20 1.44E-17 
Lyve1 7.5901 34.1101 2.1680 1.39E-03 1.53E-02 
Meiob 8.7682 39.4210 2.1686 2.21E-06 8.85E-05 
H2-Aa 9.2964 42.3075 2.1862 1.70E-04 3.06E-03 
Dmrtc1b 21.3668 97.2520 2.1864 4.08E-07 2.18E-05 
Inca1 23.1858 106.6915 2.2021 4.35E-10 6.26E-08 
 168 
Noxa1 5.0155 23.1439 2.2062 1.91E-03 1.95E-02 
Gfra3 22.7472 105.5811 2.2146 2.25E-07 1.30E-05 
Pdk4 43.3203 201.8718 2.2203 1.26E-07 8.11E-06 
Dsc3 5.0131 23.4586 2.2263 4.11E-04 6.07E-03 
Gbp6 7.7075 36.2657 2.2343 6.92E-04 9.01E-03 
Tgtp1 11.4743 54.7080 2.2533 2.99E-04 4.76E-03 
Hs3st4 16.4733 78.7340 2.2569 2.33E-08 1.95E-06 
Erich3 5.4428 26.0528 2.2590 5.03E-03 3.92E-02 
Zbp1 32.6508 157.6930 2.2719 6.18E-08 4.42E-06 
Gbp2 638.2094 3085.4140 2.2734 3.75E-15 1.56E-12 
Cntd1 32.5003 158.2836 2.2840 8.76E-10 1.15E-07 
Ptrf 753.6068 3690.6393 2.2920 7.47E-29 1.78E-25 
Gbp8 19.5336 95.7148 2.2928 1.02E-06 4.58E-05 
Gbp2b 508.7398 2499.3653 2.2966 3.73E-22 3.78E-19 
Abhd3 13.8024 67.8264 2.2969 8.39E-09 8.42E-07 
C1ra 9.8832 48.6397 2.2991 5.69E-05 1.27E-03 
Ccr7 17.6914 88.1887 2.3175 1.03E-06 4.64E-05 
H2-T24 6.3883 31.9598 2.3228 1.43E-03 1.57E-02 
Dmrtc1a 4.9966 25.3599 2.3435 4.44E-03 3.57E-02 
Gsdmd 48.8375 250.6210 2.3594 4.89E-11 8.50E-09 
Ifi47 8.0243 41.2272 2.3611 1.60E-04 2.92E-03 
 169 
Dmrtb1 130.3161 683.9977 2.3920 3.40E-09 3.77E-07 
Igtp 140.2607 747.0062 2.4130 1.00E-16 5.38E-14 
G730013B05Rik 7.7897 41.6581 2.4190 4.02E-05 9.53E-04 
AI481877 12.1689 65.1723 2.4211 1.15E-05 3.41E-04 
Usp26 251.0676 1349.9356 2.4267 2.90E-07 1.64E-05 
4930524B15Rik 3.5815 19.2581 2.4268 1.61E-03 1.72E-02 
Mat1a 18.7438 101.4092 2.4357 8.18E-06 2.62E-04 
Pla2g2f 15.9243 86.1939 2.4364 5.04E-07 2.58E-05 
Rasl10a 17.7248 95.9877 2.4371 3.82E-11 6.85E-09 
Gbp7 357.2126 1936.0299 2.4382 6.25E-42 3.81E-38 
Fer1l4 2.5065 13.6946 2.4498 6.18E-03 4.55E-02 
Cyp4v3 24.6408 135.4510 2.4587 8.00E-12 1.68E-09 
Pyroxd2 3.6331 20.1263 2.4698 4.25E-03 3.46E-02 
Sgcg 5.2364 29.0494 2.4719 1.82E-03 1.89E-02 
Irgm2 119.7274 679.6037 2.5049 4.00E-14 1.33E-11 
Gm11413 7.7405 43.9678 2.5059 1.23E-05 3.61E-04 
Gm1141 78.6071 455.5574 2.5349 1.38E-11 2.62E-09 
Il12rb1 6.3815 37.7044 2.5628 5.34E-06 1.83E-04 
Asb9 55.0431 330.3876 2.5855 2.87E-05 7.23E-04 
Hrasls 4.7503 29.4810 2.6337 5.69E-07 2.81E-05 
Tnfsf10 10.8710 68.6165 2.6581 7.81E-07 3.69E-05 
 170 
Irf7 4.1776 26.4221 2.6610 1.42E-03 1.56E-02 
Rsad2 130.1580 825.0134 2.6642 3.02E-10 4.56E-08 
Lgi3 3.3703 21.5882 2.6793 1.99E-03 2.01E-02 
Gm23833 4.1309 26.6453 2.6894 2.60E-03 2.43E-02 
Clec1a 11.1293 74.1915 2.7369 1.09E-07 7.20E-06 
Gm44 8.8175 60.0158 2.7669 7.72E-07 3.65E-05 
Gm26868 2.7601 19.1104 2.7916 1.36E-03 1.52E-02 
Cytip 9.6156 67.0765 2.8024 8.45E-08 5.82E-06 
Ddx60 95.9453 722.5454 2.9128 5.86E-13 1.51E-10 
Gm2420 3.5465 27.5058 2.9553 2.61E-05 6.72E-04 
Gbp11 16.3073 128.0661 2.9733 4.53E-08 3.43E-06 
Atcayos 2.2039 17.4212 2.9827 2.76E-05 7.04E-04 
Hsd11b1 41.7933 352.0992 3.0746 4.51E-16 2.17E-13 
Prss38 2.5182 21.4179 3.0883 3.22E-05 7.97E-04 
Erg 17.4494 150.6751 3.1102 3.27E-03 2.87E-02 
Esr1 6.6491 61.3878 3.2067 6.87E-09 7.01E-07 
Ifit1 7.6910 83.4372 3.4394 6.04E-11 1.02E-08 
Adm 33.9373 374.1789 3.4628 7.38E-10 9.92E-08 
Ramp1 2.5041 28.9935 3.5333 1.36E-05 3.94E-04 
Casp4 1.3825 16.1626 3.5474 5.35E-03 4.11E-02 
Alox12b 2.2788 29.3741 3.6882 3.61E-05 8.74E-04 
 171 
Ifit3 1.8706 31.4014 4.0693 1.12E-05 3.35E-04 
Gm13404 0.8613 18.6097 4.4334 5.76E-06 1.93E-04 
B830012L14Rik 6.1211 0.0000 #NAME? 2.11E-03 2.09E-02 
 
FDR, False discovery rate; FC, Fold change. 
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Appendix 2 List of genes with altered expression levels upon Gcn5 loss 
in day 3 EBs identified by RNAseq (FDR 0.05, FC2) 
Gene name 
Normalized expression 
Log2ratio P-value FDR 
Gcn5fx/fx  Gcn5-/- 
H19 295.7229 39.5608 -2.9021 4.47E-04 1.84E-02 
Mid2 22.2336 50.6207 1.1870 1.57E-03 4.59E-02 
Gm38393 1476.4408 2955.2626 1.0012 3.28E-09 2.00E-06 
Nfix 21.1839 59.8629 1.4987 6.82E-05 4.63E-03 
Ptrf 459.9491 932.0316 1.0189 3.17E-07 7.51E-05 
Sgce 249.6504 573.1940 1.1991 2.02E-12 3.35E-09 
Ndrg1 656.7510 2437.9021 1.8922 2.91E-05 2.44E-03 
Trh 9789.4798 4550.6930 -1.1051 5.47E-06 7.49E-04 
Scube2 57.4297 15.1001 -1.9272 1.11E-05 1.25E-03 
Tex14 387.3497 855.7284 1.1435 2.25E-11 2.41E-08 
Ifi35 86.5145 308.3013 1.8333 6.40E-05 4.42E-03 
Phox2b 12.4354 0.5961 -4.3828 9.69E-04 3.19E-02 
St3gal1 26.2187 54.6358 1.0593 1.82E-03 4.97E-02 
Pax5 29.8262 7.2078 -2.0490 3.85E-06 5.66E-04 
Stc1 129.8966 344.9942 1.4092 7.19E-04 2.60E-02 
Cd34 99.9102 214.2235 1.1004 8.33E-05 5.42E-03 
Mpp2 180.3525 404.6391 1.1658 5.71E-08 1.96E-05 
 173 
Aldoc 909.9353 2177.9662 1.2591 2.15E-07 5.53E-05 
Tns4 9.7900 32.6697 1.7386 1.30E-04 7.34E-03 
H13 1182.0507 575.5301 -1.0383 1.46E-12 2.65E-09 
Aim1 95.0254 207.5686 1.1272 1.22E-05 1.30E-03 
P4ha1 1985.6404 4031.5676 1.0217 4.32E-04 1.80E-02 
Grb10 11086.8733 1345.4841 -3.0427 6.58E-23 4.00E-19 
Slc5a4b 91.5091 245.5334 1.4239 4.70E-07 1.04E-04 
Upp1 3509.6201 7527.8257 1.1009 1.26E-03 3.89E-02 
Id2 214.1148 77.5601 -1.4650 3.86E-07 8.91E-05 
Ace 27.5621 103.0379 1.9024 1.08E-06 2.03E-04 
Tekt1 10.0719 31.9644 1.6661 1.51E-03 4.46E-02 
Abcc3 64.1262 137.7773 1.1034 8.70E-04 3.00E-02 
Myh3 67.0591 164.8064 1.2973 2.19E-06 3.67E-04 
Krt19 149.2674 346.1946 1.2137 4.30E-04 1.80E-02 
Kat2a 2227.8727 701.2760 -1.6676 3.98E-32 7.26E-28 
Dhrs7 626.2132 1524.7409 1.2838 9.67E-19 2.52E-15 
Meg3 410.5595 18.8993 -4.4412 1.64E-11 1.87E-08 
Rnf180 90.5018 189.8833 1.0691 7.74E-06 9.73E-04 
Fst 328.7240 148.3242 -1.1481 1.58E-06 2.74E-04 
Otx2 290.1915 141.1145 -1.0401 2.17E-04 1.06E-02 
Angpt1 53.3111 9.0722 -2.5549 5.58E-04 2.18E-02 
 174 
Fbxo32 359.3874 176.5819 -1.0252 1.41E-08 6.58E-06 
Col2a1 865.9088 422.0682 -1.0367 1.35E-05 1.40E-03 
C3 23.7365 82.7934 1.8024 1.46E-05 1.47E-03 
Psmb8 46.6289 165.3420 1.8262 1.41E-05 1.44E-03 
Tap2 82.7309 205.5175 1.3128 3.03E-04 1.38E-02 
Pdgfrb 25.8384 62.9024 1.2836 1.79E-03 4.91E-02 
Dmrt1 1342.9145 2874.4468 1.0979 8.00E-07 1.68E-04 
Pik3ap1 8.4033 26.9442 1.6810 6.79E-04 2.50E-02 
Il1r2 11.9409 36.9845 1.6310 1.75E-03 4.84E-02 
Epha4 703.4733 182.3822 -1.9475 8.29E-08 2.65E-05 
Ifih1 47.5933 129.4857 1.4440 1.10E-08 5.52E-06 
Nmi 78.3630 167.5192 1.0961 1.53E-04 8.28E-03 
Neb 105.8289 243.3978 1.2016 8.70E-07 1.76E-04 
Meis2 1236.1904 287.7491 -2.1030 9.16E-06 1.09E-03 
Chst1 62.7585 132.1654 1.0745 7.25E-05 4.84E-03 
Zbp1 17.3788 62.1533 1.8385 1.28E-05 1.34E-03 
Ctso 20.5854 46.6214 1.1794 2.81E-04 1.30E-02 
Gbp3 94.1590 341.8391 1.8601 4.00E-14 8.10E-11 
Gbp2 303.3540 839.8920 1.4692 1.04E-07 3.15E-05 
Dmrtb1 145.2507 456.5793 1.6523 1.55E-05 1.53E-03 
Rhd 65.3627 139.0487 1.0891 6.20E-04 2.34E-02 
 175 
Espn 336.9615 731.2654 1.1178 4.89E-08 1.75E-05 
Hes3 21.3594 1.3014 -4.0367 4.79E-08 1.75E-05 
Prkg2 41.2820 85.6695 1.0533 9.21E-04 3.08E-02 
Fgf5 219.1651 92.2737 -1.2480 3.27E-04 1.45E-02 
Oasl2 225.2595 606.4064 1.4287 2.42E-06 3.84E-04 
Ptn 478.2054 187.6812 -1.3493 1.74E-05 1.66E-03 
Slc13a4 30.9451 80.7136 1.3831 1.90E-05 1.79E-03 
Plxnd1 235.1387 475.2960 1.0153 4.53E-08 1.68E-05 
Tdrd12 423.2191 937.6618 1.1477 3.99E-10 3.31E-07 
Asb9 45.7565 184.9153 2.0148 1.16E-03 3.65E-02 
Cdyl2 310.0220 676.8534 1.1265 5.18E-04 2.05E-02 
Psmb10 513.8166 1049.4042 1.0302 7.05E-04 2.57E-02 
Car12 167.6581 354.2381 1.0792 1.17E-07 3.47E-05 
Rasl10a 24.9890 75.0985 1.5875 1.39E-05 1.43E-03 
Parp14 157.5274 482.8653 1.6160 3.38E-14 7.69E-11 
Nkx6-1 16.3448 2.9697 -2.4605 1.11E-03 3.53E-02 
Lpar3 13.4404 47.0794 1.8085 3.15E-06 4.71E-04 
Apln 76.6080 201.0613 1.3921 3.62E-08 1.46E-05 
Mgarp 351.1918 734.0375 1.0636 1.62E-11 1.87E-08 
Ephx3 186.5985 417.0694 1.1603 1.00E-05 1.16E-03 
Cdkn1c 616.6902 163.4825 -1.9154 9.78E-22 4.46E-18 
 176 
Pcdh18 194.3579 71.6024 -1.4406 3.39E-05 2.72E-03 
Ddx60 45.7988 204.5236 2.1589 4.06E-08 1.57E-05 
Rapgefl1 71.7653 159.9583 1.1563 8.64E-04 2.99E-02 
Tlcd2 159.4359 332.9265 1.0622 2.36E-08 1.03E-05 
Stx11 21.7452 57.3821 1.3999 7.29E-04 2.63E-02 
Prss23 119.3074 40.4708 -1.5597 1.01E-04 6.17E-03 
Cbx4 72.6579 150.5833 1.0514 2.48E-05 2.20E-03 
Gbp7 127.0694 402.6418 1.6639 1.23E-19 3.75E-16 
Gbp2b 227.0553 654.1423 1.5266 5.78E-11 5.85E-08 
Cyp2s1 68.4012 176.9613 1.3713 1.37E-06 2.44E-04 
Map7d2 397.3767 804.7087 1.0180 1.46E-10 1.35E-07 
Sox15 55.6940 112.4348 1.0135 8.79E-04 3.02E-02 
Dlgap3 765.9737 300.7296 -1.3488 4.57E-07 1.03E-04 
Zc3h6 141.7489 314.4933 1.1497 2.96E-08 1.23E-05 
Gm9785 4.3222 28.5719 2.7248 8.69E-04 3.00E-02 
Neurog3 116.4951 307.4676 1.4002 1.61E-03 4.67E-02 
Sowaha 30.2589 94.6631 1.6454 4.48E-06 6.38E-04 
Smtnl2 1032.3725 2351.8311 1.1878 4.02E-06 5.85E-04 
Fam83h 534.5661 234.3295 -1.1898 2.04E-06 3.48E-04 
Ppp1r3b 118.2135 238.3038 1.0114 6.33E-04 2.37E-02 
Gap43 82.8168 35.9024 -1.2058 9.40E-04 3.12E-02 
 177 
Nccrp1 34.4972 3.3456 -3.3662 1.36E-06 2.44E-04 
Sp8 338.7400 108.0426 -1.6486 4.05E-06 5.85E-04 
Prss50 98.4685 222.1058 1.1735 2.48E-05 2.20E-03 
Gal3st1 43.8119 129.3119 1.5615 3.52E-05 2.80E-03 
Fam161a 62.5269 126.7662 1.0196 4.52E-04 1.84E-02 
Sarm1 96.8237 216.1714 1.1587 1.30E-06 2.42E-04 
Pnma5 86.4028 372.7974 2.1092 1.21E-05 1.30E-03 
Sv2c 34.5522 107.3978 1.6361 1.22E-04 7.03E-03 
4933427D06Rik 26.5821 132.1078 2.3132 4.43E-04 1.83E-02 
Usp26 576.8641 2633.6663 2.1908 2.53E-06 3.93E-04 
Kdm5d 197.1656 404.3364 1.0361 1.62E-04 8.59E-03 
A930024E05Rik 327.0260 157.4958 -1.0541 9.30E-05 5.84E-03 
Nxf3 89.3717 388.9137 2.1216 1.64E-26 1.49E-22 
Inca1 29.5235 64.8825 1.1360 9.17E-04 3.08E-02 
Tmem140 11.3854 28.7399 1.3359 1.25E-03 3.87E-02 
H2-Q7 143.8002 292.8012 1.0259 4.00E-05 3.05E-03 
Lsamp 0.6802 7.6615 3.4937 7.08E-04 2.57E-02 
Sox21 339.4044 106.9601 -1.6659 7.04E-07 1.49E-04 
Usp17lb 40.3897 12.8864 -1.6481 1.43E-03 4.30E-02 
Parp10 233.4522 471.6549 1.0146 4.37E-04 1.81E-02 
Ifi27 7.5372 24.1861 1.6821 9.73E-04 3.20E-02 
 178 
Efcab1 27.3559 58.1989 1.0891 1.02E-03 3.35E-02 
Il3ra 88.5823 30.5425 -1.5362 1.19E-05 1.29E-03 
Uba1y 208.8711 434.7815 1.0577 9.14E-07 1.83E-04 
Irgm2 99.3136 265.9235 1.4209 1.32E-05 1.37E-03 
Fbxo47 67.2402 151.2119 1.1692 2.29E-05 2.08E-03 
Rgma 353.6609 159.8469 -1.1457 1.40E-05 1.43E-03 
Rbm44 562.3924 1137.7533 1.0165 6.56E-08 2.21E-05 
Zscan4f 133.7923 38.1506 -1.8102 3.21E-04 1.43E-02 
Cebpd 173.7531 85.6049 -1.0213 1.95E-04 9.83E-03 
Nup62cl 218.9731 453.1032 1.0491 3.87E-05 2.97E-03 
Gm1141 151.0135 405.4066 1.4247 3.43E-05 2.75E-03 
Gm9 0.3023 9.1533 4.9202 1.54E-03 4.50E-02 
Lrp8os2 59.5906 137.4819 1.2061 5.56E-05 4.01E-03 
Rec114 131.5090 283.5878 1.1086 5.23E-04 2.06E-02 
1810010H24Rik 38.3081 80.6864 1.0747 9.18E-04 3.08E-02 
Cntd1 54.6588 131.6818 1.2685 4.56E-04 1.85E-02 
Igtp 146.7145 331.5726 1.1763 2.71E-05 2.33E-03 
Gbp4 73.5510 221.4101 1.5899 1.11E-09 8.33E-07 
H2-T10 33.0454 74.9007 1.1805 8.93E-04 3.04E-02 
Hist3h2bb-ps 461.3166 1079.6088 1.2267 3.45E-12 5.23E-09 
Kis2 558.4567 250.8900 -1.1544 6.75E-07 1.45E-04 
 179 
2700033N17Rik 28.6467 7.8726 -1.8635 4.41E-04 1.82E-02 
BC064078 51.8482 17.9813 -1.5278 8.27E-05 5.42E-03 
Zscan4d 113.2395 35.3590 -1.6792 3.52E-04 1.53E-02 
Peg10 2280.4827 6904.8484 1.5983 5.30E-04 2.08E-02 
Mirg 237.1671 7.2003 -5.0417 2.47E-21 8.99E-18 
Rian 2408.3454 107.2252 -4.4893 1.16E-09 8.33E-07 
G730013B05Rik 4.0055 23.6903 2.5643 5.70E-05 4.07E-03 
Gm26945 32.4924 2.3032 -3.8184 4.23E-06 6.07E-04 
B830012L14Rik 17.1328 1.2220 -3.8095 1.29E-03 3.95E-02 
Tcf24 51.5219 111.3713 1.1121 1.05E-03 3.39E-02 
Snrpn 1040.7031 2155.8370 1.0507 1.03E-06 1.97E-04 
Gm37899 77.0838 5.3044 -3.8612 1.32E-06 2.43E-04 
Pcdhga11 59.7718 25.4418 -1.2323 1.68E-03 4.75E-02 
Gbp10 15.0419 63.1312 2.0694 1.34E-06 2.44E-04 
Gm2762 93.6145 201.5682 1.1065 3.03E-05 2.51E-03 
 
FDR, False discovery rate; FC, Fold change. 
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Appendix 3 List of genes with decreased H3K9ac levels in promoter 
region upon Gcn5 loss in day 5 EBs (FDR0.05) 
Gene name 
Distance 
to TSS Gene name 
Distance 
to TSS Gene name 
Distance 
to TSS 
Mir363 -471 Gtf2e1 0 Rad51ap1 0 
Ints7 0 Rpl37a 0 Arhgef7 0 
Prr11 0 Mak16 0 Dscr3 0 
Efnb2 0 Mir7067 0 Chchd4 0 
Fbxl18 0 Snora81 0 Thap1 0 
Sugt1 0 
1700001G1
7Rik 0 Cep44 0 
Ankrd28 0 Vps35 0 Pik3r2 0 
Lins 0 Snord2 0 Nsl1 0 
Rab13 0 Mcm5 0 Qtrtd1 0 
Snora74a 0 Tbc1d31 0 Snord83b -8 
Ubr5 0 Acd 0 Snora7a 0 
Cnnm2 0 Mir18b 0 Dusp4 0 
Zcchc4 0 Rnf165 0 Gm10052 0 
Cirh1a 0 Zwilch 0 Enkd1 0 
Eif4a2 0 
C130036L2
4Rik 0 Kis2 0 
 181 
Gapdh 0 Cadps 0 Rpl4 0 
Snord45b 0 Naa40 0 Eef1g 0 
Snrpa1 0 Rpl7l1 0 Xpc 0 
Gldc 0 Rpl3 0 Upf3a 0 
Sall2 0 Urb2 0 Srm 0 
Wdr76 0 Mthfd2 0 
2810428I15R
ik 0 
Snord16a 0 Mar11 0 Rpl18a 0 
Eif4ebp1 0 Ncl 0 Rnf20 0 
Prim2 0 Slc20a2 0 Mcm6 0 
Nqo1 0 Rps9 0 Smim19 0 
B230354K17
Rik 0 Prkdc 0 Cript 0 
Gnl3 0 Pola1 0 Fmn2 0 
Mir7238 0 Cdc5l 0 Srp19 0 
Spns1 0 Hells 0 Lincenc1 0 
Rabggtb 0 
2610015P0
9Rik 0 Dtl 0 
Rnf150 0 Gins2 0 Uba52 0 
Mir1949 0 Tuba1b 0 Taf5l 0 
Hnrnpa1 0 Pard6a 0 Asb7 0 
 182 
Sox1 0 Bcat1 0 Hsbp1 0 
Ccdc115 0 Gm12191 0 Mt2 0 
Setbp1 0 Cxcr4 0 Zfp524 0 
Ipo9 0 Set 0 Mir92-2 -310 
Bdh1 0 
1600020E0
1Rik 0 Tatdn3 0 
Ap4m1 0 Klf2 0 Afg3l1 0 
Fbxo8 0 
1110038B1
2Rik 0 Chtf8 0 
Bccip 0 Hspe1 0 Tex30 0 
Snord47 0 Snord19 0 Orc6 0 
Tardbp 0 
2310035C2
3Rik 0 Huwe1 0 
4930429B21
Rik 0 Rpl30 0 Rmi2 0 
Txnl4b 0 Cct2 0 Cenpq 0 
Eno1b 0 Gm31763 0 Aldh6a1 0 
Zbtb37 0 Tmem183a 0 Orc1 0 
Osbpl1a 0 Uros 0 Nat10 0 
Mir301 -347 Ska2 0 Snord45c 0 
Mir8109 0 Mad1l1 0 Eno1 0 
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Rplp2 0 Bola1 0 Rps27 0 
Nmnat2 0 Snhg1 0 Apba1 0 
Snhg4 0 Zranb3 0 
2500002B13
Rik 0 
Paxip1 0 Dhx38 0 Anapc4 0 
Snord43 0 Pigf 0 Snord52 0 
Zfyve26 0 Rad51b 0 Mir1967 0 
Ipo5 0 Lsm3 0 Pign 0 
Cbx5 0 Grb10 0 Utp14a 0 
Msmo1 0 Timeless 0 Cox20 0 
Dpp7 0 Carf 0 Ankrd10 0 
Pcna 0 
2210408I21
Rik 0 Pcbp1 0 
Lin52 0 Hspd1 0 Mcm4 0 
Gas5 0 Slc3a2 0 Snora33 0 
Ifi30 0 Aars 0 Rps21 0 
Ptp4a1 0 Rabl3 0 Atp6v1b2 0 
Snord82 0 Ankrd32 0 Pbrm1 0 
Cstf2 0 U2surp 0 Sap30 0 
4933405L10
Rik 0 Rps27rt 0 Gm5643 0 
 184 
R3hdm1 0 Mcm7 0 Snord22 0 
Mir106a 0 Tmem43 0 Mut 0 
Rps12 0 Rps5 0 Mcm2 0 
Gins1 0 Mfap1a 0 
2010320M18
Rik 0 
Mir3091 0 Gja1 0 Snord100 0 
Mir20b -46 
D6Wsu163
e 0 Gm13363 0 
Mir19b-2 -172 Nuf2 0 Slc18a1 0 
Zmat3 0 Prpf38a 0 Imp4 0 
Lipt1 0 Rps6ka2 0 Fiz1 0 
Mir124a-3 0 Rpl32 0 Dhps 0 
Wdr12 0 Snora52 0     
Snora68 0 Impa2 0     
 
FDR, False discovery rate. 
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